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ABSTRACT 
 UNDERSTANDING THE EFFECT OF BVDV ON ANTIGEN PRESENTING CELLS 
AND CYTOPLASMIC TRAFFICKING 
Mrigendra Rajput 
2013 
Bovine viral diarrhea viruse (BVDV) causes immunosuppression and persistent 
infection that are great threats to the health of cattle. Antigen presenting cells (APC), like 
dendritic cells (DC), provide active surveillance and present antigens to the immune 
system. Monocyte-derived dendrite cells (MDDC) were used as an in vitro model to 
evaluate the effect of BVDV on DC cell surface markers expression and the role of DC in 
BVDV dissemination. The study used 4 different strains of BVDV: severe acute 
noncytopathic (ncp) BVDV2a-1373, mild acute ncpBVDV2a-28508-5, and type1b 
mucosal disease virus pair, cytopathic (cp) TGAC or ncp TGAN strains. 
MDDC did not produce infectious virus. However viral RNA was replicated and 
translated into the NS5a viral protein. The MDDC precursor, monocytes were infected 
and produced infectious BVDV. The infectious BVDV production was reduced over time 
as the monocyte differentiated to MDDC and virus production was completely lost by 
120 hr of differentiation. The cp-BVDV1b-TGAC up regulated the MHCI, MHCII and 
CD86 expression while the three ncp BVDV strains reduced the MHCI, MHCII and 
CD86 expression in MDDC. 
 The role of BVDV infection in autophagy induction and effect of autophagy in 
BVDV replication was examined. BVDV infection induced autophagy in MDBK cells 
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and Bt cells. There was no significant difference between cp or ncp strains of BVDV in 
autophagosome formation. The autophagy inducing drug, rapamycin, enhanced the viral 
replication while the autophagy inhibiting drug, 3MA (3-Methyladenine), suppressed 
viral replication. The co-localization study, using BVDV NS5A or E1 with GFP-LC3 
revealed that BVDV did not replicate in autophagosomes.  
The effect of cp or ncp BVDV infection in vivo on immune polarization to T 
helper-2 (TH2) or T helper-1 (TH1) by measuring serum IgG1 and IgG2 concentrations 
was done using the TGAC-TGAN virus pair. Ncp TGAN directed the immune response 
toward a TH1 or cellular immune response while the TGAC cytopathic strain of BVDV 
directed the immune response toward TH2 or humoral immune response. The cumulative 
findings of these studies contributed to the general body of knowledge regarding 
immunosuppression associated with BVDV infections. 
. 
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CHAPTER 1.  
RESEARCH OBJECTIVES AND LITERATURE REVIEW 
INTRODUCTION 
Infections with bovine viral diarrhea viruses (BVDV) are a major problem for the 
cattle industry. BVDV causes a wide variety of respiratory, gastrointestinal and 
reproductive syndromes. Dendritic cells (DC) are important antigen presenting cells that 
play a crucial role in antigen monitoring, processing and presentation. Because of their 
important role of DC in activating the acquired immune system, BVDV infection of DC 
may have a devastating impact on the immune system and virus dissemination in body. 
Host immunity has two components: innate and adaptive immune response.  The 
innate immune response is quicker but is not pathogen-specific and has no 
immunological memory. The adaptive immune response is slower but is pathogen-
specific with long lasting immunological memory. When the adaptive immune system 
encounters a pathogen for the second time, it produces a rapid and more effective 
response against that pathogen. DC play a critical role in connecting the innate and 
adaptive immune response through antigen presentation and naive T cell activation.  
BVDV infects a wide variety of cell types and has a predilection for cells of the 
immune system including antigen-presenting cells like monocytes that develop into DC. 
The viral infection of DC may interfere with its surface markers expression, antigen 
presentation and T-cell activation. Interference in DC activity may be one of the causes 
of immunosuppression associated with BVDV infections. The impairment of DC 
function may also result in evasion from the immune response. The major objective of 
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this study was to investigate the effect of BVDV infection on monocyte-derived dendritic 
cell (MDDC).  
The hypotheses were: 1) MDDC are targets of BVDV  production resulting in 
dissemination of BVDV to secondary lymphoid tissues and other tissues; 2) Infection of 
monocyte-derived dendritic cell (MDDC) with BVDV causes changes in the phenotype 
of MDDC (cell surface molecules expression); 3) BVDV infection induces autophagy 
and uses autophagosome for its replication and productive infection and 4) In vivo 
antibody response against cytopathic BVDV polarizes the T cell response to TH2 
response while the antibody response to noncytopathic BVDV is polarized to TH1 
response  
RESEARCH OBJECTIVES 
1) To generate bovine monocyte-derived dendritic cells (MDDC) for use as an in 
vitro model for studying host cell-virus interaction. Under this objective three 
approaches were taken: 
a) Optimize a previously described method for separation of monocytes from bovine 
peripheral blood that yields a high number of viable monocytes. 
b) Optimize culture conditions for maturation of monocytes to MDDC. 
c) Characterize morphological and phenotypic characteristics of MDDC. 
2) Investigate the effect of BVDV on MDDC viability and BVDV replication and 
virus production in MDDC  
The three approaches were: 
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a) Study the effect of BVDV biotypes and virulence on MDDC viability through 
trypan blue exclusion assay 
b)   Investigate the ability of BVDV to replicate in MDDC  
c) Investigate BVDV virus production in MDDC. 
3) Investigate the effect of BVDV on MDDC phenotypes  
Under this objective, one approach was taken: 
a) Study the cell surface marker expression (MHC I, MHC II and CD86) in MDDC 
following BVDV exposure through flow cytometry analysis 
4) Effect of BVDV infection on autophagosome induction in infected cells. 
The three approaches were: 
a) Determine the effect of BVDV strains on autophagosome formation. 
b) Determine the relationship between autophagosome formation and virus 
production  
c) Determine the interrelation between viral replication and autophagosome 
formation through co-localization study of viral proteins with autophagosome 
marker (LC3). 
5) Effect of BVDV strains on polarity of immune response.  
Two approaches were taken: 
a) Determine the effect of cytopathic and non cytopathic stain of BVDV on total 
serum IgG levels in calves.  
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b)  Determining ratio of IgG1 to IgG2 in serum profile after infection of cytopathic 
or noncytopathic stain of BVDV to determine TH2 and TH1 immune response 
respectably.  
LITERATURE REVIEW 
1.1  BVDV Associated Disease:  
 Bovine viral diarrhea viruses (BVDV) are viral pathogens that are the source of 
several different diseases and syndromes that impact the cattle industry. Despite 60 years 
of vaccination, BVDV infections remain a source of significant economic loss for 
producers in the United States (Ridpath, 2012) and world (Stahl and Alenius, 2012). 
The evidenced by outbreaks of hemorrhagic syndrome and severe acute bovine viral 
diarrhea beginning in the 1980s and 1990s (Goens, 2002). The International 
Committee on Virology Taxonomy recognizes two species of BVDV, BVDV1 and 
BVDV2 (ICTV, 2013).There are significant antigenic and genomic differences between 
isolates from the two species (Ridpath et al., 2003). In addition, some BVDV2 strain 
cause a severe clinical disease, known as hemorrhagic syndrome, that has not been 
observed following infection with BVDV1 (Corapi et al., 1989; Carman et al., 1998; 
Ridpath, 2003).  Viruses from both BVDV species are further classified into two 
biotypes: cytopathic (cp) BVDV and noncytopathic (ncp) BVDV. This distinction is 
based on morphological changes in cultured epithelial cells following infection  
(Gillispie et al., 1962). 
 BVDV is capable of a wide spectrum of disease and clinical symptoms. 
The clinical presentation of disease can range from clinically mild to severity 
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form of disease depending  on the virulence of the strain and health state of the 
infected host.  It may be clinically mild acute, clinically severe acute, abortion, 
fetal death, congenital defects, persistent infection and mucosal disease 
(Pritchard, 1963; Brownlie, 1990; Moennig and Liess, 1995; Peterhans et al., 
2010). Acute infection is also known as primary infection or transient infection. 
Typically, cattle develop an immune response against BVDV that effectively 
clears the virus during the course of acute infection. Acute infections can be 
caused by either biotypes of BVDV. Clinical signs of acute BVDV infection may 
include fever, diarrhea, general respiratory sysmptoms, inappetance, depression, 
lymphopenia, and thrombocytopenia with decreased milk productionand nasal 
discharge (Carman et al., 1998; Baule et al., 2001).  Acute infection of BVDV 
in cattle plays an important role as an immunosuppressive agent or act as a 
potentiator for other diseases (Houe, 1995; Potgieter, 1995; Taylor et al., 1997). 
In typical acute infections, virus is generally found in lymphoid-associated tissues 
as well as intestinal mucosa (David et al., 1993; Hibberd et al., 1993). In rare 
cases, acute infections may progress to highly severe presentation known as 
severe acute of periacute BVDV. Periacute BVDV is associated with high 
virulence strains of BVDV. The clinical manifestation of severe acute infection 
include fever, pneumonia, diarrhea, and sudden death occurring  in all age groups 
of cattle. Gross lesions in the alimentary tract are similar to those associated with 
mucosal disease. Some animals develop severe thrombocytopenia with 
hemorrhages (hemorraghic syndrome) (Bolin and Ridpath, 1992; David et al., 
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1994; Carman et al., 1998). The chronic BVDV infection can be established 
when BVDV maintained itself in immunoprivileged sites such as ovarian tissue, 
testicular tissue and central nervous system tissue, and circulating white blood 
cells. Infections of circulating white blood cells may change their ability to 
stimulate adaptive immune response and facilitate chronic infection of these cells 
(Givens and Marley, 2013).  
 Following implantation, transplacental infection of the developing fetus can 
occur from the dam with either biotype of BVDV (Fredriksen et al., 1999). The 
outcome of the infection is largely dependent on the timing of the infection, the 
immunocompetence of the developing fetus, the virus biotype involved, and the 
virulence of the virus (Grooms, 2004). During pregnancy, the ncp BVDV strains 
generally infect the trophobloast cells of the placental and infect the growing fetus 
by crossing placental barrier (Fredriksen et al., 1999). BVDV infection during 
pregnancy may result in early embryonic death, abortion, congenital defects, 
immunotolerance and birth of weak calves (Grooms, 2004). The congenital 
defect in calves may include brachygnathism, growth retardation, malformations 
of the brain and cranium, and rare extracranial skeletal malformations 
(Blanchard et al., 2010).  However, if ncp BVDV infects  bovine fetuses during 
the first 40-120 days of pregnancy persistently infected (PI) calves may be the 
result (Chase et al., 2004). PI calves are immunotolerant and remain a source of 
infection to other animals. Superinfection of PI animals with either an 
antigenically homologous or a vaccine cpBVDV strain may results in mucosal 
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disease, a fatal disease syndrome (Brownlie et al., 1984). Mucosal disease is 
characterized by high mortality and extensive lesions in gastrointestinal tract 
(Nettleton and Entrican 1995). 
1.2 Bovine Viral Diarrhea Virus:  
 Bovine viral diarrhea virus (BVDV) is a member of the Pestivirus genus and the 
family Flaviviridae (Handelet al., 2011). It is a single-stranded, positive-sense RNA 
virus. BVDV has a genome of approximately 12.5 kb with single open reading frame. 
The genome translates a single polyprotein that is cleaved into individual viral proteins 
by host cell and viral proteases (Figure 1-1). The C protein functions to package the 
genomic RNA and provide structure for the virion envelope. The other structural proteins 
include three envelope-associated glycoproteins, Erns (gp48), E1 (gp25), and E2 (gp53) 
that are cleaved by cellular proteases (Figure 1-1).  The Erns, E1, and E2 have important 
roles in virus binding and cell entry as well as for immunologic recognition by the host. 
The E2 protein contains the major recognition sites for BVDV neutralizing antibodies 
against BVDV. The neutralizing epitopes of E2 are important targets for BVDV vaccine 
efficacy to induce effective humoral immune response against BVDV (Donofrio et al., 
2006; Chimeno Zothet al., 2007). Unlike E1 and E2, Erns is dispensable for cellular 
entry (Iqbal et al., 2004; Ronecker et al., 2008). The E1 protein is predicted to have 
various functions such as a membrane anchor for E2. The E1 and E2 form E1-E2 
heterodimers. The E1-E2 heterodimers appears to be essential for cell entry of BVDV 
(Rumenapf et al., 1993; Ronecker et al., 2008). Among the six nonstructural proteins in 
the noncytopathic BVDV genome, the Npro (p20) is the first protein produced from the 
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open reading frame (Figure 1-1). It has papain-like protease activities. The next 
nonstructural protein produced is NS23 (p125) (Figure 1-1). This protein has several 
unique characteristics that suggest its involvement in multiple functions like, a protease, 
and a helicase. In cytopathic BVDV strains, the NS23 protein cleaves into two proteins: 
NS2 (p54), and NS3 (p80) (Figure 1-1). The NS3 protein, which is  unique to the 
cytopathic BVDV biotype contains the protease and helicase activity of the NS23 protein. 
Other nonstructural proteins include NS4A (p10), NS4B (p32), NS5A (p58) and NS5B 
(p75) (Figure 1-1). The NS5B (p75) acts as RNA-dependent-RNA polymerase and is 
needed to replicate the viral genome (Elbers et al., 1996). The virus replicates in the 
cytoplasm and is released by budding (Grummer et al., 2001). The NS5A protein of 
HCV (hepatitis C virus), other virus of family Flaviviridae has key roles in viral RNA 
replication and modulation of the physiology of the host cell. The NS5A protein of HCV 
modulate the cellular environment that favor the virus replication and initiate the 
persistence HCV infection (Macdonald and Harris, 2004). 
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Figure 1-1 The schematic representation of the BVDV encoded proteins. 
BVDV is a single-stranded RNA virus comprised of 12,300 nucleotides. BVDV consists of a single open 
reading frame between two untranslated regions (5’ and 3’). The poly protein encoded is autocleaved into 
single proteins both structural and non-structural. In cytopathic biotype viruses NS23 protein cleave in to 
NS2 and NS3 proteins (lower panel)  while in noncytopathic biotype viruses NS23 does not cleave (upper 
panel). from:  Morarie, S.E. (2012). “Unraveling the biology of bovine viral diarrhea virus (bvdv) 
persistent infections: integrating field and laboratory studies.” Ph.D. Thesis. South Dakota State 
University, Brookings, SD 57007, U.S.A (Pt): 9. 
 
1.3 BVDV-induced Immunosuppression:  
An acute BVDV infection results in transient immunosuppression.  BVDV 
infection affects both adaptive and innate immune system. The granulocytes and 
monocytes of the innate immune system are equally susceptible to BVDV with reduction 
in numbers and inhibited functions observed in both the populations (Brewoo et al., 
2007). BVDV affects thymic and follicular T-lymphocytes, as well as follicular B-
lymphocytes resulting in severe reduction of circulating lymphocytes number and 
decreased functions.  
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BVDV infects almost all types of bovine cells including antigen-presenting cells 
(APC). The APC infected with ncp BVDV isolates does not result in induction of  type I 
interferons  (1FNF) in vitro (Diderholm and Dinter 1966; Adler et al., 1997) and to 
blocks the induction of type 1 IFN by double-stranded RNA (dsRNA) or infection with 
other viruses (Schweizer and Peterhans, 2001). 
An acute BVDV infection or vaccination with MLV BVDV results in decreased 
delayed type hypersensitivity (DTH) to Mycobacterium avium subspecies. DTH 
responses to Mycobacterium paratuberculosis purified protein derivative (PPD) were 
decreased in cows experimentally exposed to M. paratuberculosis 7 days vaccination 
with a modified-live bovine viral diarrhea virus (ML-BVDV) vaccine (Thoen and 
Waite, 1990). Acute infections of cattle with non-cytopathic BVDV temporarily 
compromises diagnostic tests for M. bovis infections and result in a failure to identify 
cattle with tuberculosis. MLV BVDV vaccination inhibited neutrophil mediated 
antibody-dependant cellular cytotoxicity (Roth and Kaeberle, 1983). Further,  BVDV-
infected monocytes have marked reductions in leukotriene B4; leukotriene B4 is an 
important mediator in IL-1, IL-2 and IFN-alpha production (Atluru et al., 1992). 
Protective immunity against intracellular pathogens requires a strong TH1 
immune response. TH1 immune response is predominantly characterized by the 
production of IFN-γ (Abbas et al.,  1996; O'Garra, 1998) and IL-12 (Trinchieri, 1995; 
Kalinski et al., 1999). Type I IFN and IL-12 gene expression were significantly up 
regulated in monocytes within 1 hr p.i. with ncp BVDV but not cp BVDV. The 
differences between Type I IFN and IL-12 were not observed between cp and ncp BVDV 
11 
 
after 24 hours p.i. Both BVDV biotypes also suppressed pro-inflammatory cytokines 
including TNF-alpha, IL-1 beta, IL-6, and co-stimulatory molecules CD80 and CD86 
24hr p.i. (Lee et al., 2008). 
 1.4 Effect of BVDV on humoral Immune Response:  
Passively acquired antibodies against BVDV confer immunity to newborn calves 
(Ridpath et al., 2003). The amount of passive immunoglobulin transferred from dam to 
newborns vary with the dam’s condition and age. Calves born to younger dams tend to 
have have lower immunoglobulin levels, resulting from passive transfer, than calves that 
were born to older cows (Perino et al., 1995). The presence of passive antibodies at the 
time of vaccination can inhibit the development of the specific antibodies. The half-life of 
maternally-derived BVDV antibody is between 20 and 23 days. For calves, the amount of 
time required for maternal antibody decay to reach seronegative status for BVDV 1 
ranged between 118 and 192 days and for BVDV 2 between 94 and 158 days (Fulton et 
al., 2004). In the absence of passive antibodies, the primary antibody response to BVDV 
challenge develops within one to three weeks post-vaccination. Neutralizing serum 
antibodies against BVDV were monitored for three years in 35 cattle that were infected 
with live modified  virus as calves. Twenty-four (24) of the calves were inoculated 
intramuscularly or intranasally while 11 contracted the infection naturally. All the 
experimentally infected calves seroconverted within 14 to 28 days after inoculation, and 
all the animals had the detectableserum  antibodies to BVDV, three years after infection 
(Fredriksen et al., 1999). Serum antibodies have the ability to protect against viral 
infection. The protection provided from the vaccine response dependents on the strain of 
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the virus administered along with the level and the isotype of antibodies produced (Chase 
et al., 2004)and adjuvant used in the vaccine (Leroux-Roels, 2010). Both cytopathic and 
non-cytopathic BVDV biotypes can be neutralized by IgG1 and IgG2 in absence of 
complement (Howard, 1990). A study conducted with 14 type 1 and 6 type 2 BVDV 
strains indicated that both genotypse produced similar amounts of neutralizing antibody 
against respective strains in calves (Fulton et al., 1997). Neutralizing antibody provided 
protection against BVDV infection and reduced the BVDV shedding from infected 
animals (Howard et al., 1989). BVDV infection reduced circulating B and T cells in cp 
BVDV-infected cattle (Bolin  et al., 1985). The incubation of bovine splenic lymphoid 
cells with ncp bovine viral diarrhea virus (BVDV) for 5 days inhibited the development 
of plasma cell with reduced synthesis of IgG or IgM (Atluru et al., 1979). 
1.5 The Effect of BVDV on Cell Surface Molecules Important for Antigen 
Presentation: 
The major histocompatibility complex (MHC) was originally discovered as 
transplantation antigens that determine the compatibility of tissues between different 
individuals. The complex is comprised of three classes of genes. Class I and II genes 
encode molecules that are expressed on cell surface and class III genes was discovered 
that encode several components of the complement system. Later studies with inbred 
strains of mice showed that class I and class II genes play an important role in controlling 
both humeral and cell-mediated immune responses. The MHCI molecules are used as 
context by cytotoxic T-lymphocytes and MHCII are used as context by helper and other 
regulatory T cells (Klein and Figueroa, 1986). In humans, the major histocompatibility 
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complex (MHC) contains at least 128 functional genes in human of which, more than 
20% of which have functions in immunity..  
The MHC molecule in cattle is known as the bovine leucocyte antigen complex 
(BoLA ) (Untalan et al., 2007). The BoLA spans approximately 2.6 megabase pairs 
(Mb) of the cattle genome while the MHC in human and mice  is 4 Mb and 1.5 Mb 
respectively (Lewin, 1996; Rothschild et al., 2000). In BoLA, the genes are organized 
into three distinct classes (class I, II, and III) similar to human and mice. In BoLA, each 
of these classes is divided into regions and sub-regions, containing genes and pseudo 
genes (Andersson and Davis, 2004). In cattle, BoLA genes are located on chromosome 
23 (Fries et al., 1986; Fries et al., 1993) while in human and mice MHC genes are 
located at chromosome 6 and chromosome 17 respectively (Lewin, 1996). The structure 
and organization of the MHC genes of cattle is similar to human and mice with few 
differences. The major difference between the organizations of the BoLA of cattle and 
MHC molecules of human and mice is that the BoLA complex is found in two separate 
regions of the chromosome rather than a single cluster of genes. The larger gene cluster is 
located at BTA (Bos taurus autosome) 23 band 22 and apparently contains all of the 
bovine class I and class III sequences, and genes encoding both subunits of the classical 
class II proteins DQ and DR. The DQ and DR regions are tightly linked to other BoLA 
genes, including HSP70, CYP21, and several class I loci (Bishop et al., 1994). The 
remaining BoLA class II loci (DIB, DNA, DOB, DYA, DYB, TCP1, LMP2, LMP7 and 
TAP2) are located in a cluster near the centromere at BTA 23 band 12-13 (Rothschild et 
al., 2000). The class I region contains at least 10 class I genes and pseudogenes 
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(Lindberg and Andersson 1988; Bensaid et al., 1991) and at least four class I loci are 
transcribed in cattle (Ellis et al., 1999). The BoLA class I genes are polymorphic and 28 
distinct BoLA class I sequences have been identified (Takeshima and Aida, 2006). The 
BoLA genes I and II are associated with genetic resistance and susceptibility to a wide 
array of diseases and other traits such as milk yield, growth and reproduction (Weigel et 
al., 1990; Rupp et al., 2007; Untalan et al., 2007). 
In many vertebrate species, including cattle the MHC class I and class II loci 
exhibit an extraordinarily high degree of polymorphism, particularly in exon 2 of the beta 
genes. This variation is probably maintained through selection involving interactions of 
the immune system and the pathogens (Parham and Ohta, 1996). MHC II molecules are 
primarily expressed in antigen presenting cells (APC). These cells include B-cells, 
macrophages and dendritic cells. MHCII can be induced in epithelia cells using various 
cytokines like TNF alpha and IFN gamma (Helbig et al., 1990; Makhoul et al., 2012).  
The activation of naïve T cells requires several steps. The first step is the danger 
signal or signal zero. The danger signal plays an important role in T cell communication 
to APC (Gallucci and Matzinger, 2001;  Di Virgilio, 2005). The danger signal or signal 
zero is followed by first signal. The first signal is generated by interaction of MHC-
peptide complex at the surface of APC with the T cell receptor (TCR) on the T cell.  The 
first signal confers specificity to the immune response.  However, this primary signal is 
not sufficient to completely activate T cells. To activate T cell, a second, nonspecific co-
stimulatory signal is often required. The co-stimulatory signal is induced by interaction of 
co-stimulatory molecules (CD80/86) on APCs with CD28 on T cells (Lombardi et al., 
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2010). Co-stimulatory molecules such as CD80 (B7-1) and CD86 (B7-2) belong to the 
B7 family of immune regulatory ligands. The lack of co-stimulation leads to anergy or 
apoptosis of antigen-stimulated T cells (Orlikowsky et al., 2003). While presence of  co-
stimulation significantly lowers the activation threshold and allows naive T cells to be 
readily activated (Lenschow et al., 1996;  Greenwald et al., 2005).  T cell activation is 
regulated in a well-organized manner.  The interaction of CD80/86 on APC with CD28 
on T cell activates the T cell while the interaction of CD80/86 with CTLA4 (Cytotoxic T-
Lymphocyte Antigen 4) on T cell suppresses T cell activation. CTLA4 compete for 
CD80/86 ligation with CD28 to maintain the T cell activation (Slavik et al., 1999; Berg 
and Zavazava, 2008).  The CD28 is expressed on most resting and activated cells while 
CTLA-4 is generally restricted to activated T cells (Rudd, 2009).  Besides the negative 
signaling function of CTLA-4, CTLA-4 expression promotes the down-regulation of 
CD28 via enhanced internalization and degradation of CD28 (Berg and Zavazava, 
2008). DC dynamically regulate CD86 levels depending on their need to harness or 
reduce their T cell-activating ability. DC up regulate CD86 expression following their 
contact with microbial antigens (Mellman and Steinman, 2001) while DC down 
regulate CD86 expression following exposure to immune suppressive cytokines such as 
IL-10, produced either by other immune cells or by DC, itself (De Smedt et al., 1997; 
Corinti, Albanesi et al., 2001; Haase et al., 2002). Although CD80 and CD86 are 
predominantly found on DC and professional antigen-presenting cells such as 
macrophage and activated B cells, they can be induced on other cell types including T 
cells (Azuma et al., 1993; Inaba et al., 1994). In general, CD86 is the more abundant in 
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terms of expression, and is up regulated more rapidly upon activation on APC.  In 
contrast to CD86, CD80 is not generally found on resting APC and is induced more 
slowly upon cellular activation (Sansom, 2000). The CD86 expression on APC is up 
regulated in presence of granulocyte-macrophage colony-stimulating factor (GM-CSF), 
IFN gamma (Freedman et al., 1991; Larsen et al., 1994; Liu et al., 1999), IFN-alpha 
(Radvanyi et al., 1999), IFN-beta (Wiesemann et al., 2008) and LPS 
(lipopolysaccharide) (Ding et al., 1993). There is also evidence suggesting that CD86 
expression can be induced or enhanced on lymphocytes. IL-4 induces CD86 (B7.2) in B 
cell within 6 hr of treatment (Stack et al., 1994) similarly IL2 up regulated the CD86 
expression on human CD4+ and CD8+ T cells (Paine et al,. 2012).  Type I interferon, 
most likely IFN-beta, is crucial in the pathway leading to CD86 upregulation induced by 
both LPS and poly (I:C). Trif/ Toll-interleukin 1 receptor domain (TIR)-containing 
adaptor molecule (TICAM-1) acts as a common adapter molecule in TLR3- and TLR4-
mediated responses that lead to upregulation of CD80 and CD86 while poly(I:C) up 
regulate the CD80/CD86 expression mediated in part by a TLR3-Trif-independent 
pathway (Hoebe et al., 2003). The role of Membrane-Associated RING-CH Protein 
(MARCH1) in CD86 regulation has also been demonstrated (Ohmura et al., 2009). 
MARCH1 is a membrane-anchored E3 ubiquitin ligase that has previously been shown to 
ubiquitinate MHC class II molecule through lysosomal degradation (Ohmura et al., 
2006;  Matsuki et al., 2007). MARCH1 upregulation inversely correlated with CD86 
expression (Thibodeau et al., 2008). 
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Viruses have evolved numerous strategies to avoid the host immune response via 
antigen presentation (Figure 1-2, Table 1-1)  
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Virus Encoding Proteins Mechanism Effect References 
The Epstein–Barr 
virus (EBV) 
EBV nuclear antigen 
1 (EBNA1) 
Escaping the 
processing by the 
proteosomes  
Reduced MHCI 
presentation  
(Levitskaya 
et al., 1995) 
The Epstein–Barr 
virus (EBV) 
BILF1 Degradation of 
MHC-I via 
lysosomes 
Reduced MHCI 
presentation 
(Zho, 2011) 
Kaposi’s sarcoma-
associated herpes 
virus 
(KSHV) 
Latency-associated 
nuclear antigen1 
(LANA1) 
Prevents viral 
protein degradation 
Reduced MHCI 
presentation 
(Kwun et al., 
2007) 
Herpes Simplex 
Virus (HSV) 
Immediate early 
infected cell peptide 
47 
(ICP47) protein and 
Unique short 6 
(US6) glycoprotein 
Blocks the TAP 
mediated peptide 
transport 
Reduced MHCI 
presentation 
(Fruh et al., 
1995 ; Hill et 
al., 1995; 
Hengel et al., 
1997) 
Human 
Cytomegalovirus 
(HCMV) 
Immediate early 
infected cell peptide 
47 
(ICP47) protein and 
Unique short 6 
(US6) glycoprotein 
Blocks the TAP 
mediated peptide 
transport 
Reduced MHCI 
presentation 
(Fruh et al., 
1995 , Ahn et 
al., 1997; 
Hengel et al., 
1997, Lehner 
et al., 1997) 
Human 
Cytomegalovirus 
(HCMV) 
Unique short 3 
(US3). 
Inhibits tapasin 
activity 
Reduced MHCI 
presentation 
(Lee et al., 
2000) 
Bovine Herpes 
Viruses 
Unique long 49.5 
(UL49.5) 
Degrades the TAP 
protein 
Reduced MHCI 
presentation 
(Koppers- 
Lalic, et al.; 
2005) 
Equine 
Herpes Viruses 
Unique long 49.5 
(UL49.5) 
Blocks the binding 
of ATP to TAP 
Reduced MHCI 
presentation 
(Koppers- 
Lalic, et al.; 
2005) 
Cowpox virus 
encodes  
CPXV203 protein Help in retaining 
the MHCI 
molecules  in 
the ER 
Reduced MHCI 
presentation 
(Byun et al., 
2007) 
Human 
immunodeficiency 
virus (HIV) 
Nef protein Down-regulates 
the 
surface expression 
of CD80 and CD86 
Reduced T cell 
activation 
(Chaudhry et 
al., 2005; 
Shen et al., 
2010) 
Table 1-1. Viral mechanisms to cause immunosuppression.  
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Only a few studies have investigated the effect of BVDV on MHC expression. 
The antigenically identical pair of non-cytopathic (Pep515ncp) and cytopathic 
(Pep515cp) BVDV isolates were used to determine their effect on MHCI and MHCII 
expression on MDDC. The ncp BVDV increased MHCI expression while it reduced 
MHCII and CD86 expression in MDDC. The cp BVDV reduced MHCI, MHCII and 
CD86 expression in MDDC in 48 hrs post infection (Glew et al., 2003). The Canadian 
24515 field isolate of BVDV reduced the expression of MHCII and CD21-like (B-B7) on 
bovine peripheral blood mononuclear cells (PBMCs) (Archambault et al., 2000). The 
bovine macrophages infected with cp and high virulence ncp strains of BVDV 
downregulated MHC II expression, while the high virulence  strains had no effect on 
MHC II expression. In contrastcp strains of BVDV up regulated MHCI (Chase et al., 
2004).  An analysis of mononuclear cells from lymph node and Peyer’s Patch as revealed 
decreased expression of MHC II-expressing in from BVDV-infected calves at 9
th
 day p.i. 
(Brodersen and Kelling, 1999). 
1.6 Dendritic cells: 
Dendritic cells (DC) are a subpopulation of morphologically distinct adherent 
mononuclear cells (Mosier, 1967). DC are morphologically distinct cells isolated in vitro 
from peripheral lymphoid organs of mice and were initially discovered in mouse spleens. 
DC do not represent morphological variants of either lymphocytes or macrophages. In 
1999, the first in vitro monocyte derived DC were generated from mice in 1999 
(Randolph et al., 1999). They lacked lymphocyte surface differentiation markers and do 
not exhibit the endocytic capacities of macrophages (Steinman and Cohn, 1974). 
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DC can be distinguished from other members of the monocyte lineage (i.e. 
monocytes and macrophages) by their unique morphology. Immature DC are active 
phagocytic cells. Immature DC are scattered in close proximity to body surfaces, where 
they constantly sample the environment for antigen. As soon as any foreign antigen 
enters into body, immature DC engulf it. The uptake of antigen by immature DC can 
occur by several different mechanisms such as constitutive macropinocytosis (Sallusto et 
al., 1995) FcR-mediated endocytosis (Sallusto and Lanzavecchia, 1994), caveaolae 
formation (Werling et al., 1999) and phagocytosis (Reis e Sousa et al., 1993).  The 
endosomes containing antigen fuse, with lysosomes and form an endolysosome. In 
endolysosomes, antigen is processed via proteolytic enzymes into peptides. These peptide 
antigens are presented in the groove of a major MHCII (Figure 1-2). The MHCII 
molecules are synthesized in ribosome. The MHCII molecules form a tricomplex 
containing alpha and beta chains and invariant Class II-associated invariant chain peptide 
(CLIP) peptide molecule (Figure 1-2). The invariant CLIP peptide molecule temporarily 
occupies the groove between alpha and beta chains.  This tricomplex is transported to the 
lysosome through the Golgi apparatus. The foreign antigen is phagocytized and is 
contained in the endosome (Figure 1-2). The endosome fuses with the lysosome for 
antigen processing.  Following the fusion, the CLIP peptide is removed from the grove. 
The free grove of MHC II molecule is occupied by the peptide antigenic fragment. The 
MHCII molecule containing antigen complex moves to the plasma membrane and 
presents it to T cell (Figure 1-2).  
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Figure 1-2 MHCI and MHCII antigen presentation. Owen et al., 2013 Kuby Immunology. 
W. H. Freeman Publishers Ltd, New York. 
  
 
The formation of the central supramolecular activation complex (C-SMAC) 
results in the initial immunological synapse (the first activation signal). The C-SMAC 
comprises interaction of TCR with MHCII containing antigen peptide, MHC II with CD4 
molecule, CD2 with CD2L, and CD28 (on T cell) with (CD80/86, B7) on DC. Interaction 
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between CD28 and CD80/86 provides co-stimulation that amplify signal from TCR. An 
additional interaction also occurs between the LFA-1 and ICAM-1 adhesion molecules in 
the peripheral supramolecular activation complex (P-SMAC). All of these interactions 
result in formation of the complete immunological synapse. The immunological synapse 
activates the T cell. The activated T cell produces IL-2 (Interleukin-2), IL-2 increases T 
cell proliferation and prevents the induction of anergy and cell death. In DC, PAMPs 
(pathogen-associated molecular patterns) are also recognized by pathogen recognition 
receptors (PRRs). The PRRs are present either on surface of DC or in its cellular 
compartments (Figure 1-3).  
 
Figure 1-3 DC with Pathogen Recognition Receptors and T cell Activation Owen et 
al., 2013 Kuby Immunology. W. H. Freeman Publishers Ltd, New York 
 
 
The PRRs recognize pathogen-associated molecular patterns (PAMP) like LPS 
(Rescigno et al., 1999), bacterial DNA (Akbari et al., 1999) and double-stranded RNA 
(Cella et al., 1999). Interaction of PAMPs and PRRs activates signal-transduction.  
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Signal-transduction results in expression of variety of immune-response genes. Immune-
response genes are translated into various cytokines like TNF, IL-6, IL-12, IL-10, IL-17 
and IFN-α that activate cells of innate as well as adaptive immune system. Recognition of 
PAMPs via PRRs along with stimulation by pro-inflammatory cytokines leads to 
activation and maturation of DC. During maturation, DC change from being a specialized 
phagocyte cell to professional antigen presenting cell. The mature DC home to secondary 
lymphoid organs to present antigen to T cells. The immature DC express CCR5 on their 
surface while activated DC decrease expression of CCR5 and up regulate chemokine 
receptor CCR7 (Lei and Hostetter, 2007). The DC also produce anti-microbial proteins 
and peptides such as defensins and members of the complement system.  
1.7 DC subsets in other species:  
DC can be generated from a number of different precursor cells with in 
vitro using cytokine-supported culture. They can be derived from purified, primitive self-
renewing haemopoietic stem cells as well as lineage-restricted common lymphoid 
progenitors (CLP), common myeloid progenitors (CMP), granulocyte/macrophage-
restricted precursors and pro-T cells (Manz et al., 2001). DC can also be generated from 
populations of Lin
-
 (lineage negative) CD117 (c-kit)
+
 BM or fetal liver cells (Zhang et 
al., 1998) or from  'CD4 low' T precursor cells in the thymus (Ardavinet al., 1993) or 
from peripheral blood mononuclear cell (Schreurs  et al., 1999). Mice have two distinct 
DC subsets, myeloid DC and lymphoid DC.  CD11c
+
MHCII
-
B220
+
CD19
-
 blood DC 
precursor can develop from either CMP or CLP. The CMP generates myeloid DC while 
the CLM develops into lymphoid DC in mice. Both the subsets express high levels of 
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CD11c, MHCII and CD86 and CD40. The myeloid and lymphoid DC can be 
distinguished on the basis of CD8a, CD1d and DEC 205 expression. CD8a is expressed 
on the lymphoid DC while it is absent in myeloid subset. The DEC-205 and CD1d are 
expressed with higher levels on lymphoid DC but they can be up regulated on myeloid 
DC by in vitro culture (Wu et al., 1996; Vremec and Shortman 1997). The lymphoid 
DC make higher levels of interleukin (IL)-12 that induces production of IFN gamma.  
The lymphoid DC have less phagocytic capacity than myeloid DC (Pulendran et al. 
1997; Leenen et al. 1998). The Flt3 ligand (Flt3-L) and GM-CSF can expand mature DC 
in mice. Both lymphoid and myeloid DC increase in number following Flt3-L injection 
(Maraskovsky et al., 1996). The Flt3-L treatment leads to an increase in DC numbers in 
multiple organs in mice, including spleen, lymph nodes, blood, thymus, Peyer’s patch, 
liver and lungs. In contrast, GM-CSF preferentially expands the myeloid DC subset in 
vivo (Pulendran et al., 1999). 
In humans, three subsets of DC have been identified. Two subsets originate from 
CD34+ myeloid precursors while the third subset originates from CD34+ lymphoid 
precursors (Figure 1-4). 
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Figure 1-4 Human dendritic cell subsets. From Banchereau et al., 2000. Immunobiology of 
dendritic cells, Annual Review Of Immunology. 18:767-811.  
 
The CD34+ lymphoid precursors give rise to plasmacytoid and Langerhans 
dendritic cells. The plasmacytoid DC produce high amounts of IFN-alpha (Banchereauet 
al., 2000). The CD34+ myeloid progenitors differentiate into monocytes (CD14+ 
CD11c+ DC precursors) that are further differentiated into immature DC in response to 
granulocyte/macrophage colony-stimulating factor–positive (GM-CSF) and interleukin-4 
(IL-4) or macrophages in response to macrophage colony stimulating factor (M-CSF). 
The myeloid progenitors can also differentiate into CD11c+ CD14- precursors, which 
yield Langerhans cells in response to GM-CSF, IL-4 and transforming growth factor 
(TGF) beta (Banchereau et al., 2000). The CD14
- 
CD11c
+
CD1a
+
 Langerhans cell 
precursors migrate into the skin epidermis and become Langerhans cells while the 
CD14+ CD11c
+
CD1a
−
 cells migrate into the skin dermis and other tissues to become 
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interstitial DC (Liu, 2001). The myeloid DC express all TLR except TLR7 and TLR9 
while the plasmacytoid DC selectively express TLR7 and TLR 9. 
1.8 Monocyte-derived dendritic cells: 
DC are continuously produced in the bone marrow from hematopoietic stem cells. 
After exiting the bone marrow, DC migrates into lymphoid and non-lymphoid tissues as 
epidermal Langerhans cells, splenic marginal zone dendritic cells and/or interstitial 
dendritic cells (Banchereau and Steinman, 1998). It is very difficult to isolate DC from 
these peripheral tissue sites without affecting their structure, viability and phenotype. 
Most experimental and clinical studies rely on the in vitro development of DC. The In 
vitro DC can be generated either from CD34+ progenitor cells or from non-proliferating 
blood monocytes (Sallusto and Lanzavecchia, 1994). The monocyte is the most 
common source for in vitro generation of DC. Monocytes develop in the bone marrow 
and enter and circulate in the blood stream until they are recruited to extravascular 
compartments.  The recruitment of monocytes occurs in inflammation as well as under 
steady-state condition to maintain the homeostasis of the monocyte cell system (Leon 
and Ardavin, 2008). The monocyte-derived DC (MDDC) are generated by culturing 
monocytes with granulocyte-macrophage colony stimulating factor (GM-CSF) in the 
presence of either toll-like receptor ligand (TLR-L) or thymic stromal lymphopoietin 
(TSLP) (Encabo et al., 2004) or IL-4 (Yi and Kwak, 2005) or TNF alpha (Tosi et al., 
2004). The monocytes may, particularly in the setting of inflammation, become MDDC 
that have DC-like phenotype (CD11c+MHCIIhi) and/or DC-like functions (ex. ability to 
stimulate naive T cells or cross present antigens to T cells) (Geissmann et al., 2003; 
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Fahlen-Yrlid et al., 2009). The differentiation of monocytes to DC may be affected by 
inflammatory mediators in the local environment (Serbina et al., 2008).  
1.9 Bovine Monocyte-derived DC (MDDC): 
The most common procedure to generate DC is culturing blood monocytes in the 
presence of GM-CSF and IL-4 (Romani et al., 1994). The bovine MDDC express 
moderate to high levels of the co-stimulatory molecules (CD80/86), DEC 205 and MHC 
class II molecules. MDDC have a down regulated expression of the myeloid cell 
differentiation molecule CD14 as compare to monocytes and macrophages(Beekhuizen 
et al. 1991; Bajer,Mahke et al., 2000; Garcia-Tapia et al., 2003;Flores-Mendoza et 
al., 2012). 
1.10 Autophagy an important component of antigen presentation and innate immunity: 
Autophagy is a cellular process where cytoplasmic components are sequestered 
and recycled to maintain cellular homeostasis (Mizushima, 2007). It is a normal 
physiological mechanism for the degradation of proteins and organelles. Regulation of 
autophagy is necessary to maintain metabolic equilibrium and immune homeostasis. 
Reduced autophagy is associated with  cancer, neurodegeneration, and infectious diseases 
(Heath and Xavier, 2009).  
Autophagy acts as an innate immunity effector against intracellular bacteria and 
viruses (Gutierrez et al., 2004; Nakagawa et al., 2004) including herpes simplex virus-1 
(Orvedahlet al.,2007) and vesicular stomatitis virus (Shelly et al., 2009). Autophagy can 
be induced by interferon-gamma (Inbal et al., 2002; Gutierrez et al., 2004, Dengjel et 
al., 2005; Paludan et al., 2005). The autophagy is induced by various toll-like receptors 
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(TLR), nucleotide-binding oligomerization domain (NOD)-like receptors, retinoic acid-
inducible gene I (RIG-I)-like receptors, damage associated molecular patterns such as 
high-mobility group box 1 (HMGB1) protein (Deretic, 2011).  The autophagy is induced 
by LPS through a Toll-interleukin-1 receptor domain containing adaptor inducing 
interferon beta (TRIF) dependent, myeloid differentiation factor 88 (MyD88) 
independent TLR4 signaling pathway(Xu et al., 2007).   
The discovery of autophagy genes and its signaling pathways allowed the 
identification of the machinery involved in autophagosome formation, fusion, and 
degradation (Klionsky and Emr, 2000; Huang and Klionsky, 2002).. The positive-
stranded RNA viruses such as poliovirus and coxsackie virus (Jackson et al., 2005; 
Wong et al., 2008), the viruses from Flaviviridae family like hepatitis C virus (HCV) 
(Dreux and Chisari, 2009), and dengue virus (DENV) exploit autophagy for their 
efficient replication  (Lee et al., 2008; Panyasrivanit, Khakpoor et al., 2009; Heaton et 
al., 2010). The NS5A and NS5B proteins of HCV co-localize with autophagosomes with 
increased viral replication indicating that HCV replicates in autophagosomes and up 
regulates of autophagy to facilitate HCV replication (Sir et al., 2012)  
There has been little work done to examine the role of BVDV with autophagy. An 
interesting finding was that a cp BVDV isolated from an animal died due to mucosal 
disease contained an insertion of cellular mRNA coding for light chain 3 (LC3), an 
autophagy marker (Kuma et al., 2007).. This finding indicated a possible role for BVDV 
replication with the autophagy machinery (Fricke et al., 2004). 
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SUMMARY 
BVDV infection is associated with immunosuppression and increases the risk of 
secondary infections. An antigen-specific immune response is mounted by activation of 
the well-controlled T cell response via APC. APC process and present antigen to T cell 
through MHC molecules. The interaction of MHC-peptide complex with T cell receptor 
along with co-stimulation confers specific immune response.  The co-stimulatory signal 
is induced by interaction of co-stimulatory molecules (CD80/86) on APC with CD28 on 
T cell. Lack of co-stimulation leads to anergy or apoptosis of reactive T cells. BVDV 
infects a wide variety of cell types and has a predilection for cells of the immune system 
including antigen-presenting cells like monocytes that develop into DC. DC are the most 
important APC that activate naïve T cells.  It is hypothesized that the virus infection of  
DC may interfere with surface marker expression, antigen presentation and T-cell 
activation. Interference with DC activity may be one of the causes of BVDV 
immunosuppression. The infected DC may also potentially play an important role in 
dissemination of the virus . it is difficult to study DC in situ is difficult without affecting 
their viability and phenotypic characteristics. As an in vitro DC model, DC can be 
differentiated from their monocyte precursor into monocyte-derived dendritic cells 
(MDDC). In the current study, a reproducible method to differentiate large number of 
MDDC was optimized. MDDC were used as in vitro model to DC to investigate effect of 
BVDV with different virulence levels and biotypes, on MHCI, MHCII and CD86 
expression. The ability of BVDV-infected MDDC to maintain and produce infectious 
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BVDV was studied to determine a possible role for DC in dissemination of BVDV 
infection. 
In the current study, the role of BVDV on autophagy induction and use of 
autophagy machinery for its effective replication was investigated. Finally this study also 
studied the primary in vivo humoral antibody response against cytopathic or 
noncytopathic BVDV infection was investigated.  
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CHAPTER 2. 
RESTRICTED REPLICATION OF BVDV IN BOVINE MONOCYTE-
DERIVED DENDRITIC CELLS 
ABSTRACT 
Bovine viral diarrhea virus (BVDV) is one of the most economically important 
diseases of ruminants. Dendritic cells (DC) are important antigen presenting cells and are 
present in skin or mucosal surfaces for active surveillance of the antigens. The immature 
DC are highly phagocytic cells that capture, process and present antigen to T cell in 
secondary lymphoid organs. Tissue-resident DC that migrate from peripheral sites to 
lymphoid organs are essential in the initiation of adaptive immune response and for the 
maintenance of peripheral tolerance.  The BVDV-infected DC may play an important 
role in BVDV dissemination in the body. In this chapter, bovine monocytes were cultured 
with bovine recombinant GM-CSF (100ng/ml) and IL-4 (200ng/ml). Over a period of 5-7 
days in culture, the monocytes differentiated into monocyte-derived dendritic cells 
(MDDC). The MDDC had morphological and phonotypical characteristics similar to 
classical dendritic cells. The MDDC were positive for MHCI, MHCII, DEC205 and 
CD86 and negative for CD21 and CD14. During differentiation of MDDC, it was found 
that monocytes from Brown Swiss calves had higher capability to differentiate MDDC 
than the monocytes from Holstein Friesian calves. It was found that 20-30% isolated 
monocytes from Brown Swiss calves e differentiated in MDDC while only 5-10% 
monocytes isolated from Holstein Friesian differentiated in to MDDC. Further, the ability 
of BVDV to replicate in bovine monocyte-derived dendritic cells (MDDC) or its 
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progenitors (monocytes or intermediate MDDC) was investigated. MDDC were 
differentiated from blood monocytes by in vitro culturing. Over a period of 5-7 days in 
culture, the monocytes differentiated into MDDC. The culture, which depending on time 
point was made up of fully differentiated MDDC, monocytes or intermediate stages of 
MDDC were infected with BVDV at 2, 3, 4 or 5 days of culture were infected with 
BVDV. Four strains of BVDV were used in this study: the high virulent BVDV2a- 1373, 
typical virulent BVDV2a-28508-5, and a virus pair, cytopathic (cp) BVDV1b-TGAC and 
noncytopathic (ncp) BVDV1b-TGAN recovered from an animal that died of mucosal 
disease. The cells were infected at a multiplicity of infection (MOI) of 6 with each of the 
viruses. The supernatant and cells were harvested at regular intervals for up to 192 hr p.i. 
The Virus titer was determined by virus isolation and viral RNA using qRTPCR in cell 
lysate at each time point. The results showed no virus in MDDC and MDDC supernatant 
following BVDV infection while viral RNA increased in MDDC through 144 hr after 
infection. The kinetics of viral RNA production along with the amount of viral RNA was 
significantly different between the different viral strains. The lowest amount of cell 
associated viral RNA was observed in MDDC infected with the ncpBVDV2a-28508-5 
strain of BVDV while maximum viral RNA accumulated occurred in the MDCC infected 
with the high virulent BVDV2a-1373 strain or cp BVDV1b-TGAC strain of BVDV. 
Virus replication was then compared between MDDC and monocytes. The monocytes 
supported the production of infectious virus. The peak virus titer for all 4 strains in 
monocytes was observed at 72 hr p.i. although the amount of virus varied by strain. The 
intermediate stage of MDDC produced viral RNA up to 4 days (96 hr) after infection. 
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The titer of infectious virus decreased with MDDC differentiation and completely 
stopped at 5 days (120 hr) of differentiation. These findings suggested the ability of 
MDDC to produce infectious virus reduced with MDDC differentiation and was 
completely lost in fully developed MDDC. 
INTRODUCTION 
Since the first discovery of BVDV in the 1940s, it has been an important disease 
in ruminants around the world. The economic importance of BVDV is increasing with the 
emergence of seemingly more virulent viruses, as evidenced by outbreaks of hemorrhagic 
syndrome and severe acute bovine viral diarrhea beginning in the 1980s and 1990s 
(Goens, 2002). The genetic diversity between different strains of BVDV classified the 
BVDV in two genotypes on the basis of highly conserved 5’UTR region. These two 
groups are BVDV Type I and BVDV Type II (Ridpath, 2003).  The survey report 
indicated that three subgenotypes, BVDV-1a, BVDV-1b, and BVDV-2a are commonly 
circulating in the United States. (Ridpath et al., 2011). BVDV is capable of a wide 
spectrum of disease and clinical symptoms. The severity of the disease can range from 
mild acute infection to severe infection depending up on both on the virulence of the 
strain and the state of the infected host. BVDV infection can be manifested clinically as 
acute infection, severe acute infection, chronic infection, congenital infection, persistent 
infection or mucosal disease (Pritchard, 1963; Brownlie, 1990; Moennig and Liess, 
1995; Peterhans et al., 2010). BVDV is an important immunosuppressant viral disease. 
The level of suppression of the adaptive immune response is strain dependent (Chase, 
2013). The ncp BVDV evades the immune system of pregnant dam and establishes a 
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persistent infection (PI) in the fetus during 40-120 days of gestation (Chase et al., 2004). 
PI calves are immunotolerant and remain a source of infection to other animals. 
Superinfection of PI animals with antigenically homologous cp BVDV strain results in 
fatal mucosal disease (Brownlie et al., 1984).  
Dendritic cells (DC) are important antigen presenting cells (APC) that play a 
crucial role in mounting the immune response. DC provide active surveillance to monitor 
invading pathogens and present it to the immune system. After engulfing the pathogen, 
the DC migrate from peripheral sites to lymphoid organs to initiate the adaptive immune 
response. The infected DC may play an important role in the dissemination of BVDV in 
the body and facilitate in the establishment of infection. DC are susceptible to various 
pathogens including BVDV. BVDV infected DC may have altered cell surface marker 
expression that are necessary to mount the effective immune response. Altered cell 
surface marker may facilitate the establishment of persistent infection. DC infection with 
cp strain of BVDV does not show CPE (cytopathic effect). The presence of BVDV viral 
protein in DC indicated that BVDV replicate in MDDC (Glew et al., 2003).   
In this study, we optimized a simple, reproducible culture system that allows 
monocytes to mature and differentiate into MDDC with high yield and viability. The cells 
generated were confirmed as DC by morphological and phenotypical characteristics and 
investigated the ability of BVDV to replicate in the various stages of MDDC from 
monocyte to fully differentiated MDDC. Four strains of BVDV were used in this study 
including the high virulent BVDV2a-1373, typical virulent BVDV2a-28508-5, and a 
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virus pair cytopathic (cp) BVDV1b-TGAC and noncytopathic (ncp) BVDV1b-TGAN 
recovered from an animal that died of mucosal disease. 
MATERIALS AND METHODS 
Animals 
Eighteen (18) Holstein Friesian and six (6) Brown Swiss female calves (8-12 
months of age) housed at Dairy Farm, South Dakota State University (SDSU), 
Brookings, SD, USA were used in this study. All animals were healthy. The SDSU 
Institutional Animal Care and Use Committee approved animal handling and blood 
collection. 
Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were isolated as per method 
previously described (Ulmer et al., 1984) and differentiated into MDDC (Mwangi et al., 
2005) with following modifications; 2-mercaptoethanol, 2 mM GlutaMax and 25 mM 
HEPES were replaced with 1mM sodium pyruvate (personal communication, Dr 
Waithaka Mwangi, Texas A&M University, USA) and the medium used for MDDC 
differentiation was RPMI-1640 medium supplemented with 20% FBS, 1mM sodium 
pyruvate, penicillin (100 U/ml), streptomycin (100μg/ml), bovine recombinant 
granulocyte macrophage-colony stimulating factor (GM-CSF (100ng/ml) and IL-4 
(200ng/ml). In the previous method fresh, complete RPMI-1640 medium and cytokines 
was added at every 3
rd
 day while in current study 750 µl fresh, complete RPMI-1640 
medium with cytokines was added every 2
nd
 day (every other day).  The addition of 
sodium pyruvate and increasing the concentration of FBS from 10% to 20% improved the 
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differentiation of MDDC.  The beneficial effect of sodium pyruvate may be due to its 
protective effect to nutrients in media and providing energy to the cell (Giandomenico et 
al., 1997). 
Briefly, sixty (60) ml of heparinized venous blood was collected from healthy 
calves. The buffy coat layers were separated by centrifuging the blood at 1100g for 30 
minutes at 4°C. The cells from buffy coat layer were suspended into heparinized (10 
U/ml) PBS in 1:3 ratio. The diluted cells were overlaid on 3ml, 65% Percoll (GE 
Healthcare Biosciences, Pittsburgh, PA, USA) in 15 ml conical tubes (Falcon, Oxnard, 
CA, USA) and centrifuged for 30 min, at 1100g at 4°C. The white cell layer of PBMC 
was aspirated by pipette from the interphase. The collected PBMC were suspended in 
heparinized PBS (10 U/ml) and pelleted by centrifugation at 1700 rpm for 15 min at 4°C. 
The PBMC were washed two times by suspending them in PBS and centrifugation at 
1700 rpm for 15 min at 4°C. Finally, PBMC were suspended in RPMI 1640 medium 
supplemented with 10% FBS, 1mM sodium pyruvate, penicillin (100 U/ml) and 
streptomycin (100μg/ml) to achieve final concentration of 1x 10
7
cells/ ml. Three (3) ml 
of the cell suspension was added to each well of a 6-well plate (Falcon, Oxnard, CA, 
USA) and incubated at 37°C in a humidified CO2 incubator for 3 hr. 
Separation of adherent monocytes 
The monocytes were isolated by the plastic adhesion method (Mwangi et al., 
2005). The PBMC were cultured in 6-well plates for 3 hr at 37°C in a humidified CO2 
incubator. The unattached cells were discarded and plates were washed 4 times with PBS. 
The attached cells were detached with Accuatase (eBioscience, San Diego, CA, USA). 
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Detached cells were washed two times by suspending them in PBS and centrifugation at 
500g for 15 min at 4°C.  
Monocyte-derived dendritic cell (MDDC) culture 
The accuatase-detached cells were characterized as MHCI
+
 MHCII
+ 
and CD14
+ 
monocytes based on flow cytometer analysis done on a FACScan (Becton-Dickson, 
Mountain View, CA) using MHC-I (H58A), MHC-II (H42A), CD21 (BAQ15A) 
andCD14 (MM61A) primary antibodies (VMRD Inc., Pullman, WA, USA). The 
harvested CD14+ monocytes were counted and the yield determined. The monocytes 
were differentiated into monocyte-derived dendritic cells (MDDC) (Mwangi et al., 2005) 
with some modifications as described above. Briefly, the monocytes were diluted in 
RPMI 1640 medium supplemented with 20% FBS, 1mM sodium pyruvate, penicillin 
(100 U/ml), streptomycin (100 μg/ml), bovine recombinant GM-CSF (100 ng/ml) and IL-
4 (200 ng/ml) kindly provided by Dr. Waithaka Mwangi (Texas A&M University, USA) 
to achieve the final concentration of 5x10
5
cells/ml. Three (3) ml of this cell suspension 
was added to each well in 6-well plates. The cells were incubated at 37°C in a humidified 
CO2 incubator for 7 days. Seven hundred and fifty µl (750 µl) of RPMI 1640 medium 
supplemented with 20% FBS, 1mM sodium pyruvate, penicillin (100 U/ml), 
streptomycin (100μg/ml), bovine recombinant GM-CSF (100 ng/ml) and IL-4 (200 
ng/ml) was added to each well at alternate day. At day seven, differentiated cells were 
collected and examined for morphological and phenotypical characteristics. The MDDC 
were either loosely attached or floating. The viability of loosely attached or floating 
MDDC was determined by trypan blue exclusion assayThe trypan blue exclusion assay 
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was done to determine the cell viability by staining the MDDC with 0.4% trypan blue 
stain (Strober , 2001). Briefly, the 500 µl MDDC aliquots of cell suspensions from 6-
well plates was centrifuged at 200g for 2 minutes in 1.5 ml tubes and cell pellet was 
suspended in 200 µl PBS.   Two hundred (200) µl of 0.4% trypan blue was added to the 
cell suspension. The cells were incubated for 3-4 minutes at room temperature and 
examined under microscope. A total 100 cells were examined. The non-stained viable 
cells were counted and cell viability was calculated using the following formula: 
Cell viability percentage = Number of viable cells (none trypan blue stained cells) cells X   
100/Total counted cells. 
Characterization of MDDC 
Morphological characterization 
The cells were examined at day 1, 4 and 7 days of incubation using an inverted 
compound microscope at 40x (Olympus, PA, USA) to determine morphological changes.  
Cells were examined for changes in size and shape and dendrites formation. 
Photomicrographs were taken at each time point.  The percentage differentiation of 
monocytes to MDDC was determined at day 7 of culture. During differentiation, cells 
were also considered for their animal source (Brown Swiss and Holstein Friesian) to 
determine the effect of breed on MDDC differentiation.  
Phenotypic characterization using flow cytometry. 
For flow cytometry analysis, monocytes or the differentiated MDDC were 
collected by removing the media containing the cells from the 6-well plates by gentle 
mixing and aspiration. After collection, the cell suspension was centrifuged for 10 min at 
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200g and washed 1x with PBS. Cell number was adjusted to 1x10
6
/ml. Six primary 
mouse mAb antibodies for MHC-I (H58A), MHC-II (H42A), CD86 (IL-A190A), CD21 
(BAQ15A) andCD14 (MM61A)(VMRD Inc., Pullman, WA, USA) and DEC205 (Kindly 
provided by Dr. Waithaka Mwangi, Texas A&M University, USA) were used to 
characterize the cells. The primary antibodies were diluted 1:100 in PBS containing 1% 
FBS.  The 100 µl of cells suspension was incubated with 50µl of diluted primary 
antibodies at 4°C for 10 min followed by washing by centrifugation at 200g for 4 minutes 
at 4 °C in round bottom 96 well plates. After centrifugation cell pallet was suspending 
them in 200 µl  PBS. After primary staining and washing, cells were incubated  with 50 
µl FITC labeled anti-mouse secondary antibody (VMRD Inc., Pullman, WA, USA)  
which was diluted 1:1000 dilution in PBS containing 1% FBS at 4°C for 10 min. After 
incubation with secondary antibody, cells were washed two times with PBS. Cells were 
suspended for in 200 µl of 1% paraformaldehyde for fixing. The cells fixed in1% 
paraformaldehyde analyzed using FACScan (Becton-Dickson, Mountain View, CA). At 
least 20,000 cells were run at each time points and each experiment was repeated at least 
3 times.  
Virus: 
The four BVDV strains were used in this study included a pair of cp/ncp 
BVDV1b viruses, Tifton GeorgiA Cytopathic (BVDV1b-TGAC) and Tifton GeorgiA 
Non-cytopathic (BVDV1b-TGAN) and recovered from an animal that died of mucosal 
Disease (Brownlie et al., 1984; Fritzemeier et al., 1995; Ridpath et al., 1991), A high 
virulence noncytopathic strain from the BVDV2 species (BVDV2a-1373) isolated 
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following an outbreak of peracute BVDV (Carman et al., 1998; Stoffregen et al., 2000) 
and the typical virulence noncytopathic virus from the BVDV2 species isolated from an 
asymptomatic persistently infected calf (BVDV2a-28508-5) (Liebler-Tenorio et al., 
2003) (Table 2-1). 
 Five (5) ml of 5x10
5
 MDBK cells/ml were seeded in T25 flasks and culture were 
grown to 60-70% confluency at the time of inoculation with virus.  At the time of 
inoculation, the media was removed and 0.75 ml of virus inoculum with a multiplicity of 
infection [MOI] of one was added to each T25 flask. Virus was adsorbed for 1 hr at 37°C 
in a humidified CO2 incubator. After one (1) hr incubation, inoculum was removed and 
the cells were washed with sterile PBS. After washing, 5 ml of media was added to each 
flask. The cells were incubated at 37°C in a humidified CO2 incubator for 4-5 days for 
cultures infected with noncytopathic virus or or 70-80% cytopathic effect forcultures 
infected with cytopathic virus, TGAC. Cultures were harvested by two freeze thaw 
cycles. After 4-5 days for cultures infected with noncytopathic virus orof incubation cells 
were freezed at (-80˚C for 15 minutes followed by thawing at 25˚C).. The cell debris was 
pelleted by centrifugation at 1200g for 10 min at 4°C. The virus in the resulting 
supernatants was titrated and the supernatants were, aliquoted and stored at -80 °C for 
further use.  
The virus titration was determined by Reed and Munech method (Reed and Munech, 
1938). Briefly MDBK cells were detached from tissue culture flask. The number of cells 
was adjusted to 5x10
5
 cells/ ml.  One hundred eighty (180) µl cell suspensions was added 
to each well of 96-well plate. Twenty (20) µl of virus was added to the first row of the 
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plate. The virus was mixed with MDBK cells and 20 µl of this dilution was added to next 
row to achieve 10 fold dilutions. No virus was added to the last two rows of wells. These 
wells served as negative controls. The four replicates of each dilution was performed to 
determine the virus titer. The plate was incubated at 37 °C at humidified incubator for 
next 4 days. The plate was examined every day for cytopathic effect (CPE) of the virus. 
The highest dilution showing CPE is used as end point to calculate the proportionate 
distance (PD). The PD was used to determine the viral concentration (TCID50) as per 
formula as described earlier (Reed and Munech, 1938). 
1. Proportionate distance (PD) = (% CPE at dilution above 50%) – (50%)/ (% CPE 
at dilution above 50%)- (% CPE at dilution below 50%) (e.g.  60-50/60-0= 0.166) 
2. Calculation of end point just next to 50% CPE and conversion into  – Log (e.g.10-
6
 dilution would be -6) 
3. Calculation of TCID50.  
4.  TCID50 for 20 µl= 
(PD+ - Log dilution above 50%)  
(e.g. 1x10
6.166
) 
For ncp BVDV, the same procedures with the exception of determining the end point 
since no CPE were produced.  The end point for ncp BVDV was determined by staining 
the MDBK cells with anti-BVDV antibody (IDEXX Laboratories, Westbrook, ME, USA) 
followed by biotinylated rabbit anti-mouse IgG (Zymed, Invitrogen Corporation,  
Frederick, MD, USA)  Steptavidin-HRP ( Invitrogen Corporation, Camarillo, CA, USA) 
and AEC reagent (3 amino-9 ethyl-carbazole) (Sigma-Aldrich, St. Louis, MO, USA). The 
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end point for ncp BVDV was determined by the presence of red stained cell showing 
BVDV protein.  
The Cooper strain of bovine herpesvirus 1 (BHV-1) was used as a positive control 
as it had been previously shown to infect and produce infectious virus in monocyte-
derived macrophages (MDM) (Elmowalid, 2003). 
Madin Darby bovine kidney (MDBK) cells: 
BVDV-free MDBK cells (passage 95-110) were grown in MEM (pH 7-7.4) 
supplemented with 10% BVDV free fetal calf serum (PPA, Pasching, Austria), penicillin 
(100 U /ml) and streptomycin (100 μg /ml).  MDBK cells were used for viral propagation 
and titration of BVDV and BHV-1. 
MDDC, MDBK cells or Monocyte infection:  
The fully differentiated MDDC were collected at 7 days of culture. The MDDC 
were centrifuged at 1700 rpm at 4°C for 15 min in 15 ml conical tubes and suspended in 
RPMI 1640 medium supplemented with 20% FBS, 1mM sodium pyruvate, penicillin 
(100 U /ml) and streptomycin (100 μg /ml), bovine recombinant GMCSF (100 ng/ml) and 
IL-4 (200 ng/ml) to achieve final concentration 5x10
5
/ml. One (1) ml of cell suspension 
was added to each well of 24-well plates and infected with virus at 6 MOI with one of 
BVDV strains.  Because the cells were in suspension, the inoculum was not removed 
from the MDDC. Mock-infected MDDC were used as controls. The BVDV infected 
MDDC and their supernatants were collected at 1 hr, 6 hr, 12 hr, 24 hr, 72 hr, 96 hr, 120 
hr, 144 hr, 168 hr or192 hr p.i. The MDBK cells produce infectious BVDV virus. 
Because of the permissive nature of MDBK cells for BVDV, the MDBK cells were used 
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as a positive control for BVDV growth at each time point. The MDBK cells were 
detached from tissue culture flask by 0.25% trypsin. The MDBK cells were adjusted at 
cells 5x10
5
 cells /ml. One (1) ml of cell suspension was added to each well of 24-well 
plates and MDBK cells were attached overnight. MDBK cells were infected with virus at 
6 MOI of infection with each one of the BVDV strains. Virus was adsorbed for 1 hr and 
non-adsorbed virus was removed by washing with PBS. MDBK cells were supplemented 
with MEM (pH 7-7.4) supplemented with 10% BVDV free fetal calf serum (PPA, 
Pasching, Austria), penicillin (100 U /ml) and streptomycin (100 μg /ml). The BVDV 
infected MDBK cells and their supernatants were collected at 1 hr, 6 hr, 12 hr, 24 hr, 72 
hr, 96hr, 120 hr, 144 hr, 168 hr or192 hr p.i as was done for MDDC.  
For monocyte infection, freshly collected monocytes were adjusted to 5 x10
5
 cells 
/ml in RPMI 1640 medium supplemented with 10% FBS, 1mM sodium pyruvate, 
penicillin (100 U /ml) and streptomycin (100 μg /ml). Monocytes were infected with one 
of the virus of BVDV at MOI of 6. Virus was adsorbed for 1 hr. The non adsorbed virus 
was removed by washing the monocytes with PBS. The monocytes were washed by 
suspending them in PBS and centrifugation at 1700 rpm for 15 min at 4°C. Finally 
monocytes were suspended in RPMI 1640 medium supplemented with 10% FBS, 1mM 
sodium pyruvate, penicillin (100 U /ml) and streptomycin (100 μg /ml) to achieve final 
concentration 5x10
5
 cell/ml. One ml of this cell suspension was added to each well of 24 
well plates.  The BVDV infected monocytes and their supernatants were collected at 1 hr, 
6 hr, 12 hr, 24 hr, 72 hr, 96 hr, 120 hr, 144 hr, 168 hr or192 hr p.i. 
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The BVDV titer in MDDC, monocytes or in MBBK cells and their supernatant 
was measured at each time points as per the method described above (Reed and 
Munech, 1938). The MDM (monocyte-derived macrophage) has been shown to be 
susceptible to BHV1 infection and produce infectious virus (Elmowalid, 2003). Because 
of the similar nature of MDM and MDDC, the Cooper strain of BHV1 was used as a 
positive virus control for MDDC infection. MDDC or MDBK cells were infected with 
Cooper strain of BHV1 with 6 MOI of infection. The BHV1 infected MDDC or MDBK 
cells and their supernatants were collected at 1 hr, 6 hr, 12 hr, 24 hr, 72 hr,  96 hr p.i. and 
titrated for virus production as per method described earlier (Reed and Munech, 1938). 
For infectious BVDV production studies in the intermediate stage of MDDC, 
MDDC were collected at 2 (48 hr), 3 (72 hr), 4 (96 hr) or 5 (120 hr) days of 
differentiation. The cells were infected with the 1373 strain of BVDV at 6 MOI of 
infection. The cells of intermediate stage of MDDC were collected at 24 hr or 48 hr p.i.  
for virus titration per method described earlier (Reed and Munech, 1938).  
UV inactivation of Virus:  
The current study revealed that BVDV infect and replicate viral RNA in MDDC 
but do not produce infectious virus. To validate the result for viral RNA replication, the 
UV inactivated 1373 strain of BVDV was used as negative control. The virus was UV 
inactivated as per method described earlier (Fortunato et al., 2000) with some 
modifications. Briefly, three (3) ml of 1373 (virus titer 7 log10/ml) strain of BVDV was 
placed in 5 ml glass beaker.  The virus was exposed to 302 nm wavelength UV 
irradiation (Ultra-Violet Products Inc, San Gabriel, CA, USA) for 15 minutes at a 
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distance of 2 mm. The sodium pyruvate (5 mM final concentration) was added to the 
inoculum immediately after irradiation. The inactivation of viruses was confirmed by 
immunohistochemistry (IHC) as described below. The MDBK cells were treated with 
UV-irradiated virus with equivalence to MOI of 6. The live high virulent BVDV2a-1373 
strain with same MOI was used as positive control. One (1) ml MDBK cell suspension 
(5x10
5
 cells/ml) was added to each well (4 wells) in 24-well plate. The MDBK cells were 
attached overnight at 37°C in a humidified CO2 incubator.  The MDBK cells were 
exposed to UV-treated virus or the live high virulent BVDV2a-1373 virus. The UV- 
treated or live virus was adsorbed for 1 hr at 37°C in a humidified CO2 incubator. After 
the 1 hr incubation, the inoculum was removed and cells were washed with sterile PBS. 
After the washing, 1 ml MEM medium supplemented with 10% FBS, penicillin (100 
U/ml) and streptomycin (100μg/ml) was added to each well. The cells were incubated at 
37°C in a humidified CO2 incubator for 4 days. After 4 days, cells were fixed with 20% 
acetone. The fixed cells were stained for presence of BVDV protein  using anti Erns 
BVDV antibody (Mab 15C5) (IDEXX Laboratories, Westbrook, ME, USA) followed by 
biotinylated rabbit anti mouse IgG (Zymed, Invitrogen Corporation,  Frederick, MD, 
USA)  Steptavidin-HRP ( Invitrogen Corporation, Camarillo, CA, USA) and AEC 
reagent (3 amino-9 ethyl-carbazole) (Sigma-Aldrich, St. Louis, MO, USA) (Baszler, 
Evermann et al. 1995).  AEC produced red color in MDBK cells infected with live 1373 
strain of BVDV but not in UV-treated virus, indicating UV irradiation inactivated the 
BVDV. 
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Viral RNA isolation and quantification through qRT-PCR in  BVDV-infected MDDC, 
monocytes or in MDBK cells: 
The differentiated MDDC, monocytes or MDBK cells were infected at a MOI of 
6 with one of the four BVDV viruses. The cells were collected at 1 hr, 6 hr, 12 hr, 24 hr, 
72 hr, 96 hr, 120 hr, 144 hr, 168 hr or 192 hr p.i. The cells were washed 3 times by 
centrifugation at 200g and suspending in sterilize PBS in 1.5 ml tubes at room 
temperature (25 °C). The cells were finally suspended in RNAase free water. The cells 
were lysed by freezing at -80 °C for 15 minutes and thawing at 4°C for 30 minutes. The 
cell lysate was centrifuged at 200g rpm at 25°C for 10 minutes. The supernatant of cell 
lysate was used to isolate the viral RNA using QIAamp Viral RNA Mini kit (Qiagen, 
Valencia, CA, USA).  
The quantification of viral RNA was done using qRTPCR (Stratagene MX3000P 
Real-Time Thermocycler (StratageneInc, La Jolla, USA) in 25µl reaction with FAM dye. 
The qRTPCR targeted the 5’ untranslated region of viral genome (5’UTR) using 
following primers (forward: 5-GGGNAGTCGTCARTGGTTCG-3; BVDV reverse: 5-
TGCCATGTACAGCAGAGWTTTT-3). These primers amplify a fragment of 
approximately 190 bases in both BVDV type I and BVDV type II (Mahlum et al., 2002). 
To compare the amount of viral RNA in samples at different time points, the standard 
curve was plotted using viral RNA of known concentrations. The virus with known titer 
(7 log10/ml) was serially diluted (spiked) as 1:10 in MDBK cells suspension (5x10
5
 cells/ 
ml) The Ct (critical) values (Figure 3-1) with known virus titers were used to plot the 
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standard curve (Figure 3-2). The standard curve was used to calculate the approximate 
virus concentration (virus equivalence) in the samples.  
Western blot: 
To find out whether viral RNA was translated into viral proteins, a Western blot 
was performed using BVDV infected MDDC lysate. The Western blot assay was done as 
described previously (Devireddy and Jones, 1999) with some modification. The MDDC 
were infected with ncpBVDV2a-1373 strain of BVDV at a MOI of 6 for 72 hr. After 72 
hr, MDDC were washed with PBS and lysed with 200 μl of RIPA buffer 
(Radioimmunoprecipitation assay buffer) containing complete ULTRA tablet containing 
protease inhibitor (Roch Diagnostic, GmbH, Sandhofen, Germany). The cell lysate were 
centrifuged at 13,000 rpm for 5 min and supernatant was collected.  A 40 μl of cell lysate 
was mixed with 5μl of 5x loading dye containing beta mercaptoethanol. The cell lysate 
was denatured by boiling at 100 ºC for 10 minutes. The samples were loaded in 12.5% 
sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS-PAGE) resolving get. 
The dual color protein ladder (10-250kD) (Bio-Rad, Hercules, CA, USA) was used as a 
standard.  The proteins were transferred onto a nitrocellulose membrane (Whatman 
GmbH,Hahnestraße, Germany). The nitrocellulose membrane was blocked by 5% skim 
milk in PBS for 30 minutes at room temperature. The membrane was incubated with anti-
BVDV NS5A rabbit polyclonal antibody at a dilution of 1:1000 in PBS containing 1% 
skim milk at 4 ºC overnight (anti-BVDV NS5A rabbit polyclonal antibody was kindly 
provided by Dr. Julia F Ridpath, Ruminant Diseases and Immunology Research Unit, 
National Animal Disease Center, USDA, Ames, IA, USA.) After primary antibody 
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incubation, the membrane was washed three times with PBS containing 0.5% Tween 20. 
The membranes were incubated with goat anti-rabbit- IRDye 800CW (LI-COR 
Biosciences, Lincoln, NE, USA) with 1:3000 dilutions in PBS containing 1% skim milk 
overnight. The specific protein band was visualized by using the Odyssey Imaging 
system and software (LI-COR Biosciences, Lincoln, NE, USA).  
Statistical analysis:  
The virus and viral RNA production in monocytes, MDDC and intermediate 
stages of MDDC were done at least in three different experiments. The variation in 
results was calculated by standard deviation at reach time points. The significance 
difference in virus production between different cell types was calculated with paired T 
test at 5% level of significance (Glantz, 2002). 
RESULTS 
MDDC yield, morphology and viability  
The PBMC yield from 60 ml of blood from the Brown Swiss calves was 
1.56±0.5110
8
 compared to 5.36±0.73x10
8
 PBMC from 60 ml of Holstein Friesian calf 
blood (Table 2-2).  Following incubation for 3 hr on 6-well plates, the adherent cells were 
harvested using Accutase (Figure 2-1, panels A & D). The harvested cells were 
confirmed as CD14+ monocytes.  A total 1.36±0.40x 10
7
 viable monocytes were 
obtained from 60 ml blood of Brown Swiss calves compared to 2.833±0.35x10
7
 viable 
monocytes, obtained from 60 ml blood of Holstein Friesian calves (Table 2-2). The 
monocytes were incubated in RPMI medium supplemented with cytokines for their 
differentiation to MDDC as described above. After 4 days of differentiation, the 
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monocytes developed dendrites. 24.59±13.74% of monocytes isolated from Brown Swiss 
exhibited development of dendrites (Figure 2-1, Panel B) while only 11.03±9.70 % of 
monocytes isolated from Holstein Friesian developed dendrites at day 4 of differentiation 
(Figure 1, Panel E). At 7 days of differentiation, monocytes became non-adherent and 
increased in size four to five times with long dendrites.. The monocytes that did not 
differentiate into MDDC, shrieked and appeared as debris. At day 7 of differentiation, 
monocytes isolated from Holstein Friesian had more debris (Figure 2-1, Panel C) 
compared to Brown Swiss (Figure 2-1, Panel F). The differentiated cells were collected 
by gentle pipetting and further characterized on the basis of morphology and phenotype. 
A total of 4.2±0.72x10
6 
MDDC/collection were harvested from the Brown Swiss calves 
while in a total of 1.96±2.91x10
6
 MDDC/collection were harvested from the Holstein 
Friesian (Table 2-2).  
The comparative study between Holstein Friesian and Brown Swiss indicated that 
Brown Swiss were able to differentiate superior to MDDC than Holstein Friesian. The 
monocytes were isolated from eighteen (18) Holstein Friesian and six (6) Brown Swiss 
calves. Out of the eighteen (18) Holstein Friesian calves used as monocyte donors to 
differentiate MDDC, one (1) Holstein Friesian calf differentiated higher MDDC in which 
25.93% monocytes differentiated to MDDC as compare to other Holstein Friesian calves 
in which 11.03±9.70% monocytes differentiated into MDDC. The 24.59±13.74% of the 
total monocytes isolated from the six (6) Brown Swiss calves differentiated into MDDC.  
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Phenotypic characterization of monocytes and MDDC 
At day 0 monocytes were positive for MHCI (96.62±0.50), MHCII (80.58±19.69) 
and CD14 (16.54±1.49) (Figure 2-2). After 7 days of differentiation, MDDC were stained 
for MHCI, MHCII, DEC 205, CD86, CD21 or CD14. These MDDC were positive for 
MHCI (98.58±0.34), MHCII (94.1±2.81), DEC205 (55.97±45.48) and CD86 
(77.83±17.83) while they are negative for CD21 (3.42± 0.19) and CD14 (1.025±0.45) 
(Figure 2-3). During 7 days of differentiation from monocyte to MDDC, the MHCI 
expression increased ~2.0% (96.62±0.50 to 98.58±0.34) and MHCII expression increased 
~17% (80.58±19.69 to 94.1±2.81) while expression of CD14 was significantly (p> 0.05) 
reduced ~94% (16.54±1.49 to 1.025±0.45) (Figure 2-2 and Figure 2-3). 
The Effect of BVDV infection on MDDC viability  
To determine the effect of BVDV infection on MDDC viability, MDDC were 
infected with cp BVDV1b-TGAC, ncp BVDV1b-TGAN, ncp BVDV2b-1373 or, ncp 
BVDV2b-28508-5 strains of BVDV. MDDC were collected at 1 hr, 6 hr, 12 hr, 24 hr, 48 
hr or 72 hr p.i. along with mock-infected control. The MDDC viability did not change 
significantly during the course of infection (Figure 2-4). The 100±00%, 99.33±1.15%, 
99.33±1.15% and 98.66±1.15% MDDC were viable after 1 hr of infection with ncp 
BVDV2a-1373, ncp BVDV2a-28508-5, cp BVDV1b-TGAC and ncpBVDV1b-TGAN 
respectively as compared to 99.33±1.15 % of mock-infected control MDDC (Figure 2-4). 
At 6 hr p.i., 97.33±1.15%, 97.33±1.15%, 98.00±00%, 96.66±1.15% MDDC were viable 
following infection with ncpBVDV2a-1373, ncpBVDV2a-28508-5, TGAC and TGAN 
strains of BVDV respectively as compared to 98.66±1.15% in mock-infected control 
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MDDC at that time point (Figure 2-4). Viability was still high at 12 hr p.i. with 
96.66±1.15%, 96.00±2%, 96.66±1.15%, and 95.33±2.309% MDDC following infection 
with ncpBVDV2a-1373, ncp BVDV2a-28508-5, cp BVDV1b-TGAC and ncp BVDV1b-
ncpTGAN strains respectively as compared to 97.33±1.15% in mock-infected control 
MDDC at 12 hr (Figure 2-4). 
At 24 hr p.i. with ncpBVDV2a-1373, ncp BVDV2a-28508-5, cp BVDV1b-TGAC 
or ncp BVDV1b-TGAN strains 96.00±2.30%, 96.66±2.30%, 96.00±1.15%, and 
94.66±1.15% MDDC respectively were viable as compared to 97.33±1.15% of mock-
infected control MDDC at 24 hr (Figure 2-4). The 96.00±3.4%, 96.66±2.30%, 
94.00±3.46% and 94.66±1.15% MDDC were viable after 48 hr p.i. with ncpBVDV2a-
1373, ncpBVDV2a-28508-5, ncpBVDV1b-TGAC and ncpBVDV1b-TGAN strains of 
BVDV respectively as compared to 96.66±1.15% in mock-infected control MDDC at that 
time point. The 94.66±3.055%, 94±2%, 94±3.46% and 94±2 % cells were viable 72 hr 
p.i. with ncpBVDV2a 1373, ncpBVDV2a 28508-5, cpBVDV1b TGAC or ncpBVDV1b-
TGAN infection respectively as compared to 96.66±1.15% viability in mock-infected 
MDDC (Figures 2-4 and Table 2-3). During this period MDDC infected with cp TGAC 
strain of BVDV didn’t produce any cytopathic effect (Figure 2-5).  
Infectious BVDV production in MDDC, Monocytes or in MDBK cells:  
The purpose of this experiment was to investigate whether MDDC supported 
BVDV replication and to compare BVDV virus production in MDDC with BVDV virus 
production in monocytes or in MDBK cells. The BVDV virus production was measured 
at 1hr, 6 hr, 12hr, 24 hr, 48hr, 72 hr or 96 hr p.i. BVDV-infected MDBK cells were used 
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as a positive BVDV replication control at each time point. There was no infectious 
BVDV produced by MDDC at any time point from 1 hr to 96 hr p.i. The inoculum virus 
of MDDC declined from 5.698 log 10/ml to zero within 96 hr p.i. in all BVDV strains 
used in the study (Figures 2-8, 2-9, 2-10, 2-11).  
The MDDC infected with cp BVDV1b-TGAC strain of BVDV did not produced 
any infectious virus while its precursor, monocyte became infected and produced 
infectious virus as early as 24 hr p.i. Monocytes produced the cp BVDV1b-TGAC strain 
at a titer of 2.70±00 log 10/ ml at 24 hr p.i.  The supernatant of monocyte had a virus titer 
of 3.20±0.70 log 10/ml at same time point (24 hr p.i.). The virus titer of cp BVDV1b-
TGAC strain in monocytes peaked at 4.698±00 log10/ml at 72 hr p.i. and declined to 
4.198±0.70 log10/ml at 96 hr p.i. The virus titer of cp BVDV1b-TGAC in monocyte 
supernatant reached its peak at 4.698±00 log10/ml at 48 hr p.i. and maintained this titer 
up to 96 hr p.i.  
The virus production of cp BVDV1b-TGAC stains in MDBK cell started as early 
as 12 hr p.i., which was 12 hr earlier than in monocytes. At 12 hr p.i., MDBK cells had a 
virus titer of 2.70±00 log 10/ ml that peaked at 72 hr p.i. as 6.20±0.70 log 10/ ml and 
maintained same up to 96 hr p.i. The production of cp BVDV1b-TGAC in MDBK 
supernatant began at 24 hr p.i. with a titer of 4.20± 0.70 log10/ml and peaked at 6.70± 
0.00 log10/ml at 96 hr p.i. (Figure 2-8).  
Similar to its homologues, the infectious virus of ncp BVDV1b TGAN strain of 
BVDV was not produced by MDDC while monocytes produced ncp BVDV1b-TGAN. In 
monocytes, the ncp BVDV1b-TGAN virus was detected as early as 24 hr p.i. as 2.20± 
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0.70 log 10/ml that increased and reached to its peak at 72 hr p.i. as 4.70 ± 0. 0 log 10/ml 
and declined at 96 hr p.i. (4.20 ± 0.70 log 10/ml) in monocytes. The infectious ncp 
BVDV1b-TGAN released in monocyte supernatant as early as 24 hr p.i. At 24 hr p.i. ncp 
BVDV1b-TGAN titer was detected as 3.20± 0.70 log 10/ml that reached to its peak as 
4.70± 0.00 log 10/ml at 48 hr p.i. and maintained it up to 96 hr p.i. (Figure 2-9)  
In MDBK cells the ncp BVDV1b-TGAN virus was detected as early as 12 hr p.i. 
with titer of 2.7-± 0.00log 10/ml and reached to its peak at 96 hr p.i. (6.20± 0.70 log 
10/ml). In MDBK cell supernatant, the ncp BVDV1b-TGAN virus was detected as early 
as 12 hr p.i. with titer of 0.85±1.2 log10/ ml and reached to its peak at 96 hr p.i. as 
6.70±00 log 10/ml (Figure 2-9).  
The MDDC also not supported the production of typical virulent ncpBVDV2a-
28508-5 strain of BVDV while monocytes start producing ncpBVDV2a 28508-5 as early 
as 24 hr p.i. The monocyte and its supernatant revealed the titer of ncpBVDV2a-28508-5 
as 1.70±00 log10/ ml and 2.20±71 log10/ ml respectively at 24 hr p.i. The virus titer of 
ncpBVDV2a-28508-5 reached to its peak in monocytes and its supernatant as 2.70±00 
log10/ ml and 5.70±00 log10/ ml at 72 hr p.i. than declined at 96 hr p.i. as 2.20±0.70 
log10/ ml and 4.70±00 log10/ ml respectively (Figure 2-10). 
The MDBK cells start producing ncpBVDV2a-28508-5 as early as 24 hr p.i. that 
was 12 hr later than any other viral strains used in the study. The virus titer of 
ncpBVDV2a-28508-5 was observed in MDBK cells as 1.35±1.9 log10/ ml at 24 hr p.i. 
The virus titer of ncpBVDV2a-28508-5 increased and reached to its peak, in both MDBK 
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cells and its supernatant at 96 hr p.i. as 6.70±00 log10/ ml and 6.70±70 log10/ ml 
respectively (Figure 2-10).  
The MDDC infected with high virulent ncpBVDV2a-1373 strain of BVDV did 
not produce any infectious virus while its precursor, monocyte became infected and 
produced infectious virus. The monocytes start producing ncpBVDV2a-1373 strain of 
BVDV at 24 hr p.i. The titer of ncpBVDV2a-1373 strain of BVDV in monocytes 
revealed as 2.20± 0.70 log 10/ml at 24 hr p.i. while titer of ncpBVDV2a-1373 strain of 
BVDV in supernatant of monocytes was found as 2.70 ±00 log 10/ ml at 24 hr p.i. The 
titer of ncpBVDV2a-373 strain of BVDV reached to peak as 3.70±00 log 10/ ml at 48 hr 
p.i. in both monocytes and its supernatant and maintained up to 72 hr p.i. than declined in 
monocytes as 2.70±00 log 10/ ml at 96 hr p.i. (Figure 2-11).  
The ncpBVDV2a-1373 strain start producing infectious virus in MDBK cells 12 
hr earlier than monocytes. The MDBK cells showed the ncpBVDV2a-1373 virus 
production at 12 hr p.i. with titer of 2.20± 0.70 log 10/ml while virus released in 
supernatant 12 hr later and detected as early as 24 hr p.i. with titer of 4.20± 0.70 log 
10/ml. The virus titer of ncpBVDV2a-1373 strain of BVDV reached to its peak in 
MDBK cells as 6.20± 0.70 log 10/ml at 72 hr p.i. that maintained up to 96 hr p.i. The 
peak titer of ncpBVDV2a-1373 strain of BVDV in MDBK cells supernatant was 
observed 12 hr later than its cell at 96 hr p.i. as 7.20±0.70 log 10/ml (Figure 2-11).  
BHV1 production in MDDC:  
The experiments described above established that BVDV was produced in 
monocytes (the precursor of MDDC) while fully differentiated MDDC did not supported 
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the production of infectious BVDV. To deterimine if this inhibition in MDDC was 
specific for BVDV or a generalized property of MDDC, the MDDC were infected with 
the Cooper strain of BHV1 and virus production determined. BHV1 was choosed as a 
positive control virus because earlier studies showed that MDM (monocyte-derived 
macrophage) supported BHV1 production while MDM did not produce any infectious 
BVDV following BVDV infection (Elmowalid, 2003).  
The MDDC were infected with the Cooper strain of BHV1 at a MOI of 6. After 1 
(one) hr adsorption, MDDC were washed three times by suspending them in PBS and 
centrifugation at 1700 rpm for 15 min at 4°C. Finally, MDDC were suspended in RPMI 
1640 medium supplemented with 10% FBS, 1mM sodium pyruvate, penicillin (100 
U/ml) and streptomycin (100 μg/ml) to achieve final concentration of 5x 10
5
cells/ ml.  
One ml of this cell suspension was added to each well of a 24-well plate. The cells from 
one well were collected at a time point. The cells and supernatant were collected at 1 hr, 
6 hr, 12 hr, 24 hr, 48 hr, 72 hr or 96 hr p.i. The cells were examined for their viability and 
BHV1 production. The cell viability was examined by trypan blue exclusion assay as 
described in chapter 2.   The cell viability was reduced following BHV1 infection from 
99.33±0.58% at 1 hr p.i. to 78.33±0.58% at 96 hr p.i. as compare to mock-infected 
MDDC as 99.66±0.577% at 1 hr to 94.33±0.577% at 96 hr p.i. (Table 2-4, Figure 2-12). 
The MDDC produced infectious BHV1 as early as 12 hr p.i. At 12 hr p.i., MDDC 
BHV1 virus titer was 2.03±0.58 log 10/ml while MDDC supernatant had a BHV1 titer as 
0.57±0.98 log 10/ml (Figure 2-13).The BHV1 titer increased during the course of 
infection and peaked at 48 hr p.i. in both cell and supernatant and maintained up to 96 hr 
86 
 
p.i. At 48 hr p.i., the MDDC BHV1 virus titer was 4.70±0.00 log 10/ml while MDDC 
supernatant had a BHV1 titer of 7.70±0.00 log 10/ml (Figure 2-13). The MDBK cells 
produced BHV1 as early as 6 hr p.i. The MDBK BHV1 titer was 6.36±0.58 log 10/ml at 
6 hr p.i. and increased to 7.70±0.00 log 10/ml at 12 hr p.i. and maintained this titer up to 
24 hr p.i.  The BHV1 titer declined in MDBK cells at 48 hr p.i. as 7.37±0.58 log 10/ml, at 
72 hr p.i. as 6.70±0.00 log 10/ml and 6.03±0.58 log 10/ml (Figure 2-13).  
BHV1 virus appeared in MDBK supernatant as early as 6 hr p.i. The BHV1 virus 
titer in MDBK supernatant was 5.03±0.58 log 10/ml at 6 hr p.i. and increased to 
7.70±0.00 log 10/ml at 12 hr p.i. (Figure 2-13). This level of virus was maintained up to 
72 hr p.i. The virus titer of BHV1 declined in MDBK cell supernatant at 96 hr p.i. to 
7.36±0.58 log 10/ml (Figure 2-13).  
The decline in BHV1 titer in MDBK cells within 24 hr p.i. was due to death of 
MDBK cells as there were no viable cells at 24 hr p.i. using trypan blue exclusion assay 
(data not shown).   
Replication of BVDV in intermediate stages of MDDC development: 
Since BVDV replicated in monocytes but not in monocyte-derived dendritic cell 
(MDDC), the stage of MDDC differentiation and its effect on BVDV replication was 
examined. The monocytes were cultured as described above for MDDC development. 
The cytokine-treated monocytes were harvested at 48 hr (2 days), 72 hr (3 days), 96 hr (4 
days) or 120 hr (5 days) of differentiation. These intermediate stages of MDDC were 
infected with BVDV ncpBVDV2a-1373 strain at a 6 MOI of infection. Cells were 
collected at 24 and 48 hr p.i. for each differentiated stage and just the cells were tested for 
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virus production. Virus titer was determined in intermediate stages of MDDC as 
described above. Virus production decreased with the length of time of differentiation. 
The intermediate stage of MDDC infected at 48 hr of differentiation produced virus with 
a titer of 3.70±00 log10/ml at 24 hr p.i. and the virus titer was reduced one log (2.70±00 
log10/ml) at 48 hr p.i.  The intermediate stage of MDDC infected at 72 hr of 
differentiation, produced virus with a titer of 2.20±0.71 log10/ml at 24 hr p.i. that was 
reduced to 1.70±00 log10/ml at 48 hr p.i. The intermediate stage of MDDC infected at 96 
hr of differentiation produced virus at a titer of 1.70±00 log10/ml at 24 hr p.i. that was 
reduced to 0.85±1.2 log10/ml at 48 hr p.i. The intermediate stage of MDDC infected at 
120 hr of differentiation did not produce any virus at either 24 hr p.i. or 48 hr p.i. (Figure 
2-14), indicating that MDDC loss the ability to produce virus between 96 and 120 hr of 
differentiation. Interestingly during this period from 96-120 hr of differentiation, when 
the cells lost the ability to produce infectious virus the MDDC showed significantly 
morphological changes. The MDDC increased 4-5 times in size and had extensive 
development of dendrites.  
Replication of BVDV viral RNA in MDDC or in MDBK cells: 
Since MDDC were unable to produce infectious BVDV, to determine whether 
BVDV replicates in MDDC, the MDDC were infected with 4 strains of BVDV including 
high virulent ncpBVDV2a-1373, typical virulent ncpBVDV2a-28508-5 strains of BVDV 
and a homologous pair of ncp and cp type viruses, ncpBVDV1b-TGAN and cpBVDV1b-
TGAC, recovered from an animal that died of mucosal disease.  
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Briefly, MDDC were infected with virus at 6 MOI of infection with one of BVDV 
strains. Cells were collected at 1 hr, 6 hr, 12 hr, 72 hr, 96 hr, 144 hr, 168 hr or 192 hr p.i. 
Cells were washed with PBS and viral RNA was extracted as described above. The 
MDBK cells infected with virus at 6 MOI with one of each of the BVDV strains was 
used as controls. The ncpBVDV2a-1373 strain of BVDV with known titer (7 log10/ml) 
was serially diluted as 1 in 10 in MDBK cells suspension. The viral RNA was extracted 
from known concentrated viruses and quantified using qRTPCR.  The Ct (critical) values 
with known virus titers were used to plot the standard curve. The standard curve was used 
to calculate the approximate virus concentration (virus equivalence) in the samples 
(Figure 2-6, Figure 2-7).  
Viral RNA was extracted from MDDC following BVDV infection and quantified 
to determine if any viral RNA replicated in the MDDC.  
The results indicated that the BVDV viral RNA replicated in MDDC. The kinetics 
of viral RNA production along with the amount of viral RNA was significant different 
between different viral strains.  
cp BVDV1b-TGAC strain viral RNA replicated in MDDC as early as 1 hr p.i. 
with virus equivalence 3.70±00 log10/ml. The TGAC viral RNA concentrations 
increased up to 144 hr p.i. and reach its peak at 7.20±0.71 log10/ml virus equivalence at 
144 hr p.i. The cp BVDV1b-TGAC viral RNA concentration declined at 168 hr and 192 
hr p.i. to 5.70±0.00 log10/ml virus equivalence and 4.70±0.71 log10/ml virus equivalence 
respectively. The MDBK cells also replicated TGAC viral RNA as early as 1 hr p.i. The 
cp BVDV1b-TGAC viral RNA in MDBK cells was 4.70±0.00 log10/ml virus 
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equivalence at 1 hr p.i. and was 7.70±0.00 log10/ml virus equivalence at 72 hr p.i. cp 
BVDV1b-TGAC viral RNA in MDBK cells start declining at 144 hr p.i. The cp 
BVDV1b-TGAC viral RNA in MDBK cells was 7.198±0.707 log10/ml virus equivalence 
at 144 hr p.i. and declined 6 logs to 0.5±0.70 log10/ml virus equivalence at 168 hr p.i. 
(Figure 2-15). 
The cp BVDV1b TGAC ncp homolog pair, ncp BVDV1b-TGAN started 
replicating viral RNA in MDDC 12 hr p.i. with RNA concentration as 3.70±0.00 
log10/ml virus equivalence. The ncpBVDV1b-TGAN viral concentration increased half 
log at 48 hr p.i. (4.20±0.71 log10/ml) and one log at 72 hr p.i. as 4.70±0.00 log10/ml 
virus equivalence that was maintained to 96 hr p.i. than declined one log at 144 hr p.i. as 
3.70±0.00 log10/ml virus equivalence. The The ncpBVDV1b-TGAN viral concentration 
further declined one log at 192 hr p.i. as detected as 3.70±0.00 log10/ml virus 
equivalence (Figure 2-16).  
In MDBK cell, the ncpBVDV1b-TGAN viral RNA was detected as early as at 1 
hr p.i. as 4.70±0.00 log10/ml virus equivalence. The The ncpBVDV1b-TGAN viral 
concentration increased with course of time and reached 5.20±0.71 log10/ml virus 
equivalence at 48 hr p.i. and 6.70±0.00 log10/ml virus equivalence at 72 hr p.i. and 
declined at 96 hr p.i. as 6.2-±0.71 log10/ml virus equivalence. The TGAN viral RNA 
further declined at 144 hr and 168 hr p.i. At 144 hr and 168 hr p.i. the TGAN viral RNA 
was 5.70±0.00 log10/ml and 3.70±0.00 log10/ml virus equivalence respectively (Figure 
2-16). 
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The typical virulent ncp BVDV2a-28508-5 strain of BVDV started replicating 
viral RNA in MDDC as early as 6 hr p.i. The 28508-5 viral RNA was detected at 
1.70±0.00 log10/ml virus equivalence at 6 hr p.i. that increased one log at 12 hr p.i. 
(2.70±0.00 log10/ml virus equivalence) and an additional log at 48 hrs p.i. (3.698±0.00 
log10/ml virus equivalence) and remain same at 72 hr p.i. The 28508-5 viral RNA 
concentration was maintained at 96 hr p.i. (3.70±0.00 log10/ml virus equivalence) while 
no ncp BVDV2a-28508-5 28508-5 viral RNA was detected after 144 hr in MDDC 
(Figure 2-17). 
The viral RNA of ncp BVDV2a-28508-5 was detected in MDBK cells as early as 
1 hr p.i. At 1 hr p.i.. The 28508-5 viral RNA was 2.70±0.00 log10/ml virus equivalence 
that increased one log to 3.70±0.00 log10/ml virus equivalence and maintained this level 
at 12 hr p.i. The ncp BVDV2a-28508-5 viral RNA increased approximate two logs from 
12 hr p.i. (3.70±0.00 log10/ml virus equivalence) to 48 hr p.i. (5.70±0.00 log10/ml virus 
equivalence) and one approximate log further at 72 hr p.i. (6.20±0.70 log10/ml virus 
equivalence) . The viral RNA concentration declined approximately three logs at 144 hr 
p.i. (3.70±0.00 log10/ml virus equivalence) and further one log at 168 hr p.i. (2.70±0.00 
log10/ml virus equivalence) (Figure 2-17). 
 The high virulent ncp BVDV2a-1373 strain of BVDV started replicating viral 
RNA at 24 hr p.i. (3.70±0.00 log10/ml virus equivalence) and reached 5.70±0.00 
log10/ml virus equivalence at 144 hr p.i. and declined one log (4.70±0.00 log10/ml virus 
equivalence)  at 192 hr p.i. (Figure 2-18). As compare to MDDC, the ncp BVDV2a-1373 
strain of BVDV started replicating viral RNA 23 hr earlier in MDBK cells. In MDBK 
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cells, the viral RNA of ncp BVDV2a-1373 strain of BVDV was detected at 1 hr p.i. 
(4.70±0.00 log10/ml virus equivalence) that increased during the course of infection and 
reached 6.70±0.00 log10/ml virus equivalence 48 hr p.i.  The viral RNA of the ncp 
BVDV2a-1373 strain of BVDV start declining in MDBK cells at 96 hr p.i. (6.20±0.70 
log10/ml virus equivalence) and declined to 5.70±0.00 log10/ml virus equivalence at 144 
hr p.i. and at 168 hr p.i.  and declined one log further at 192 hr p.i. (4.70±0.00 log10/ml 
virus equivalence) (Figure 2-18). Presence of viral RNA and its replication indicated that 
MDDC became infected with all viral strains of BVDV used in the study.  
BVDV viral RNA replication of 1373  in MDDC, in monocytes or in MDBK cells: 
Among the three cells types, the monocytes and MDBK cells began replicating 
viral RNA at 1 hr p.i. At 1 hr p.i. MDBK cell revealed highest viral RNA concentration 
as (4.70±0.00 log10/ml virus equivalence) that was approximately three (3) logs higher 
than viral RNA in monocytes at same time point (1.35±1.90 log10/ml virus equivalence). 
In monocytes, the viral RNA peaked at 24 hr p.i. as 5.20±0.70 log10/ml virus 
equivalence that was maintained up to 48 hr p.i. and declined approximately two logs at 
72 hr p.i. (3.70±1.41 log10/ml virus equivalence). The viral RNA in monocytes further 
reduced to 1.00±1.414 log10/ml virus equivalence at 96 hr p.i. while no viral RNA was 
detected in monocytes at 168 hr p.i. 
In MDBK cells, the viral RNA reached the peak at 48 hr p.i. at 6.70±0.00 
log10/ml virus equivalence. In MDBK cells, viral RNA began declining at 96 hr p.i. 
(6.20±0.70 log10/ml virus equivalence) and declined 2 logs to 4.70±0.00 log10/ml virus 
equivalence at 168 hr p.i. (Figure 2-19). In MDDC, the viral RNA start replicating at 24 
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hr p.i. (3.70±0.00 log10/ml virus equivalence) and declined at 192 hr p.i. with viral RNA 
as 4.70±0.00 log10/ml virus equivalence. 
This study indicated that BVDV viral RNA start replicating in monocytes and 
MDBK cell much earlier (1 hr p.i.) than MDDC (24 hr p.i.). The viral RNA in monocyte 
remained lower at all the time point as compared to MDBK cells. In monocytes the 
replication of viral RNA completely ceased by 168 hr p.i. These RNA findings were in 
agreement with the infectious virus production by monocytes and MDBK cells. MDBK 
cells produced more virus than monocytes at all time points (Figure 2-8, Figure 2-9, 
Figure 2-10 and Figure 2-11). BVDV viral replication in MDDC started later (24 hr p.i.) 
than monocytes and MDBK cells and viral RNA levels remained higher at 192 hr p.i. 
than in monocytes (Figure 2-19).  
Detection of UV inactivated 1373 strain of BVDV in MDDC: 
The UV inactivated ncpBVDV2a-1373 strain of BVDV did not replicate in 
MDDC. The Ct (critical value) of qRTPCR for BVDV RNA in MDDC infected with UV 
inactivated ncpBVDV2a-1373 strain of BVDV ranged from 35.37 to 36.81 from 1 hr p.i. 
to 96 hr p.i. [1 hr p.i.( 35.53), 6 hr p.i. (36.81), 12 hr p.i. (35.830, 24 hr p.i.(35.37), 72 hr 
p.i.(36.24) and 96 hr p.i. (36.29)]. These Ct values were near zero (0.0 TCID50/ml) as 
determined by the standard curve (Figure 2-6 and Figure 2-7). These results indicated that 
the input virus RNA alone did not produce Ct values with higher viral titers measured 
during the course of infection with the four strains of BVDV. 
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Presence of NS5A protein of BVDV in MDDC:  
The BVDV replicated viral RNA in MDDC but did not produce infectious virus. 
To determine whether viral RNA was translated into viral proteins, a Western blot was 
performed. The Western blot was carried out using ncpBVDV2a-1373-infected MDDC 
lysate. The MDDC were infected with ncpBVDV2a-1373 strain of BVDV. Infected 
MDDC were washed with cold PBS and lysed by RIPA buffer 
(Radioimmunoprecipitation assay buffer) containing protease inhibitor. MDDC lysate 
revealed the presence of NS5A viral protein with size of 56 kD (Figure 2-20), indicating 
that MDDC did produce viral proteins but do not release infectious virus. 
DISCUSSION 
The key findings of this chapter were the breed differences in the MDDC 
development and restricted ability of MDDC to produce infectious BVDV. All Brown 
Swiss calves used in the study produced higher numbers of MDDC as compared to 
Holstein Friesian. In case of Brown Swiss, 24.59±13.74% of the monocytes differentiated 
into MDDC while only 11.03±9.70% monocytes isolated from Holstein Friesian 
differentiated into MDDC. No cytopathic effect was noticed in MDDC infected with cp 
BVDV1b-TGAC. In previous study, cp BVDV on DC viability was observed in an in 
vivo trial in 2.5 to 7 month old Holstein Friesian PI calves. Super infection of these PI 
calves with cp BVDV did not affect the number or the morphology of dendritic cells in 
intestinal lymphoid follicles.  Interestingly these dendritic cells were surrounded by 
apoptotic lymphocytes, indicating that cp BVDV cause apoptosis in lymphocytes but not 
in DC (Teichmann et al., 2000).  
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The result revealed that MDDC became infected but did not support the 
production of infectious BVDV. The progenitor cell of the MDDC, the monocyte, 
became infected with BVDV and produced infectious virus while the intermediate stages 
of MDDC produced virus at levels that were proportional to the length of time they had 
been cultured to become MDDC. No infectious virus was produced in fully differentiated 
MDDC while viral RNA replicated in MDDC.  The kinetics of viral RNA production 
varied between the different viral strains in MDDC. The high virulent ncpBVDV2a-1373 
strain began replicating viral RNA later (24 hr p.i.) than other strains and accumulated 
viral RNA for longer duration (192 hr p.i.). The amount of viral RNA of ncpBVDV2a-
1373 strain of BVDV accumulated more in MDDC as compared to levels of viral RNA 
of ncpBVDV2a-28508 strain of BVDV. The typical virulent ncpBVDV2a-28508-5 strain 
began replicating viral RNA at an early stage of infection (6 hr p.i.) and viral replication 
declined at 96 hr p.i. while there was no viral RNA present by 120 hr unlike the three 
other strains where viral RNA could still be detected at 192 hr when the study ended. The 
replication of viral RNA of cp BVDV1b-TGAC strain began at 1 hr p.i. and peaked at 72 
hr p.i. and declined at 192 hr p.i. The ncp BVDV1b-TGAN strain of BVDV began 
replicating viral RNA in MDDC at 12 hr p.i. and reached its peak at 72 hr p.i. then began 
declining at 144 hr p.i.  
Among all strains used in the study, the cp BVDV1b-TGAC strain of BVDV start 
replicating viral RNA earlier than any of ncp BVDV strains. The cp TGAC strain of 
BVDV start replicating viral RNA at 1 hr p.i. The earlier study revealed that cp-
BVDV1b-TGAC significantly up regulate the MHCI and CD86 expression in MDDC at 
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1 hr p.i. The up regulation of MHCI and CD86 with cp BVDV1b-TGAC viral replication 
may be reason of effective immune response mounted by cp strain of BVDV in live 
modified vaccines. The cp BVDV1b-TGAC viral RNA replication showed a direct 
correlation with MHCI, MHCII and CD86 expression. The cp BVDV1b-TGAC viral 
RNA increased from 3.70±0.00 log10/ml virus equivalence at 1 hr p.i. to 5.70±0.00 
log10/ml virus equivalence at 72 hr p.i. During this period the expression of MHCI, 
MHCII and CD86 increased approximately 20% (133.51±11.88% to 158.17±52.43%) 
20% (119.16±9.33% to 156.83±54.48%) and 150% (111.40±3.55% to 261.22±162.00%) 
respectively as compare to time point control. Whereas the homologues ncp BVDV1b-
TGAN strain of BVDV showed indirect correlation between RNA replication and MHCI, 
MHCII and CD86 expression. The ncp BVDV1b-TGAN viral RNA increased from zero 
to 4.70±0.00 log10/ml virus equivalence within 72 hr p.i. During this period the 
expression of MHCI, MHCII and CD86 reduced approximately 15% (80.94±9.14% to 
64.15±9.62%) 10% (90.02.16±0.10% to 79.33±19.13%) and 25% (99.48±6.13% to 
72.64±1.38%) respectively as compare to time point control. The other ncp BVDV 
(BVDV2a-1373 and BVDV2a-28508-5) used in the study also showed the indirect 
correlation between RNA replication and MHCI, MHCII and CD86 expression. The 
difference in correlation may be due to differential effect of these biotypes in cell culture 
(Zhang et al., 1996) or, difference in induction of cytokines (Diderholm and Dinter 
1966; Adler et al., 1997) or may be due to their viral protein processing where cp BVDV 
strains cleave the NS23 viral protein into two proteins: NS2 (p54), and NS3 (p80) while it 
is not seen in ncp BVDV strains (Brownlie, 1990). 
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One of the issues in using PCR based assays is high sensitivity that does not 
translate to understanding if the virus is biologically functional.  
The BVDV viral RNA replication was compared between monocyte and MDDC 
using the high virulent ncp BVDV2a-1373 strain of BVDV. The RNA replication in 
monocytes started earlier than MDDC. The monocytes start producing infectious BVDV 
as early as 24 hr p.i. and BVDV viral RNA replicates as earlier as 1 hr p.i. The MDDC 
did not produce infectious BVDV at any time point while viral RNA replicated as early 
as 72 hr p.i. for ncp BVDV2a 1373 strain of BVDV. Monocyte accumulated less amount 
of viral RNA than MDDC whereas monocytes produced infectious virus. These findings 
indicated that MDDC either do not translate the viral proteins or there is hindrance in 
viral assembly or release in MDDC. The earlier statement could not be true because the 
BVDV viral RNA encode a polyprotein that is cleaved into various viral proteins 
including NS5B. The NS5B viral protein (p75) acts as RNA-dependent-RNA polymerase 
and replicates the viral RNA. The increasing amount of viral RNA at different time 
points of MDDC indicated the presence of the NS5B viral protein and BVDV RNA 
translation in MDDC.  
The lack of infectious virus production by MDDC was different from previous 
results in bovine MDDC (Glew et al., 2003). In a previous study, a homologous pair of 
BVDV ncp and cp viruses, Pe515ncp and Pe515cp, replicated and produced infectious 
virus in MDDC.  The difference in results may due to use of different monocyte isolation 
and MDDC culturing methods. In the previous studies, the MDDC were CD14+ adherent 
cells
 
(Glew et al., 2003; Werling et al., 1999) while in the current study the MDDC were 
97 
 
non-adherent CD14- cells. The cells in the previous studies had a more monocyte 
pheonotype and may have represented a more intermediate MDDC phenotype such as 
was observed at 2-4 days of monocyte to MDDC differentiation observed in this study.  
The adherent CD14+ cells which have phenotypical resemblance  to monocytes or 
intermediate MDDC phenotype such as was observed at 2-4 days produced infectious 
virus.  Such as in a study using BVDV Suwa Ncp strain, monocyte-derived macrophage 
replicated the BVDV RNA and produced infectious virus (Schweizer et al., 2006). 
Infection studies with hepatitis C virus (HCV), another virus of flaviviridae family were 
done in human MDDC. Human MDDC, infected with HCV JFH1 strain, neither 
supported HCV RNA replication nor antigen production (Ebihara et al., 2008).  The 
diffrence in results may be due to diffrence in cell type and virus used. The HCV 
replication is restricted to human hepatocytes or human PBMCs wheras BVDV can 
infecte and replicate in almost in all bovine cells specially epithelia cells. The HCV viral 
RNA was detected in peripheral blood DC (Goutagny et al., 2003) but HCV infected DC 
did not replicate HCV in vitro. The J6/JFH (a chimeric HCV of genotype 2a) did not 
replicate in B or T lymphocytes, monocytes, macrophages, or dendritic cells while it 
replicated and produced infectious virus in Huh-7.5 cells, a liver cell line (Marukian et 
al., 2008).  
 Another study was conducted to detect non-structural BVDV protein, p80 (NS3) 
and the structural BVDV protein, gp53 (E2) in peripheral blood mononuclear cells 
(PBMC) isolated from viremic animals infected with ncp pe515 strain of BVDV. This 
study revealed that monocytes expressed the highest level of NS3 (p80) followed by T 
98 
 
cells, B cells and γδ T cells (Sopp et al., 1994). This study also showed that the bovine 
monocyte became infected with BVDV and produced infectious virus which is in 
agreement with the current findings. The monocytes produced infectious BVDV up to 48 
hr to 72 hr p.i. The maximum BVDV virus titer was observed in monocytes at 72 hr p.i. 
followed by reduction in virus titer at 96 hr p.i.  
In this study, BVDV was produced by monocytes, the MDDC precursor, but not 
by fully differentiated MDDC. To find out at which stage of MDDC differentiation, 
MDDC lose the capacity to produce infections virus, the monocytes were harvested at 48 
hr (2 days), 72 hr (3 days), 96 hr (4 days) or 120 hr (5 days) of differentiation to MDDC. 
These intermediate stages of MDDC were infected with high virulent BVDV2a-1373 
strain of BVDV at a 6 MOI of infection. Cells were collected at 24 and 48 hr p.i. for each 
differentiation stage. Virus titer was determined in intermediate stages of MDDC. Results 
showed that virus production decreased with the length of time of differentiation. MDDC 
completely lost the ability to produce virus at 120 hr (5 days) of differentiation. This is 
the time when monocyte start changing morphologically to MDDC with development of 
dendrites and increasing in size (4-5 times than initial). 
The result of current study indicated that BVDV infects MDDC, replicate viral 
RNA and translate viral protein but is not release infectious virus from MDDC. The 
mechanism/s that prevents either packaging or release of infectious virus need to be 
explored.  
Result showed that MDDC has higher amount of viral RNA as compare to 
monocytes or MDBK cells at 168 hr or 192 hr p.i. in all the BVDV strains used in the 
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study except typical virulent ncp BVDV2a-28508-5. This viral RNA may be translated 
into viral proteins and finally infectious virus after interaction of MDDC to T cell or 
when MDDC migrate to different microenvironment.  
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Figure 2-1. Effect of breeds in differentiation of MDDC.  Panel A-C: Showing the 
differentiation of monocyte to MDDC isolated from Brown Swiss at day 0, A). day 4 B) 
and Day 7 C). Panel D-F: Representing the differentiation of monocytes to MDDC 
isolated from Holstein Friesian at day 0, D). day 4 E) and day 7 F).  At day 4 and 7 cells 
showing dendrites (with red arrows) and debris (red circle). Most of cells were either 
loosely attached or floating in the medium.  
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Figure 2-2. Phenotype of adherent bovine monocytes. The adherent monocytes were 
stained with MHCI, MHCII or CD14 primary antibodies followed by FITC-labeled 
secondary antibody. A) Secondary antibody control cells showing 2.034±0.67% gated 
cells; B) Cells showing MHCI expression with 96.62±0.5%; C) Cells showing MHCII 
expression with 80.58± 19.69% expression; D) Cells showing CD14 expression 
16.54±1.49%. 
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Figure 2-3.Phenotype of bovine monocyte-derived dendritic cell (MDDC). The 
MDDC at seven days of differentiation were stained for CD14, DEC205, MHCI, MHCII 
or CD86 A) MDCC CD14 expression was 1.025 ± 0.45%; B) MDCC CD21 expression 
was 3.42±0.19%; C) MDCC MHCI expression was 98.58± 0.34%; D) MDCC MHCII 
expression with 94.1±2.81%; E) MDCC CD86 expression was 77.83±17.83%; F) MDCC 
DEC205 expression was 55.97±45.48%. 
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Figure 2-4. MDDC viability after BVDV infection. MDDC were infected with 
cpBVDV1b-TGAC, ncpBVDV1b-TGAN, ncpBVDV2a-28508-5 or ncpBVDV2a-1373 
strain of BVDV. The viability of MDDC was measured by trypan blue exclusion assay 
and percentages of viable cells were calculated from 1 hr, 6 hr, 12 hr, 24 hr, 48 hr or 72 
hr p.i.   
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Figure 2-5. Effect of cp or ncp BVDV infection on MDDC. MDDC were infected with 
either cp BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV and examined for 
cytopathic effect at 1 hr, 6 hr, 12 hr or 24 hr p.i. A) mock-infected at 0 hr; B) mock-
infected at 1 hr; C) mock-infected at 6 hr; D) mock-infected at 12 hr and E) mock-
infected at 24hr; F) MDDC infected with cp BVDV1b-TGAC at 1 hr; H) MDDC infected 
with cp BVDV1b-TGAC at 6 hr; J) MDDC infected with cp BVDV1b-TGAC at 12hr; L)  
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MDDC infected with cp BVDV1b-TGAC At 24 hr; G) MDDC infected with ncp 
BVDV1b-TGAN at 1 hr; I) MDDC infected with ncp BVDV1b-TGAN at 6 hr; K) 
MDDC infected with cp BVDV1b-TGAN at 12hr; M) MDDC infected with cp 
BVDV1b-TGAN at 24 hr.  It might make sense to add a label like TGAC 24 hr to each 
panel.
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Figure 2-6. qR-TPCR amplification curve of serially diluted virus (spiked) of known 
concentrations. The MDBK cells were diluted in MEM medium to achieve final 
concentration 5x105 cells/ ml. The ncp BVDV2a-1373 strain of BVDV with known titer 
(7 log10/ml) was serially diluted as 1 in 10 in MDBK cells suspension. The viral RNA 
was extracted and quantified using qRTPCR.  
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Figure 2-7. Standard curve with the known BVDV virus (spiked) concentrations.  
The MDBK cells were diluted in MEM medium to achieve final concentration 5x105 
cells/ ml. The ncp BVDV2a-1373 strain of BVDV with known titer (7 log10/ml) were 
serially diluted(spiked) as 1:10 in MDBK cells suspension. The viral RNA was extracted 
and quantified using qR-TPCR.  The Ct (critical) values with known virus titers were 
used to plot the standard curve. The standard curve was used to calculate the approximate 
virus concentration (virus equivalence) in the samples.  
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Figure 2-8. Virus production of cpBVDV1b-TGAC strain. The MDDC and MDBK 
cells were infected with 6 MOI of infection with cpBVDV1b-TGAC strain of BVDV. 
Cells and its supernatants were collected at 1 hr, 6 hr, 12 hr, 24 hr, 48 hr, 72 hr or 96 hr 
p.i. and analyzed for viral titer.  
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Figure 2-9. Virus production of ncpBVDV1b-TGAN strain of BVDV. The MDDC 
and MDBK cells were infected with 6 MOI of infection with ncp BVDV1b-TGAN strain 
of BVDV. Cells and its supernatants were collected at 1 hr, 6 hr, 12 hr, 24 hr, 48 hr, 72 hr 
or 96 hr p.i. and analyzed for viral titer.  
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Figure 2-10. Virus production of ncpBVDV2a-28508-5 strain of BVDV. The MDDC 
and MDBK cells were infected with 6 MOI of infection with ncp BVDV2a-28508-5 
strain of BVDV. Cells and its supernatants were collected at 1 hr, 6 hr, 12 hr, 24 hr, 48 
hr, 72 hr or 96 hr p.i. and analyzed for viral titer.  
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Figure 2-11. Virus production of ncpBVDV2a-1373 strain of BVDV. The MDDC and 
MDBK cells were infected with 6 MOI of infection with ncp BVDV2a-1373 strain of 
BVDV. Cells and its supernatants were collected at 1 hr, 6 hr, 12 hr, 24 hr, 48 hr, 72 hr or 
96 hr p.i. and analyzed for viral titer.  
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Figure 2-12. MDDC viability after BHV1 infection. The MDDC were infected with 6 
MOI of infection with Cooper strain of BHV1. The cells were collected at 1 hr, 6 hr, 12 
hr, 24 hr, 48 hr, 72 hr or 96  hr p.i. The viability of MDDC were examined through trypan 
blue exclusion assay.  
119 
 
 
Figure 2-13. Virus production of BHV1. The MDDC or MDBK cells were infected 
with 6 MOI of infection with Cooper strain of BHV1. Cells and its supernatants were 
collected at 1 hr, 6 hr, 12 hr, 24 hr, 48 hr, 72 hr or 96 hr p.i. and analyzed for viral titer.  
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Figure 2-14. The virus production of ncp BVDV2a-1373 strain of BVDV by 
intermediate stage of MDDC. The intermediate stages of MDDC were harvested at 48 
hr, 72 hr, 96 hr and 120 hr of differentiation. The intermediate stages of MDDC were 
infected with ncp BVDV2a-1373 strain of BVDV with 6 MOI of infection. The cells 
were collected at 24 hr and 48 hr p.i. and analyzed for viral titer. 
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Figure 2-15. Replication of cpBVDV1b-TGAC viral RNA in MDDC or MDBK cells. 
MDDC or MDBK cells were infected with 6 MOI of infection with cpBVDV1b-TGAC 
strain of BVDV. Cells were collected at 0 hr, 1 hr, 6 hr, 12 hr, 72 hr, 96 hr, 144 hr or 168 
hr p.i. The viral RNA was extracted from cells at each time point. Extracted RNA was 
quantified using qRTPCR at each time points. 
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Figure 2-16. Replication of ncp BVDV1b-TGAN viral RNA in MDDC or MDBK 
cells. MDDC or MDBK cells were infected with 6 MOI of infection with ncp BVDV1b-
TGAN strain of BVDV. Cells were collected at 0 hr, 1 hr, 6 hr, 12 hr, 72 hr, 96 hr, 144 hr 
or 168 hr p.i. The viral RNA was extracted from cells at each time point. Extracted RNA 
was quantified using qRTPCR at each time points. 
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Figure 2-17. Replication of ncp BVDV2a-28508-5 viral RNA in MDDC or MDBK 
cells. MDDC or MDBK cells were infected with 6 MOI of infection with ncp BVDV2a-
28508-5 strain of BVDV. Cells were collected at 0 hr, 1 hr, 6 hr, 12 hr, 72 hr, 96 hr, 144 
hr or 168 hr p.i. The viral RNA was extracted from cells at each time point. Extracted 
RNA was quantified using qRTPCR at each time points. 
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Figure 2-18. Replication of ncp BVDV2a-1373 viral RNA in MDDC or MDBK cells. 
MDDC or MDBK cells were infected with 6 MOI of infection with ncpBVDV2a-1373 
strain of BVDV. Cells were collected at 0 hr, 1 hr, 6 hr, 12 hr, 72 hr, 96 hr, 144 hr or 168 
hr p.i. The viral RNA was extracted from cells at each time point. Extracted RNA was 
quantified using qRTPCR at each time points. 
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Figure 2-19. Replication of ncp BVDV2a-1373 viral RNA in monocytes, MDDC or 
MDBK cells. Monocytes, MDBK cells or MDDC were infected with ncp bvdv2a-1373 
stain of BVDV at 6 MOI infection. Cells were collected at 0 hr, 1 hr, 6 hr, 12 hr, 72 hr, 
96 hr, 144 hr or 168 hr p.i. Viral RNA was extracted from cells at each time point. 
Extracted RNA was quantified using qRT-PCR.  
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Figure 2-20. Presence of NS5A of BVDV in BVDV Infected MDDC through 
Western blot. The BVDV ncp BVDV2a-1373 infected MDDC cell lysate was separated 
using 12.5% SDS-PAGE resolving gel. Proteins were transferred to nitrocellulose 
membrane. The nitrocellulose membrane was stained for rabbit anti NS5A-BVDV 
antibody followed by goat anti-rabbit-IRDye 800CW. Images were obtained by using the 
Odyssey Imaging system and software (LI-COR Biosciences). Specific NS5A protein 
band was detected around 56 kD.  
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Table 2-1. BVDV Strains used in the studies 
Viral Strain  Biotype  Genotype  Reference  
BVDV1b-TGAC CP Type 1b (Ridpath et al., 1991) 
BVDV1b-TGAN NCP Type 1b (Ridpath et al., 1991) 
BVDV2a-1373 NCP Type 2a (Stoffregen et al., 2000) 
BVDV2a-28508-5 NCP Type 2a (Liebler-Tenorio et al., 2003) 
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Table 2-2. The average yield of cells from 60 ml of heparinized blood. 
 Cells 
Total number of cells from 60 ml heparinized 
blood 
Brown Swiss Holstein Friesian 
1. PBMC 1.56±0.51 x10
8
 5.36±0.73 x10
8
 
2. Monocytes 1.36±0.40x 10
7
 2.83±0.35x10
7
 
3. MDDC 4.2±0.72x10
6
 1.96±2.91x10
6
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Time 
Control 
MDDC 
MDDC 
infected 
with ncp 
BVDV2a-
1373 strain 
of BVDV 
MDDC 
infected 
with ncp 
BVDV2a-
28508-5 
strain of 
BVDV 
MDDC 
infected 
with cp 
BVDV1b-
TGAC 
strain of 
BVDV 
MDDC 
infected 
with ncp 
BVDV1b-
TGAN 
strain of 
BVDV 
1 hr 99.33±1.15 100±00 99.33±1.15 99.33±1.15 98.66±1.15 
6 hr 98.66±1.15 97.33±1.15 97.33±1.15 98.00±00 96.66±1.15 
12 hr 97.33±1.15 96.66±1.15 96.00±2 96.66±1.15 95.33±2.309 
24 hr 97.33±1.15 96.00±2.30 96.66±2.30 96.00±1.15 94.66±1.15 
48 hr 96.66±1.15 96.00±3.4 96.66±2.30 94.00±3.46 94.66±1.15 
72 hr 96.66±1.15 94.66±3.05 94.00±2 94.00±3.46 94.00±2.00 
Table 2-3. MDDC viability after BVDV infection. MDDC were infected with either 
BVDV2a-1373, BVDV2a-28508-5, BVDV1b-TGAC or BVDV1b-TGAN strains of 
BVDV at 6 MOI  of infection or mock infected control. MDDC were collected at 1 hr, 6 
hr, 12 hr, 24 hr, 48 hr or 72 hr p.i. and examined for cell viability using trypan blue 
exclusion assay, the experiment was repeated three time and mean and standard deviation 
was calculated.  
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Time BHV1-infected MDDC Mock-infected MDDC 
1 hr 99.33±0.57 99.66±0.58 
6 hr 96.33±1.15 98.33±1.15 
12 hr 94.66±0.58 97.33±0.58 
24 hr 91.33±0.58 97.00±0.58 
48 hr 89.33±1.52 95.00±1.52 
72 hr 84.00±3.08 95.66±2.64 
96 hr 78.37±0.58 94.33±0.58 
Table 2-4. MDDC viability after BHV1 infection. The MDDC were infected with 
cooper strain of BHV1 with 6 MOI of infection. The percent viability of BHV1 infected 
MDDC was examined through trypan blue exclusion assay along with mock-infected 
MDDC.  
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CHAPTER 3.  
THE EFFECT OF BVDV ON CELL SURFACE MARKERS OF BOVINE 
MONOCYTE-DERIVED DENDRITIC CELLS 
ABSTRACT 
Bovine viral diarrhea virus (BVDV) infections are a worldwide problem in cattle. 
One of the hallmarks of BVDV infections is immunosuppression. The exact mechanisms 
of this immunosuppression are not well characterized. In this chapter, the effect of 
BVDV infection on cell surface markers that are important for antigen presentation in 
dendritic cells (DC) were examined.  Dendritic cells (DC) are a heterogeneous population 
of professional antigen presenting cells (APC) that are potent stimulators of naïve T-cells. 
DC activate both innate and adaptive immune responses by antigen presentation to T 
cells and by the production of pro- and anti-inflammatory cytokines. Bovine monocytes 
were cultured with bovine recombinant GM-CSF (100ng/ml) and IL-4 (200ng/ml). Over 
a period of 5-7 days in culture. The effect of BVDV infection on MDDC cell surface 
markers expression was measured. Four (4) BVDV strains were used including a 
noncytopathic (ncp) high virulence strain (BVDV2a-1373), a ncp typical virulence strain 
(28508-5), and a virus pair, cytopathic (cp)/(ncp) pair of viruses TGAN recovered from 
an animal that died of mucosal disease (BVDV1b-TGAC/BVDV1b-TGAN). The ncp 
BVDV strains reduced the MHCI and MHCII expression on MDDC cell surface. The 
maximum reduction in MHCI and MHCII was observed in the MDDC infected with the 
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high virulence strain (BVDV2a-1373) followed by typical virulence strain (ncp 
BVDV2a-28508-5) and BVDV1b-TGAN. BVDV1b-TGAN significantly reduced the 
MHCI as early as 1 hr p.i. All ncp strains used in the study significantly down regulated 
the CD86 expression at 48 hr p.i.  The cp strain of BVDV up regulated the MHCI and 
MHCII expression in MDDC beginning at 1 hr p.i. while CD86 expression was 
significantly enhanced at 1 hr p.i.  The down regulation of cell surface marker expression 
by ncp BVDV biotypes may be the one of the mechanism that functions in causes of 
immunosuppression and development of persistent infection.  This enhancement of cell 
surface marker expression by cp BVDV may be one of the reasons for the strong immune 
response with these vaccines. 
INTRODUCTION 
Bovine viral diarrhea virus (BVDV) is one of the most widespread cattle 
pathogens worldwide. BVDV infection in cattle herds result in major economic loss due 
to poor reproductive performance, immunosuppression and increased susceptibility to 
secondary infection.  The BVDV strains can be divided into two biotypes, non-cytopathic 
(ncp) and cytopathic (cp) on the basis of their effect on cultured epithelial cells. Infection 
of bovine fetuses with ncp BVDV during first 40-120 days of pregnancy may result in 
persistently infected (PI) calves (Chase et al., 2004). The PI calves are immunotolerant 
and remain a source of infection to other animals. Superinfection of PI animals with 
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antigenically homologous cpBVDV strain results in a highly fatal form of BVDV 
associated disease known as mucosal disease (MD), (Brownlie, 1990).  
Dendritic cells (DC) are antigen-presenting cells (APC) with a unique ability to 
induce immune responses by activating naïve T cells. The DC capture, process and 
present antigen to the T cells for adaptive immune response. DC not only activates T cells 
(Steinman and Banchereau, 2007) but they also induce immunological tolerance 
through anti-inflammatory cytokines (Samarasinghe et al., 2006) and generate 
regulatory T cells.. The activated T cells produce IL-2 (interleukin-2). IL-2 increases T-
cell proliferation and prevents the induction of anergy and cell death (Borthwick et al., 
1996). The activated T helper-1 (Th1) cells either activate cytotoxic T cell to destroy 
infected cells or become T helper -2 (Th2) cells that facilitate B cell activation for 
antibody production (Constant and Bottomly, 1997).  
APC) including DC are target for many pathogens. A reproducible method to 
produce large number of monocyte-derived dendritic cells (MDDC) was used to study the 
interactions of pathogens with DC (Mwangi et al., 2005; Werling et al., 1999).  Studies 
have shown that bovine MDDC are susceptible to various pathogens including bacteria 
such as Salmonella typhimurium (Norimatsu et al., 2003), Brucella abortus (Heller et 
al., 2012), Mycobacterium paratuberculosis (Lei and Hostetter, 2007) and viruses such 
as bovine respiratory syncytial virus (Werling et al., 2002).   There have been two 
studies that have examined the ability of BVDV to infect MDDC (Glew et al., 2003; 
Gibson et al., 2011). MDDC were susceptible to  
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BVDV infection with both ncp and cp strains isolated  from a MD case (Glew et al., 
2003) or from two different ncp strains that caused either severe acute or mild acute 
symptoms (Gibson et al., 2011). Interestingly the cp strain of BVDV pair did not induce 
cytopathic effects on MDDC (Glew et al., 2003).  
Cell surface markers were affected following infection of MDDC with BVDV. 
The MDDC infected with ncp strain of BVDV up regulated MHCI expression while 
infection with cp BVDV reduced MHCI expression in MDDC. The MHCII expression 
was reduced in MDDC infected with either cp or ncp strains of BVDV while there was 
no effect on CD86 expression (Glew et al., 2003).  
In this study, we evaluated the strain effect on cell surface markers expression on MDDC. 
The cells surface expression of MHCI, MHCII and CD86 on MDDC infected with a high 
virulence strain (BVDV2a-1373), a typical virulence strain (BVDV2a-28508-5) strains or 
cytopathic/noncytopathic pair of BVDV strains isolated from a MD case (BVDV1b-
TGAC/BVDV1b-TGAN) was compared. 
MATERIALS AND METHODS 
Madin Darby bovine kidney (MDBK) cells 
BVDV free MDBK cells (passage 95-110) were grown in minimal essential 
medium (MEM, Gibco BRL, Grand Island, NY) (pH 7-7.4) supplemented with 10% 
BVDV free fetal calf serum (FCS) (PPA, Pasching, Austria), penicillin (100 U /ml) and 
streptomycin (100 μg /ml) and used for  viral propagation and titration. 
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Virus Strains and Preparation 
The four BVDV strains were used in this study included a a pair of cp/ncp 
BVDV1b viruses, Tifton GeorgiA Cytopathic (BVDV1b-TGAC) and Tifton GeorgiA 
Non-cytopathic (BVDV1b-TGAN) recovered from an animal that died of mucosal 
disease (Brownlie et al., 1984; Fritzemeier et al., 1995; Ridpath et al., 1991), a high 
virulence noncytopathic strain from the BVDV2 species (BVDV2a-1373) isolated 
following an outbreak of peracute BVDV in Canada (Carman et al., 1998; Stoffregen et 
al., 2000); and 4) typical virulence noncytopathic virus from the BVDV2 species isolated 
from an asymptomatic persistently infected calf (BVDV2a-28508-5) (Liebler-Tenorio et 
al., 2003) (Table 2-1).  Five (5) ml of 5x10
5
 MDBK cells/ml were seeded in T25 flasks 
and culture were grown to 60-70% confluency at the time of inoculation with virus.  At 
the time of inoculation, the media was removed and 0.75 ml of virus inoculum with a 
multiplicity of infection [MOI] of one was added to each T25 flask. Virus was adsorbed 
for 1 hr at 37°C in a humidified CO2 incubator. After one (1) hr incubation, inoculum 
was removed and the cells were washed with sterile PBS. After washing, 5 ml of media 
was added to each flask. The cells were incubated at 37°C in a humidified CO2 incubator 
for 4-5 days for cultures infected with noncytopathic virus or or 70-80% cytopathic effect 
forcultures infected with cytopathic virus, TGAC. Cultures were harvested by two freeze 
thaw cycles. After 4-5 days for cultures infected with noncytopathic virus orof incubation 
cells were freezed at (-80˚C for 15 minutes followed by thawing at 25˚C).. The cell debris 
was pelleted by centrifugation at 1200g for 10 min at 4°C. The virus in the resulting 
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supernatants was titrated and the supernatants were, aliquoted and stored at -80 °C for 
further use.  
The virus titration was determined by Reed and Munech method (Reed and Munech, 
1938). Briefly MDBK cells were detached from tissue culture flask. The number of cells 
was adjusted to 5x10
5
 cells/ ml.  One hundred eighty (180) µl cell suspensions was added 
to each well of 96-well plate. Twenty (20) µl of virus was added to the first row of the 
plate. The virus was mixed with MDBK cells and 20 µl of this dilution was added to next 
row to achieve 10 fold dilutions. No virus was added to the last two rows of wells. These 
wells served as negative controls. The four replicates of each dilution was performed to 
determine the virus titer. The plate was incubated at 37 °C at humidified incubator for 
next 4 days. The plate was examined every day for cytopathic effect (CPE) of the virus. 
The highest dilution showing CPE is used as end point to calculate the proportionate 
distance (PD). The PD was used to determine the viral concentration (TCID50) as per 
formula as described earlier (Reed and Munech, 1938). 
5. Proportionate distance (PD) = (% CPE at dilution above 50%) – (50%)/ (% CPE 
at dilution above 50%)- (% CPE at dilution below 50%) (e.g.  60-50/60-0= 0.166) 
6. Calculation of end point just next to 50% CPE and conversion into  – Log (e.g.10-
6
 dilution would be -6) 
7. Calculation of TCID50.  
8.  TCID50 for 20 µl= 
(PD+ - Log dilution above 50%)  
(e.g. 1x10
6.166
) 
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For ncp BVDV, the same procedures with the exception of determining the end point 
since no CPE was produced.  The end point for ncp BVDV was determined by staining 
the MDBK cells with anti-BVDV antibody (IDEXX Laboratories, Westbrook, ME, USA) 
followed by biotinylated rabbit anti-mouse IgG (Zymed, Invitrogen Corporation,  
Frederick, MD, USA)  Steptavidin-HRP ( Invitrogen Corporation, Camarillo, CA, USA) 
and AEC reagent (3 amino-9 ethyl-carbazole) (Sigma-Aldrich, St. Louis, MO, USA). The 
end point for ncp BVDV was determined by the presence of red stained cell showing 
BVDV protein.  
Animals 
Six (6) Brown Swiss female calves (8-12 months of age) housed at Dairy Farm, 
South Dakota State University (SDSU), Brookings, SD, USA were used in this study. All 
animals were healthy. The SDSU Institutional Animal Care and Use Committee approved 
animal handling and blood collection. 
Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were isolated as per method 
previously described (Ulmer et al., 1984) and differentiated into MDDC (Mwangi et al., 
2005) with following modifications; 2-mercaptoethanol, 2 mM GlutaMax and 25 mM 
HEPES were replaced with 1mM sodium pyruvate (personal communication, Dr 
Waithaka Mwangi, Texas A&M University, USA) and the medium used for MDDC 
differentiation was RPMI-1640 medium supplemented with 20% FBS, 1mM sodium 
pyruvate, penicillin (100 U/ml), streptomycin (100μg/ml), bovine recombinant 
138 
 
  
granulocyte macrophage-colony stimulating factor (GM-CSF (100ng/ml) and IL-4 
(200ng/ml). In the previous method fresh, complete RPMI-1640 medium and cytokines 
was added at every 3
rd
 day while in current study 750 µl fresh, complete RPMI-1640 
medium with cytokines was added every 2
nd
 day (every other day).  The addition of 
sodium pyruvate and increasing the concentration of FBS from 10% to 20% improved the 
differentiation of MDDC.  The beneficial effect of sodium pyruvate may be due to its 
protective effect to nutrients in media and providing energy to the cell (Giandomenico et 
al., 1997). 
Briefly, sixty (60) ml of heparinized venous blood was collected from healthy 
calves. The buffy coat layers were separated by centrifuging the blood at 1100g for 30 
minutes at 4°C. The cells from buffy coat layer were suspended into heparinized (10 
U/ml) PBS in 1:3 ratio. The diluted cells were overlaid on 3ml, 65% Percoll (GE 
Healthcare Biosciences, Pittsburgh, PA, USA) in 15 ml conical tubes (Falcon, Oxnard, 
CA, USA) and centrifuged for 30 min, at 1100g at 4°C. The white cell layer of PBMC 
was aspirated by pipette from the interphase. The collected PBMC were suspended in 
heparinized PBS (10 U/ml) and pelleted by centrifugation at 1700 rpm for 15 min at 4°C. 
The PBMC were washed two times by suspending them in PBS and centrifugation at 
1700 rpm for 15 min at 4°C. Finally, PBMC were suspended in RPMI 1640 medium 
supplemented with 10% FBS, 1mM sodium pyruvate, penicillin (100 U/ml) and 
streptomycin (100μg/ml) to achieve final concentration of 1x 10
7
cells/ ml. Three (3) ml 
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of the cell suspension was added to each well of a 6-well plate (Falcon, Oxnard, CA, 
USA) and incubated at 37°C in a humidified CO2 incubator for 3 hr. 
Separation of adherent monocytes 
The monocytes were isolated by the plastic adhesion method (Mwangi et al., 
2005). The PBMC were cultured in 6-well plates for 3 hr at 37°C in a humidified CO2 
incubator. The unattached cells were discarded and plates were washed 4 times with PBS. 
The attached cells were detached with Accuatase (eBioscience, San Diego, CA, USA). 
Detached cells were washed two times by suspending them in PBS and centrifugation at 
500g for 15 min at 4°C.  
Monocyte-derived dendritic cell (MDDC) culture 
The accuatase-detached cells were characterized as MHCI
+
 MHCII
+ 
and CD14
+ 
monocytes based on flow cytometer analysis done on a FACScan (Becton-Dickson, 
Mountain View, CA) using MHC-I (H58A), MHC-II (H42A), CD21 (BAQ15A) 
andCD14 (MM61A) primary antibodies (VMRD Inc., Pullman, WA, USA). The 
harvested CD14+ monocytes were counted and the yield determined. The monocytes 
were differentiated into monocyte-derived dendritic cells (MDDC) (Mwangi et al., 2005) 
with some modifications as described above. Briefly, the monocytes were diluted in 
RPMI 1640 medium supplemented with 20% FBS, 1mM sodium pyruvate, penicillin 
(100 U/ml), streptomycin (100 μg/ml), bovine recombinant GM-CSF (100 ng/ml) and IL-
4 (200 ng/ml) kindly provided by Dr. Waithaka Mwangi (Texas A&M University, USA) 
to achieve the final concentration of 5x10
5
cells/ml. Three (3) ml of this cell suspension 
140 
 
  
was added to each well in 6-well plates. The cells were incubated at 37°C in a humidified 
CO2 incubator for 7 days. Seven hundred and fifty µl (750 µl) of RPMI 1640 medium 
supplemented with 20% FBS, 1mM sodium pyruvate, penicillin (100 U/ml), 
streptomycin (100μg/ml), bovine recombinant GM-CSF (100 ng/ml) and IL-4 (200 
ng/ml) was added to each well at alternate day. At day seven, differentiated MDDC were 
collected.  
Virus infection of MDDC 
After 7 days of culture, MDDC were collected by aspiration and centrifuged at 
500g at 4°C for 15 min in 15 ml conical tubes. MDDC were then suspended in RPMI 
1640 medium supplemented with 20% FBS, 1mM sodium pyruvate, penicillin (100 U 
/ml) and streptomycin (100 μg /ml), bovine recombinant GM-CSF (100ng/ml) and IL-4 
(200ng/ml) to final concentration 5x10
5
 /ml. One (1) ml of the cell suspension was added 
to each well of the 24-well plates. An aliquate of BVDV inoculum with MOI of 6  was 
added to each well. Mock-infected MDDC with no virus were used as control. BVDV 
and mock-infected MDDC were collected at 1 hr, 6 hr, 12 hr, 24 hr, 48 hr or 72 hr p.i. 
from different wells to measure their viability and cell surface marker expression. At least 
three replicates were performed to determine the final result. These time points were 
chosen because most cell surface marker genes are affected within 24 hr of infection in 
human monocyte-derived macrophages (MDM) or MDDC (Lehtonen et al., 2007) and 
maximum BVDV titer was observed at 72 hr post infection in BVDV permissive cells 
(e.g. MDBK cells) in previous studies in our laboratory.  
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Change in cell surface marker expression following BVDV infection  
The mock-infected and BVDV –infected MDDC were collected and stained for 
MHCI, MHCII or CD86 at 1 hr, 6 hr, 12 hr, 24 hr, 48 hr or 72 hr p.i.  For staining cells 
number was adjusted to 1x10
6
/ml. Three primary mouse mAb antibodies for MHC-I 
(H58A), MHC-II (H42A) and CD86 (IL-A190A) (MM61A)(VMRD Inc., Pullman, WA, 
USA) were used. The primary antibodies were diluted 1:100 in PBS containing 1% FBS.  
The 100 µl of cells suspension was incubated with 50µl of diluted primary antibodies at 
4°C for 10 min followed by washing by centrifugation at 200g for 4 minutes at 4 °C in 
round bottom 96 well plates. After centrifugation cell pallet was suspending them in 200 
µl  PBS. After primary staining and washing, cells were incubated  with 50 µl FITC 
labeled anti-mouse secondary antibody (VMRD Inc., Pullman, WA, USA)  which was 
diluted 1:1000 dilution in PBS containing 1% FBS at 4°C for 10 min. After incubation 
with secondary antibody, cells were washed two times with PBS. Cells were suspended 
for in 200 µl of 1% paraformaldehyde for fixing. The mean fluorescent intensity (MFI) in 
fixed cells was analyzed using FACSCalibur software (BD Biosciences). At least 20,000 
cells were run at each time points and each experiment was repeated at least 3 times.  
Statistical analysis 
Three replicates were performed to confirm the reproducibility of the method to 
differentiate the monocyte to MDDC. The percent change in cell surface marker 
expression in BVDV-infected MDDC were done three times in different trials.  The 
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significance difference in cell surface markers from its time point control was calculated 
by paired t-test (p<0.05) (Glantz, 2002).  
RESULTS 
Effect of BVDV on MHC I, MHC II and CD86 expression  
The MDDC were infected with ncp BVDV2a-1373, BVDV2a-28508-5, 
BVDV1b-TGAN strains or cp BVDV1b-TGAC strain of BVDV at a MOI of 6. The 
MDDC were stained for MHCI, MHCII or CD86 and fixed at 0 hr, 1 hr, 6 hr , 12 hr p.i. 
24 hr, 48 hr or 72 hrs p.i. to measure the changes on cell surface expression following 
BVDV infection. The experiments were repeated at least three times using three different 
animals. The mean MFI in mock-infected MDDC at zero time point was treated as 100%. 
The mock-infected MDDC at each time point were used as control. The percent change at 
each time was calculated.   
MHCI 
The MFI of MHC I in MDDC infected with cp BVDV1b-TGAC increased 12 hr 
p.i.  The MFI of MHC I in MDDC infected with cp BVDV1b-TGAC strain of BVDV 
increased around 33% (133.50±11.88%), 89% (189.10±34.3%) and 130% (230.2±5.22%) 
at 1 hr, 6 hr and 12 hr p.i. respectively, compared to mock-infected MDDC (Table 3-1, 
Figure 3-1). Similarly, the MFI of MHC I also increased from 24 hr p.i. to 72 hr p.i. 
following TGAC infection .The MFI of MHCI increased around 12% (112.22±17.29%), 
44%(144.60±53.14%) and 58% (158.16±52.43%)  at 24 hr, 48hr and 72 hr p.i. as 
compared to mock-infected MDDC respectively (Table 3-1, Figure 3-1). Small changes 
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in MHCI expression was observed at (98.32±1.38%) at 1 hr; (99.24±1.09%) at 6 
hr,(100.63±1.2%) at 12 hr, (91.44±5.44%) at 24 hr, (90.47±5,85%) at 48 hr and 
(78.90±25.81%) at 72 hr in time-matched mock-infected MDDC (Table 3-1, Figure 3-1). 
The MHC I expression on BVDV1b-TGAC infected MDDC was significantly up 
regulated following 1 hr, 6 hr, 12 hr, 24 hr and 48 hr p.i. of TGAC as compared to 
controls (p˂0.05). 
In contrast, the MFI of MHC I decreased at over time in MDDC infected with the 
three different ncp BVDV strains. The MFI of MHCI in ncpBVDV1b- ncpBVDV1b-
TGAN infected MDDC decreased around 18% (82.15±3.72%), 30% (70.58±0.76) and 
46% (54.61±2.03) at 1 hr, 6 hr and 12 hr p.i. respectively and 23%(77.96 ±9.93%), 35% 
(65.23 ± 11.90%) and 36% (64.15± 9.25%) at 24hr, 48hr and 72 hr p.i respectively 
(Table 3-1, Figure 3-1, Figure 3-5). The down regulation of MHCI expression following 
ncpBVDV1b-TGAN infection was significant different at 1 hr, 6 hr, 12 hr and 24 hr p.i. 
as compare to mock-infected MDDC (p˂0.05). The MFI of MHCI in MDDC infected 
with ncpBVDV2a-28508-5 was reduced 22% (78.62±17.19%), 36%(64.05±37.01%) and 
43% (57.94±27.84%) at 1 hr, 6 hr, and 12 hr  respectively and 32% (68.14±18.62%), 
57% (43.57±6.63%) and 59% (41.30±5.95%) at 24 hr, 48 hr and 72 hr p.i. respectively as 
compared to mock-infected MDDC (Table 3-1, Figure 3-2, Figure 3-7). The down 
regulation of MHCI in ncpBVDV2a-28508-5 infected MDDC was significantly lower at 
24 hr and 72 hr p.i. (p˂0.05). The MFI of MHCI in MDDC infected with ncpBVDV2a-
1373 strain of BVDV reduced expression around 14% (86.73±18.33%), 40% 
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(60.26±18.02%) and 48%(52.31±20.05%) at 1 hr, 6 hr and 12 hr p.i. respectively and 
35% (64.32±7.41%), 59% (41.85±13.64%), and 60% (40.10±7.18%)  at 24 hr, 48 hr and 
72 hr p.i. respectively as compared to mock-infected controls (Table 3-1, Figure 3-2, 
Figure 3-6). BVDV2a-1373 infection to MDDC significantly down regulated the MHCI 
expression at 24 hr and 48 hr p.i. as compare to time matched control (p˂0.05). 
MHCII 
There was also a biotype difference in MHCII expression. The cp biotype 
cpBVDV1b-TGAC unregulated the MHCII expression while its homologue 
ncpBVDV1b-TGAN strain down regulated the MHCII expression. cpBVDV1b-TGAC 
increased the MHCII expression during the course of infection. The MHCII expression 
increased around 19% (119.15±9.23%), 23% (123.96±12.17%) and 50% (150.49±24.69 
%) at 1 hr, 6 hr or 12 hr p.i. respectively and ~22% (122.19±31.38%), ~40% 
(140.97±48.37) and ~56% (156.83±54.48%) at 24 hr, 48 hr and 72 hr p.i. respectively in 
cpBVDV1b-TGAC-infected MDDC as compared to mock-infected controls (Table 3-2, 
Figure 3-2, Figure 3-4).  In contrast to its cp homologue, the ncpBVDV1b-TGAN down 
regulated that MHC II expression. The MFI of MHC II ncpBVDV1b-TGAN- infected 
MDDC was reduced ~10% (90.02±0.101%), ~28% (76.62±3.09%) and ~33% 
(67.32±.006%) at 1 hr, 6 hr and 12 hr p.i. respectively and ~2% (98.27±0.72%) at 24 hr 
p.i., ~21% (79.78± 23.69%) at 48 hr p.i. and ~21% (79.33±19.33%) at 72 hr p.i. as 
compared to mock-infected control (Table 3-2, Figure 3-2, Figure 3-5). The down 
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regulation of MHCII expression in ncpBVDV1b-TGAN infected MDDC was 
significantly different than the mock infected controls at 6 hr and 12 hr p.i. (p˂0.05). 
The MHCII expression also was reduced in MDDC infected with ncpBVDV2a-
28508-5 strain of BVDV. The ncpBVDV2a-28508-5 infection in MDDC reduced MHCII 
expression ~9% (89.90±20.73%), 33 % (67.67±8.06%) and 36% (64.11±8.85%) at 1 hr, 6 
hr and 12 hr p.i.  respectively and ~22% reduction (78.10±0.38%) at 24 hr;~39% 
reduction (61.41±14.62%) at 48 hr and ~44% reduction (56.44±13.01%) at 72 hr p.i. 
(Table 3-2, Figure 3-2, Figure 3-7). The down regulation of MHCII on MDDC by mild 
acute 28508-5 was significantly different than its time point control at 6 hr, 12 hr and 72 
hr p.i. (p˂0.05). 
Infection of MDCC with the high virulent ncpBVDV2a-1373 strain of BVDV 
reduced MHCII expression during the course of infection [~9%(89.04±15.59%) at 1 hr, 
37% ( 63.81±1.57%)  at 6 hr and 38% (62.79±5.10%) at 12 hr and  ~29% 
(81.15±10.71%) at 24 hr, ~38% (63.65±8.03%) at 48 hr and 45% (55.10±8.39%) at 72 hr 
p.i]. (Table 3-2, Figure 3-2, Figure 3-7). The ncpBVDV2a-1373 strain of BVDV 
significantly down regulated the MHCII expression at 12 hr and 72 hr p.i. as compared to 
mock-infected controls (p˂0.05). 
CD86 
Like MHCII expression, the BVDV biotype had affected the CD86 expression. 
The cpBVDV1b- TGAC strain of BVDV increased CD86 expression ~11% 
(111.40±3.55%), 5% (105.82±0.29%) and 7% (107.44±5.08%) at 1 hr, 6 hr and 12 hr p.i. 
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respectively. The cpBVDV1b-TGAC did not affect CD86 MFI at 24 hr p.i. 
(92.83±23.47%) but dramatically increased MFI by ~150% at 48 hr [147% 
(247.498±172.29%)] and 161% (261.22±162.00) 72 hr p.i. (Table 3-3, Figure 3-3, Figure 
3-4). Statistically, cpBVDV1b-TGAC significantly up regulated the CD86 expression at 
1 hr p.i. 
This was in contrast to ncpBVDV1b-TGAN strains that decreased expression of 
CD86 by 1% (99.48±6.13%), 5% (95.09±0.29%) and 3% (93.55±2.49%) 1 hr, 6 hr and 
12 hr p.i. respectively  and ~ 20-30% from 24 hr to 72 hr p.i. [~20% (80.73±2.65%), 
~29% (71.26±2.21%) and ~28% ( 72.64±1.38%) at 24 hr, 48 hr and 72 hr p.i. (Table 3-3, 
Figure 3-3, Figure 3-5). The ncp BVDV strains including high virulent ncpBVDV2a-
1373, typical virulent ncpBVDV2a-28508-5 and ncpBVDV1b-TGAN significantly 
reduced the CD86 at 48 hr p.i. (p˂0.05). 
The CD86 expression in MDDC infected with ncpBVDV2a-1373 increased 
around 8% (108.42±11.49%), 11% (111.14±17.02%) and 6% (106.47±9.3) at 1 hr, 6 hr 
and 12 hr p.i. than reduced ~23% (77.75±10.55%), ~28% (72.16±4.63%), and ~29% 
(71.36±4.08%) at 24 hr, 48 hr and 72hr p.i. respectively (Table 3-3, Figure 3-3, Figure 3-
6). 
 The ncpBVDV2a-28508-5 strain of BVDV reduced CD86 expression ~ 1% 
(99±10.08%),~ 2% (98.17±8.96%) at 1 hr and 6 hr p.i. followed by a slight upregulation 
at 12 hr p.i. as ~6% (106.22±20)  while down regulated CD86 expression at 24 hr, 48 hr 
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and 72 hr p.i. as ~ 21% (79.61±13.77%) , ~24% (76.53±10.84%) and~ 24% 
(76.31±11.03%)  respectively (Table 3-3, Figure 3-3, Figure 3-7). 
DISCUSSION 
There were seveal key findings on the effect of BVDV on antigen presentation 
and co-stimulation marker expression/concentration). The cp BVDV1b-TGAC strain of 
BVDV enhanced the MHCI, MHCII and CD86 concentration during the course of 
infection. The cp BVDV1b-TGAC strain of BVDV significantly up regulated the MHCI 
expression at 1 hr, 6 hr, 12 hr, 24 hr and 48 hr p.i.  The cp BVDV1b-TGAC also 
significantly enhanced the CD86 expression at 1 hr p.i. as compared to its time point 
control (p˂ 0.05) and enhanced expression at 48 and 72 hrs. The ncp strains of BVDV 
including the high virulent ncp BVDV2a-1373, typical virulent ncp BVDV2a-28508-5 
and ncp BVDV1b TGAN all reduced the MHCI, MHCII and CD86 expression during the 
course of infection. The ncp BVDV1b-TGAN strain of BVDV significantly down 
regulated MHCI expression starting from 1 hr p.i. to 12 hr p.i. while high virulent ncp 
BVDV2a 1373 down regulated the MHCI expression at 24 hr and 48 hr p.i. and typical 
virulent ncp BVDV2a-28508-5 down regulated the MHCI expression at 24 hr and 72 hr 
p.i. (p˂ 0.05).  
Ncp BVDV1b-TGAN infection significantly down regulated the MHCII 
expression at 6 hr and 12 hr p.i. while typical virulent ncp BVDV2a-28508-5 
significantly down regulated the MHCII expression at 6 hr, 12 hr and 72 hr p.i. and high 
virulent ncp BVDV2a-1373 significantly down regulated the MHCII expression at 12 hr 
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and 72 hr p.i. All ncp BVDV strain used in the study significantly down regulated the 
CD86 expression at 48 hr p.i. (p˂ 0.05). In another study with bovine MDM showed the 
upregulation of MHCI in MDM following infection with cp BVDV while down 
regulation of MHCI expression in MDM infected with ncp strain of BVDV. Whereas 
both cp and ncp strains down regulated the MHCII expression in MDM (Chase et al., 
2004). The diffrence with our result may be due to diffrence in the isolation and culturing 
method. The MDDC were non attached, CD14- cells while MDM used in that study were 
adherent CD14+ cells. 
 One in vivo experiment, examined the effect of infection of calves with the type 2 
ncp Canadian 24515 field isolate of BVDV on expression of MHCII and CD86 on 
PBMC. The percentages of B7 (CD80/86) and MHCII expressing peripheral blood 
mononuclear cells (PBMCs) were not changed in BVDV infected calves as compared to 
mock-infected calves (Archambault et al., 2000). In another in vivo experiment, analysis 
of lymph node and Peyer’s patch cells from BVDV-infected calves found a 30% to 50% 
decrease in MHC II-expressing cells (Brodersen and Kelling, 1999). These results 
indicates that BVDV does not have effect on (CD80/86) and MHCII expression PBMCs 
while these cell surface marker (MHCII) is affected in when cell matured/differentiated 
in secondary lymphoid organs.  
In another study, a ncp strain effect was demonstrated on MHCII expression in 1-
day-old gnotobiotic calves.  The calves were exposed to one of 2 noncytopathic isolates 
of BVDV (ncp-BVDV 7937 and ncp-BVDV 126). Phenotypic analyses of peripheral 
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blood mononuclear leukocytes was done at 3, 7, and 10 days p.i. The percentage of 
MHCII positive cells from calves exposed to ncp-BVDV 7937 was significantly higher 
than calves exposed to ncp-BVDV 126 on day 3 and 10 p.i. On day 10 p.i., calves 
exposed to ncp-BVDV 7937 also had a significantly higher number of B cell than calves 
exposed to ncp-BVDV 126 and non exposed control calves. Calves exposed to ncp-
BVDV 126 had a significantly higher percentage of CD2 (BoCD2) positive T cells than 
calves not exposed to BVDV, indicating that ncp-BVDV 7937 up regulated the MHCII 
expression that further facilitate the B cell proliferation (Marshall et al., 1994). The 
difference from current finding where ncp strain of BVDV down regulated the MHCII 
may be due to difference in experimental design. The above experiment was carried out 
in vivo while current study was done in in vitro with different strain of viruses.  
What is the mechanism responsible for these changes in MHCI and MHCII expression? 
Changes in surface marker expression could be due to differences in interferon 
expression between cp and ncp BVDV in MDDC. Type 1 IFN plays an important role in 
upregulation of MHCI expression (Tovey et al., 1996). Reduced type 1 IFN production 
in ncp BVDV infected cells maybe a reason for the down regulation of MHCI and 
MHCII in ncp-infected MDDC while upregulation of MHCI and MHCII in cp BVDV 
infected MDDC may be due to an increase in type 1 interferon (Charleston et al., 2001). 
A study has shown that the BVDV Erns and Npro viral proteins inhibit the IFN 
production. The BVDV Erns protein inhibits IFN expression induced by extracellular 
viral RNA while BVDV Npro protein promotes the degradation of the transcription factor 
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IRF-3, which effectively blocks IFN expression in BVDV-infected cells (Peterhans and 
Schweizer, 2013). 
Another possible mechanism may be a direct effect on MHC expression.  
Hepatitis C Virus (HCV), another virus of Flaviviridae family, changed MHCI 
expression in infected cultured cancerous cells lines (human hepatoma and mouse 
lymphoma cells) (Mullbacher and Lobigs, 1995; Herzer, Falk et al., 2003; Tardif and 
Siddiqui, 2003). The reduced MHCI expression in HCV infected cells was due to 
disruption in MHCI protein folding and assembly. HCV replicons induce endoplasmic 
reticulum (ER) stress, which results from a decline in protein glycosylation. Decreasing 
protein glycosylation disrupts protein folding and preventing the assembly of MHC class 
I molecules and expression (Tardif and Siddiqui, 2003). Similarly, HIV (Human 
immunodeficiency virus) reduces MHCI and CD86 expression via its Nef protein in 293T 
cell line (human embryonic kidney cell line), human monocytic U937 cell line as well as 
in mouse macrophages and dendritic cells (Piguet et al., 2000; Chaudhry et al., 2005).  
The Nef protein binds and endocytose the MHC class I molecules by the ARF6 pathway 
and resulting in reduced MHCI expression (Piguet et al., 2000). The mechanism by 
which BVDV alter the cell surface marker expression need to be explored for better 
understating immunosuppression caused by BVDV. 
Differential detergent fractionation (DDF) analysis of bovine monocytes showed 
that fifty-three (53) bovine proteins involved in immune function of professional APC, 
which were altered following BVDV infection.  These molecules include adhesion 
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molecules, toll-like receptors (TLR1, 6 and 8), antigen uptake and MHC class I- and II, 
cytokines, and growth factors synthesis (Lee et al., 2006). These results indicated that 
BVDV affected the immune response via both innate as well as adaptive immune systems 
components. A previous study was done to determine the effect of noncytopathic (ncp) 
and cytopathic (cp) BVDV on gene expression of TLR, type I IFN, pro-inflammatory and 
Th1/Th2 cytokines.  The NADL strain of BVDV1a was used as cp biotype while New 
York 1 (NY-1) of BVDV1b was used as ncp biotype. (Lee et al., 2008). The results of 
this study indicated that the ncp strain of BVDV (NY1) up regulate the TLR3 and Type I 
IFN that is different than other finding where they found that ncp BVDV do not induce 
the type 1 IFN in vitro (Schweizer and Peterhans, 2001). Our finding concur with those 
of (Schweizer and Peterhans, 2001) demonstrating that ncp BVDV do not induce type 1 
IFN by down regulating MHCI and MHCII expression on MDDC infected with ncp 
strains of BVDV. The above experiment (Schweizer and Peterhans, 2001) has one 
limitation as they did not took a cp and ncp BVDV pair to see the difference in both the 
biotypes and virus taken are from two different subgenogroup of BVDV1.  In another 
previous study, the proteins related to antigen pattern recognition, uptake and 
presentation to immunocompetent lymphocytes were analyzed in cp NADL BVDV 
infected monocytes through differential detergent fractionation (DDF) analysis. Eighteen 
(18) MHC proteins (4%) out of 445 were significantly altered in cp NADL BVDV 
infected bovine monocytes. Nine (9) MHC class I and six (6) MHC class II proteins, 
including the DQ isotype were significantly down-regulated in cp BVDV infected bovine 
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monocytes while MHC class II DR-beta chain protein was increased in cp BVDV 
infected monocytes (Lee et al., 2009). These findings also support that BVDV infecting 
affect the cell surface marker expression in infected cell. Our finding showed the up 
regulation of MHCI and MHCII expression on MDDC. The differences with above study 
may be due to difference in cell types (monocytes) and technique used (DDF). The above 
study has one limitation that the DDF indicates the amount of proteins translated in the 
cell while it does not show actual protein expression on cell surface. The alteration in 
cellular proteins following BVDV infection may be associated with changes in cell 
surface expression. MHC class II molecules are physically and functionally associated 
with TLR2 in lipid raft domains of the cell membrane (Frei et al., 2010). Previously it 
has been reported that monocyte-derived macrophages (MDM) infected with ncp BVDV-
28508-5, significantly (p<0.05) decreased the amount of mRNA of TLR-2 (Tigabu et al., 
2004). The reduction in MHCII expression in ncp BVDV-28508-5 infected cell may be 
due to low expression of TLR-2. 
We observed down regulation of CD86 expression following BVDV infection 
with ncpBVDV but up regulation following cpBVDV infection. Increased expression of 
CD86 may be due to effect of type one IFN. It has been shown that injecting IFN 
alpha/beta in mice increased expression of CD86 in murine DC (Montoya et al., 2002). 
Similarly addition of IFN-alpha to the human PBMC culture greatly enhanced CD86 
concentrations on the surface of developing dendritic cells (Radvanyi et al., 1999). It has 
been obseved that there are reduced level of co-stimulatory molecules CD80 and CD86 
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and pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6 expression in bovine 
monocytes after infection with either cp or ncp strain of BVDV (Lee et al., 2008). 
Another study conducted with MDDC found no effect of cp BVDV infection on CD86 
expression while ncp BVDV increase CD86 expression (Glew et al., 2003). Difference in 
results may due to the different monocyte isolation and MDDC culturing methods. In the 
Glew study, the MDDC were CD14
+
 while in the current study the MDDC were 
determined as non-adherent CD14
-
cells (Glew et al., 2003; Werling et al., 1999). The 
presence of CD14 indicates a different cell population with different functions. The 
CD14 has been shown to function as a receptor for a complex of LPS and LPS binding 
protein (Haziot et al., 1993). Generally CD14 is expressed more in adherent cells like 
macrophage and monocytes. The CD14 expressing cells have major role in production of 
pro-inflammatory cytokines (Ebong et al., 2001) and recruitment of neutrophils 
(McAvoy et al., 2011) while DC maintain the immune balance by its pro-inflammatory 
and anti-inflammatory cytokines and induction of tolerance.   
In brief, the results of this study suggested that Brown Swiss breed of cattle is 
more efficient for in vitro differentiation of MDDC then Holstein Friesian. The ncp strain 
of BVDV reduced MHCI and MHCII expression while cp strain enhances the MHCI, 
MHCII and CD86 expression on MDDC. The modified live BVDV vaccines contain cp 
strains of BVDV. The encouraging result of modified live BVDV may be to due to up 
regulation of the cell surface marker expression specially CD86 following vaccination. 
Further studies need to be done with other cp BVDV strains to confirm this finding.   
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Figure 3-1. Effect of BVDV on MHCI expression on MDDC. Differentiated MDDC 
were infected with either of four strains of BVDV including high virulent ncpBVDV2a-
1373, typical virulent ncpBVDV2a-28508-5 or a homologous pair of ncp or cp type 1b 
viruses (ncpBVDV1b-TGAN or cpBVDV1b-TGAC) with 6 MOI of infection. The cells 
were stained for MHCI at1 hr, 6 hr, 12 hr, 24 hr, 48 hr or 72 hr p.i. The mean fluorescent 
intensity (MFI) of cells expressing MHC I was analyzed using flow cytometry. Bar 
showing (*) are significantly different than its time point control (p˂0.05).  
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Figure 3-2. Effect of BVDV on MHCII expression on MDDC. Differentiated MDDC 
were infected with either of four strains of BVDV including high virulent ncpBVDV2a-
1373, typical virulent ncpBVDV2a-28508-5 or a homologous pair of ncp or cp type 1b 
viruses (ncpBVDV1b-TGAN or cpBVDV1b-TGAC) with 6 MOI of infection. The cells 
were stained for MHCII at1 hr, 6 hr, 12 hr, 24 hr, 48 hr or 72 hr p.i. The mean fluorescent 
intensity (MFI) of cells expressing MHC II was analyzed using flow cytometry. Bar 
showing (*) are significantly different than its time point control (p˂0.05).  
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Figure 3-3. Effect of BVDV on CD86 expression on MDDC. Differentiated MDDC 
were infected with either of four strains of BVDV including high virulent ncpBVDV2a-
1373, typical virulent ncpBVDV2a-28508-5 or a homologous pair of ncp or cp type 1b 
viruses (ncpBVDV1b-TGAN or cpBVDV1b-TGAC) with 6 MOI of infection. The cells 
were stained for CD86 at1 hr, 6 hr,12 hr, 24 hr, 48 hr or 72 hr  p.i. The mean fluorescent 
intensity (MFI) of cells expressing CD86 was analyzed using flow cytometry. Bar 
showing (*) are significantly different than its time point control (p˂0.05).  
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Figure 3-4. Effect of cpBVDV1b-TGAC strain of BVDV on cell surface marker 
expression of MDDC. Differentiated MDDC were infected with cpBVDV1b-TGAC 
strain of BVDV with 6 MOI of infection. The cells were stained for MHCI, MHCII or 
CD86, at1 hr, 6 hr, 12 hr, 24 hr, 48 hr or 72 hr  p.i. The mean fluorescent intensity (MFI) 
of cells expressing MHCI, MHCII and CD86 was analyzed using flow cytometry. Bar 
showing (*) are significantly different than its time point control (p˂0.05).  
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Figure 3-4. Effect of ncp BVDV1b-TGAN strain of BVDV on cell surface marker 
expression of MDDC. Differentiated MDDC were infected with ncp BVDV1b-TGAN 
strain of BVDV with 6 MOI of infection. The cells were stained for MHCI, MHCII or 
CD86 at1 hr, 6 hr,12 hr, 24 hr, 48 hr or 72 hr  p.i. The mean fluorescent intensity (MFI) 
of cells expressing MHCI, MHCII and CD86 was analyzed using flow cytometry. Bar 
showing (*) are significantly different than its time point control (p˂0.05).  
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Figure 3-5. Effect of ncp BVDV1b-1373 strain of BVDV on cell surface marker 
expression of MDDC. Differentiated MDDC were infected with high virulent 
ncpBVDV2a-1373 strain of BVDV with 6 MOI of infection. The cells were stained for 
MHCI, MHCII or CD86, at1 hr, 6 hr, 12 hr, 24 hr, 48 hr or 72 hr p.i. The mean 
fluorescent intensity (MFI) of cells expressing MHCI, MHCII and CD86 was analyzed 
using flow cytometry. Bar showing (*) are significantly different than its time point 
control (p˂0.05).  
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Figure 3-6. Effect of cp BVDV1b-28508-5 strain of BVDV on cell surface marker 
expression on MDDC. Differentiated MDDC were infected typical virulent 
ncpBVDV2a-28508-5 with 6 MOI of infection. The cells were stained for MHCI, MHCII 
or CD86, at1 hr, 6 hr, 12 hr, 24 hr, 48 hr or 72 hr  p.i. The mean fluorescent intensity 
(MFI) of cells expressing MHCI, MHCII and CD86 was analyzed using flow cytometry. 
Bar showing (*) are significantly different than its time point control (p˂0.05). 
169 
 
  
 
MHCI 
Time  Control ncpBVDV2a-
1373 
ncpBVDV2a-
28508-5 
cpBVDV1b-
TGAC 
ncpBVDV1b-
TGAN 
1  hr 98.32±1.38 86.73±18.33 78.62±17.17 133.5±11.88* 82.15±3.72* 
6 hr 99.24±1.09 60.26±18.02 64.05±37.01 189.1±34.30* 70.58±0.76* 
12 hr 100.63±1.20 52.31±20.05 57.94±27.84 230.29±5.22* 54.61±2.03* 
24 hr 91.44±5.44 64.32±7.41* 68.14±18.62* 112.22±17.29* 77.96±9.93* 
48 hr 90.47±5.85 41.85±13.64* 43.57±6.62 144.60±53.14 65.23±11.90 
72 hr 78.90±25.86 40.10±7.18 41.30±5.95* 158.1±52.43 64.15±9.25 
Table 3- 1. Cell surface expression of MHCI on MDDC following BVDV infection. 
Virally infected cell expression was compared to the controls with the controls 
normalized at 100%. The experiment was repeated three times. The value with (*) 
representing the significant difference than its time point control (p˂ 0.05). 
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 MHCII 
Time  Control ncpBVDV2a-
1373 
ncpBVDV2a-
28508-5 
cpBVDV1b-
TGAC 
ncpBVDV1b-
TGAN 
1  hr 93.57±3.91 89.64±15.59 89.9±20.73 119.15±9.23 90.02±0.10 
6 hr 99.16±4.71 63.81±1.57 67.67±8.06* 123.96±12.17 76.61±3.09* 
12 hr 94.78±5.48 62.79±5.10* 64.11±8.85* 150.49±24.64 67.32±0.006* 
24 hr 104.55±17.26 81.15±10.71 78.10±0.38 122.19±31.38 98.27±0.72 
48 hr 122.21±40.27 63.65±8.03 61.41±14.62 140.97±48.37 79.78±23.69 
72 hr 128.00±40.86 55.10±8.39* 56.44±13.01* 156.83±54.48 79.33±19.13 
Table 3- 2. Cell surface expression of MHCII on MDDC following BVDV infection. 
Virally infected cell expression was compared to the controls with the controls 
normalized at 100%. The experiment was repeated three times. The value with (*) 
representing the significant difference than its time point control (p˂ 0.05). 
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CD86 
Time  Control ncpBVDV2a-
1373 
ncpBVDV2a-
28508-5 
cpBVDV1b-
TGAC 
ncpBVDV1b-
TGAN 
1  hr 95.94±2.13 108.42±11.49 99±10.08 111.40±3.55* 99.48±6.13 
6 hr 102.46±1.60 111.14±17.02 98.17±8.96 105.82±0.29 95.09±5.06 
12 hr 103.73±1.88 106.47±9.23 106.22±20 107.44±5.08 93.55±2.49 
24 hr 90.83±26.16 77.75±10.55 76.61±13.77 92.83±23.47 80.73±2.65 
48 hr 101.63±11.5 72.16±4.63* 76.53±10.84* 247.49±172.29 71.26±2.21* 
72 hr 95.44±26.22 71.36±4.08 76.31±11.02 261.22±162.00 72.64±11.38* 
Table 3- 3. Cell surface expression of CD86 on MDDC following BVDV infection. 
Virally infected cell expression was compared to the controls with the controls 
normalized at 100%. The experiment was repeated three times. The value with (*) 
representing the significant difference than its time point control (p˂ 0.05). 
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CHAPTER 4.  
EFFECT OF BVDV INFECTION ON AUTOPHAGOSOME INDUCTION 
ABSTRACT 
Bovine viral diarrhea virus (BVDV) is an important pathogen of cattle. The 
virulence factors responsible for BVDV pathogenesis are not well characterized.  One 
cellular pathway that has been shown to be important for viral pathogenesis in other virus 
system is autophagy. Autophagy is a cellular process to recycle and maintain the cellular 
homeostasis and an important defense process of cell against various invading pathogens. 
Autophagy occurs at low basal levels in almost all cells. It is up regulated in cellular 
stress including starvation, oxidative stress or infection.  Several viruses including 
flavivirus family have developed the strategies to subvert or use autophagy for their own 
benefit including replication. The current study was carried out to unravel the relationship 
between BVDV infection and autophagy induction and to determine the effect of cp and 
ncp strain of BVDV on autophagosome formation. Stable expressing GFP-LC3 (Green 
fluorescent protein – Microtubule-associated protein 1A/1B-)-MDBK cell or GFP-LC3-
Bt cell lines were created. The virus pair, cp BVDV1b-TGAC and ncp BVDV1b-TGAN 
were used in the study. The stable-expressing GFP-LC3 cells were infected with either 
cp. BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV at a MOI of 6. BVDV 
induced autophagy in MDBK cells as well as in Bt cells, infected with either cp 
BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV. There was no significant 
difference between cp or ncp strains of BVDV in autophagy induction. The autophagy 
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inducing drug, rapamycin enhanced viral production while autophagy inhibiting drug, 
3MA suppressed viral production. The co-localization study using, BVDV NS5A and E1 
proteins with the autophagosome marker, LC3 revealed that BVDV does not replicate in 
autophagosomes. The likely function for autophagy with BVDV infection is to support 
BVDV replication by providing energy for replication.  
INTRODUCTION 
Autophagy is a normal cellular physiological process where cytoplasmic 
components are sequestered, enzymatically digested and recycled to maintain cellular 
homeostasis (Mizushima, 2007). This “cellular recycling program” not only provides 
nutrients to maintain vital cellular functions during fasting but also provides a pathway to 
eliminate superfluous or damaged organelles, misfolded proteins, and invading 
microorganisms (Levine and Kroemer, 2008). Autophagy occurs at low basal levels in 
almost all cells. It is rapidly up regulated when cells need to generate intracellular 
nutrients and energy during starvation or high bioenergetic demands. Autophagy is also 
up regulated during oxidative stress, infection or protein accumulation (Kiffin et al., 
2006; Dreux et al., 2009; Liu et al., 2010).  
Autophagy also is important in innate and adaptive immune response against a 
variety of pathogens including bacteria and viruses (Deretic, 2005; Deretic and Levine, 
2009). The autophagy is induced by various toll-like receptors (TLR), nucleotide-binding 
oligomerization domain (NOD)-like receptors, retinoic acid-inducible gene I (RIG-I)-like 
receptors, and damage associated molecular patterns (DAMP) such as high-mobility 
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group box 1 (HMGB1) protein ligation. The interaction of single-stranded RNA with 
TLR7 was found as the most potent effector in autophagy induction (Deretic, 2011). 
Autophagy is induced by LPS through a Toll/interleukin-1 receptor domain containing 
adaptor inducing interferon beta (TRIF) dependent or myeloid differentiation factor 88 
(MyD88) independent TLR4 signaling pathway (Xu et al., 2007).  In adaptive immunity, 
autophagy increases the antigen recognition through MHCII molecule with enhanced T 
cell activation and proliferation (Paludan et al., 2005; Schmid et al., 2007). Autophagy 
controls the proliferation and survival of T and B cells (Li et al., 2006; Miller et al., 
2008). The knock down of Agt 5 gene (autophagy-related gene 5) in mice reduced total 
thymocytes and peripheral T and B lymphocytes. Agt 5 knockdown mice displayed a 
dramatic increase in cell death in peripheral CD8+ T lymphocytes and CD4+ and CD8+ 
T cells failed to undergo efficient proliferation after TCR stimulation (Pua et al., 2007). 
The antimicrobial defense mechanism of autophagy is controlled by Th1 and Th2 
polarization. The Th2 cytokines, IL-4 and IL-13 reduced autophagy in Akt or PKB 
(Protein Kinase) signaling (Harris et al., 2007) while Th1 cytokine, IFN gamma 
enhanced autophagy and suppressed intracellular survival of mycobacterium (Gutierrez 
et al., 2004).  Akt or PKB (Protein Kinase B) is a serine/threonine protein kinase that 
plays an important role in cell proliferation and apoptosis. Despite the effective role of 
autophagy in immune response, many viruses have developed strategies to subvert or use 
autophagy for their efficient replication (Jackson et al., 2005). Autophagy is utilized for 
replication of poliovirus (Jackson et al., 2005; Taylor and Kirkegaard, 2007) and 
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coxsackieviruses (Wong et al., 2008; Yoon et al., 2008). The flaviviridae use 
autophagosome in two different ways. Hepatitis C virus (HCV) (Ait-Goughoulte, et al., 
2008; Sir et al., 2008; Dreux and Chisari 2009), dengue virus (DENV) (Panyasrivanit 
et al., 2009; Heaton et al., 2010; McLean et al., 2011), and Japanese encephalitis (Li et 
al., 2012) induce autophagy for their replication while West Nile virus (WNV) induces 
autophagy for cell survival (Beatman et al., 2012). Bovine viral diarrhea virus (BVDV) 
is a member of the flavivirus family and the pestivirus virus group. BVDV causes great 
economic loss in cattle industry through its immunosuppression and persistent infection. 
A unique characteristic of BVDV is the ability of the virus to have two different 
phenotypes in cell culture: cytopathic (cp) or noncytopathic (ncp) effects. These 
phenotypes are the result of well characterized genotypic changes that occur in a fatal 
form of BVDV, mucosal disease (MD). In MD, BVDV pairs exist where the ncp strains 
has mutated and become a cp strain. The current study was carried out for better 
understanding the relationship BVDV infection and autophagy induction along with 
differential effect of cp and ncp BVDV infection and autophagosomes formation.  
MATERIALS AND METHODS 
Viruses:  
The homologous pair of ncp and cp viruses (ncp BVDV1b-TGAN and ncp 
BVDV1b-TGAC) recovered from an animal that died of mucosal disease were used in 
the study. The virus stock was prepared in MDBK cells. A 5 ml of 5x10
5
 MDBK cells/ml 
were seeded in T25 flasks using minimal essential medium (MEM, Gibco BRL, Grand 
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Island, NY) supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin 
(100μg/ml). The cells were grown up to 60-70% confluency. The cells were infected with 
viruses with 1 MOI of infection. A 0.75 ml of virus was added to each T25 flask and 
adsorbed for 1 hr at 37°C in a humidified CO2 incubator. After 1 hr incubation, non-
adsorbed virus was removed and cells were washed with sterile PBS. After the washing, 
5 ml MEM medium supplemented with 10% FBS, penicillin (100 U/ml) and 
streptomycin (100μg/ml) was added to each flask. The cells were incubated at 37°C in a 
humidified CO2 incubator for 4-5 days or up to 70-80% cytopathic effect for TGAC.  
After 4-5 days of incubation, cells were freezed (-80˚C for 15 minutes) and thawed at 
25˚C for two cycles to release the virus. The cell debris was pelleted by centrifugation at 
3000 rpm for 10 min at 4°C in 15 ml conical tubes. Supernatants containing virus were 
titrated, aliquoted and stored at -80 °C for further use. The virus titration was done as per 
method described earlier (Reed and Munech, 1938) by by inoculating the sample 
serially 1 in 10 dilutions in MEM containing MDBK cells. Briefly MDBK cells were 
detached from tissue culture flask. The number of cells was adjusted to 5x10
5
 cells/ ml. A 
one hundred-eighty (180) µl cell suspension was added to each well of 96 well plate. A 
twenty (20) µl virus was added to first row of the plate. The virus was mixed properly 
with MDBK cells and 20 µl of this dilution was added to next row to achieve 10 fold 
dilutions. Last two rows were treated as negative control with no virus. The plate was 
incubated at 37 °C at humidified incubator for next 4 days. The plate was examined every 
day for cytopathic effect (CPE) of the virus. The highest dilution showing CPE was used 
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as end point to calculate the proportionate distance (PD). The PD was used to determine 
the viral concentration (TCID50) as per formula as described earlier (Reed and Munech, 
1938). 
9. Proportionate distance (PD) = (% CPE at dilution above 50%) – (50%)/ (% CPE 
at dilution above 50%)- (% CPE at dilution below 50%) (e.g.  60-50/60-0= 0.166) 
10. Calculation of end point just next to 50% CPE and conversion into  – Log (e.g.10-
6
 dilution would be -6) 
11. Calculation of TCID50.  
12.  TCID50 for 20 µl= 
(PD+ - Log dilution above 50%)  
(e.g. 1x10
6.166
) 
The end point for ncp TGAN BVDV was determined by staining the MDBK cells 
with anti-BVDV Erns antibody (15C5; IDEXX Laboratories, Westbrook, ME, USA) 
followed by biotinylated rabbit anti mouse IgG (Zymed, Invitrogen Corporation, 
Frederick, MD, USA)  Steptavidin-HRP ( Invitrogen Corporation, Camarillo, CA, USA) 
and AEC reagent (3 amino-9 ethyl-carbazole) (Sigma-Aldrich, St. Louis, MO, USA).The 
BVDV positive cells were stained red.  
Cells:  
The BVDV free MDBK cells (passage 95-110) were used in the study. The cells 
were grown in minimal essential medium (MEM, Gibco BRL, Grand Island, NY) (pH 7-
7.4) supplemented with 10% BVDV free FBS (PPA, Pasching, Austria), penicillin (100 
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U /ml) and streptomycin (100 μg /ml). MDBK cells were used for viral propagation, virus 
titration, and transduction with pseudo-lentivirus containing GFP-LC3 gene, and co-
localization using indirect immunofluorescence assay. 
The BVDV free Bt cells (passage 31-36) obtained from calf from a BVDV 
antibody- negative dam were used in the study (McClurkin et al., 1974). The cells were 
cultured using the same conditions as described above for MDBK cells. The Bt cells were 
used for virus growth curve, transduction by pseudo-lentivirus containing GFP-LC3, co-
localization and indirect immunofluorescence assay. The 293T cells (passage 42-49) 
were cultured using the same conditions as described above for MDBK and Bt cells. The 
293T cells were used for plasmid transfection and creating of pseudo-lentivirus. 
LC3- GFP stabilized cell line: 
Autophagy was visualized in green fluorescent protein-(GFP)- Microtubule-
associated protein 1A/1B-light chain 3 (LC3) transducted cells. GFP-LC3 plasmid 
construct was transducted into Bt and MDBK cells using pseudo-lentivirus. The GFP-
LC3 gene from addgene plasmid 11546 (kindly provided by Dr. Karla Kirkegaard) 
(Jackson et al., 2005), was cut between Ndel and BamH1 or ApaLI and BamH1 
restriction sites and inserted into lentivirus vector addgene plasmid 17448 (kindly 
provided by Dr Eric Campeau) (Campeau et al., 2009). To make pseudo-lentivirus, 
293T cells were cultured in 6 well plates to 60-70% confluency. The 293T cells were co-
transfected with lentivirus vector plasmid containing GFP-LC3 gene with packaging 
addgene plasmid 22036 (kindly provided by Dr. Didier Trono, GHI, Switzerland) and the 
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plasmid containing vesicular stomatitis virus G glycoprotein, addgene plasmid 14888 
(kindly provided by Dr. Tannishtha Reya) (Reya et al., 2003). The lentivirus vector 
plasmid containing GFP-LC3, packaging plasmid and the plasmid containing VSV-G 
gene was mixed at a 2:1:1 ratio. One (1) mg DNA was transfected into 293 T cells using 
3 µl transfecting reagents (Roche Applied Science, IN, USA).  After 72 hr p.i., 
supernatant  and 293 T cells were collected. The collected 293T cells with its supernatant 
were freezed (-80˚C) and thawed two times as described earlier to release virus. The 
GFP-LC3 or LentiBrite recombinant virus (EMD Millipore Corporation, Billerica, MA, 
USA) was transducted into the MDBK cells or Bt cells. The Transducted cells produced 
green fluoresce after excitation at 395-475 nm wavelength.   
Drugs and virus production:  
The rapamycin (Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 50 nM 
in MEM (Gibco BRL, Grand Island, NY) (pH 7-7.4) supplemented with 10% free fetal 
calf serum (PPA, Pasching, Austria), penicillin (100 U /ml) and streptomycin (100 μg 
/ml) was used as the autophagy inducer while 3-methyladenine (3-MA) (Sigma-
Aldrich,St. Louis, MO, USA) at a concentration of 10 mM in MEM (Gibco BRL, Grand 
Island, NY) (pH 7-7.4) supplemented with 10% free fetal calf serum (PPA, Pasching, 
Austria), penicillin (100 U /ml) and streptomycin (100 μg /ml) was used as autophagy 
inhibitor (Lee et al., 2008).  The Bt cell or MDBK cells were grown in 6 well plates. The 
cells were infected with either cp TGAC or ncp TGAN strain of BVDV at a MOI of  6 . 
Mock-infected Bt cells or MDBK cells were used as controls. After 1 hr of incubation, 
180 
 
  
non-adsorbed virus was removed and cells were washed with sterile PBS. After washing, 
3 ml medium supplemented with or without rapamycin (50 nM) or 3-MA  (10 mM) was 
added to each well. The cell supernatant was collected at 1 hr, 6 hr, 12 hr, 24 hr, 48 hr 
and 72 hr p.i. for virus production. The virus tier at each time point was measured as per 
method described earlier (Reed and Munech, 1938) by by inoculating the sample 
serially 1 in 10 dilutions in MEM containing MDBK cells 
Autophagy measurement:  
The GFP-LC3 transducted Bt cell or MDBK cells were cultured in 4 well 
chamber slides (Thermo scientific, Wilmington, DE, USA) under the same conditions as 
described above. The cells were infected with either cp TGAC or ncp TGAN strain of 
BVDV at a MOI of 6. The mock infected cells were used as control. After 1 hr of 
incubation non-adsorbed virus was removed and cells were washed with sterile PBS. The 
cells were supplemented with medium containing rapamycin (50 nM) or 3-MA (10 mM 
MEM) or none. The cells were fixed with 4% paraformaldehyde (PFA) at 12 hr, 24 hr 
and 48 hr p.i. and mounted with vectashield mounted medium (Vector laboratories, 
Brlingame, CA, USA).The presence of green fluorescent LC3 dot formation at each time 
point was counted manually using florescent microscope (Olympus, PA, USA) and the 
percentage of autophagosome positive cells were calculated with following formula 
Percentage of autophagy = (Number of transducted cell showing autophagy/ Total 
Number of transducted cell) x100 
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Co-localization of Autophagosome and BVDV Proteins:  
The GFP-LC3 transducted Bt cells were cultured in 4-well chamber slides as 
described above. The Bt cells were infected with ncpBVDV1b-TGAN strain of BVDV at 
a MOI of 6. Mock-infected cells were used as controls. The viruses were adsorbed for 1 
hr by incubation at 37 °C in humidified CO2 incubator. After adsorption, cells were 
washed with sterile PBS. One (1) ml MEM (Gibco BRL, Grand Island, NY) (pH 7-7.4) 
supplemented with 10% fetal calf serum (PPA, Pasching, Austria), penicillin (100 U /ml) 
and streptomycin (100 μg /ml) was added to each well. The chamber slides were 
incubated 37 °C in humidified CO2 incubator for next 48 hr. The BVDV TGAN infected-
GFP-LC3 transducted Bt cells were fixed with 4% PFA for 15 minutes at room 
temperature. The fixed cells were permeabilized using 0.3% Triton in PBS containing 3% 
BSA by incubating at 37°C for 30 minutes. The permeabilized GFP-LC3 transducted Bt 
cells were stained with rabbit polyclonal anti-NS5A-BVDV or rabbit polyclonal anti-E1 
BVDV antibody (kindly provided by Dr. Julia F Ridpath, Ruminant Diseases and 
Immunology Research Unit, National Animal Disease Center, USDA, Ames, IA, USA) at 
a concentration of 1:1000 in PBS. The cells were incubated at 37 °C for 1 hr in 
humidified CO2 incubator. The cells were washed 3 times with PBS for 2-3 minutes each. 
The cells were then incubated with anti-rabbit antibody conjugated with rhodamine 
(Sigma-Aldrich, St. Louis, MO, USA) with concentration of 1:1000 in PBS at 37 °C for 1 
hr in humidified CO2 incubator. After secondary antibody incubation, cells were washed 
3 times with PBS and one additional wash with milli Q water. The cells were mounted 
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with Vectashield mounted medium containing DAPI (Vector Laboratories, Burlingame, 
CA, USA) and examined for BVDV protein and LC3 co-localization using a fluorescent 
microscope (Olympus, PA, USA). 
Statistical Analysis: 
The experiments to measure autophagsome formation in BVDV infected-GFP-LC3-
transducted cells or to measure the effect of autophagosomes on virus production were 
carried out at least three times. The mean and standard deviation were calculated. The 
significance difference between each time points was determined by use of the student T 
test at 0.5 % level of significance 
RESULT 
Induction of autophagy by cp or ncp strains of BVDV:  
The purpose of this experiment was to investigate whether BVDV induced 
autophagy in BVDV infected cell and determine the ability of cp or ncp strain of BVDV 
in autophagy induction. The immortal cell line, MDBK cells and primary cell line, Bt 
cells, were used in this study. The GFP-LC3 transducted MDBK cell or Bt cells were 
adjust to 5x105 cell/ml in MEM (Gibco BRL, Grand Island, NY) (pH 7-7.4) 
supplemented with 10% free fetal calf serum (PPA, Pasching, Austria), penicillin (100 U 
/ml) and streptomycin (100 μg /ml). One ml of this cell suspension was added to each 
well of4-well chamber slides. The cells were attached to the slide by incubating the cells 
at 37° C in humidified Co2 incubator overnight.  The cells were infected with either cp 
BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV with 6 MOI infections. Mock-
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infected cells were used as a negative control. After 1 hr virus adsorption, non adsorbed 
virus was removed and cells were either supplemented with MEM medium containing 
10% FBS and antibiotics or MEM medium containing 10% FBS, antibiotics and 
rapamycin (50 nM) or 3-MA (10 mM).The percentage of transducted cells showing 
autophagosome as indicated by green fluorescent dots was calculated. The infection of 
ncp BVDV1b-TGAN or cp BVDV1b-TGAC strain of BVDV induced the autophagy in 
MDBK cells which was approximately 24%(28.00±3.46%), 50% (72.66±5.03%), 60% 
(92.66±1.54%) or 22% (26.66±2.3%), 50%(72.00±4.00%), 56% (86.66±1.15%) higher 
than mock infected time point controls at 12 hr, 24 hr or 48 hr p.i. which were 
4.66±1.54%, 23.33±1.54% or 30.66±1.54% at 12 hr, 24 hr or 48 hr p.i. (Table 4-1, Figure 
4-1, Figure 4-2, Figure 4-3). The autophagy induction either by ncp BVDV1b-TGAN or 
cp BVDV1b-TGAC strain of BVDV was significantly different at 24 hr or 48 hr p.i. as 
compare to time point control (p˂ 0.05).  There was no significant difference in induction 
of autophagy between ncp BVDV1b-TGAN and cp BVDV1b-TGAC strain of BVDV in 
MDBK cells (p˂ 0.05).The 3MA reduced the autophagy in MDBK cells infected with 
ncp BVDV1b-TGAN or cp BVDV1b-TGAC strain of BVDV as approximately 15% 
(13.00±1.00%), 14% (58.00± 4.00%), 28% (64.66±6.11%) or 6% (10.00±5.29%), 14% 
(66.66±1.15%) and 25% (64.66±2.30%) as compare to MDBK cell infected with ncp 
BVDV1b-TGAN or cp BVDV1b-TGAC alone at 12 hr, 24 hr and 72 hr p.i. The 
rapamycin did not increased the production of autophagosomes  in MDBK cell infected 
with cp BVDV1b-TGAC while it increased the autophagosome formation in MDBK cells 
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infected with ncp BVDV1b-TGAN at as approximately 1% (29.33±2.30%) and 6% 
(78.66± 12.22%) at 12 hr and 24 hr p.i. than the MDBK cell infected with ncp BVDV1b-
TGAN alone (Table 4-1 and Figure 4-2, Figure 4-3). 
The effect of BVDV on autophagy induction in Bt primary cell line was 
measured. The GFP-LC3 transducted Bt cell were infected with ncp BVDV1b-TGAN or 
cp BVDV1b-TGAC strain of BVDV. The percentage of transducted cells showing 
autophagosome in form of green fluorescent dots was counted. Both ncp BVDV1b-
TGAN or cp BVDV1b-TGAC strains of BVDV induced autophagy that was 
approximately 7% ( 17.00±6.92%), 6% (22.66±3.21%), 12% (31.33±7.37%) or 2% 
(12.66±5.03), 5% (23.33±2.51%) and 9% (28.66±6.43%) higher than mock infected time 
point controls at 12 hr, 24 hr or 48 hr p.i. which were  10.33±0.58%, 16.66±1.15% and, 
19.33±2.88% at 12 hr, 24 hr and 48 hr p.i. respectively (Table 4-2). The supplementation 
of rapamycin increase the production of autophagosomes in ncp BVDV1b-TGAN or cp 
BVDV1b-TGAC-infected Bt cells with 7% (24.33±2.08%), 6% (32.00±3.06%), 12% 
(35.00±3.46%) and 11% (23.00±2.64%), 7% (30.66±4.72%),3% ( 31.33±4.04%)as 
compare to Bt cell infected with ncp BVDV1b-TGAN or cp BVDV1b-TGAC at 12 hr, 24 
hr and 48 hr p.i. respectively. The 3MA reduced the autophagosome production in ncp 
BVDV1b-TGAN- or cp BVDV1b-TGAC-infected cells with 6% (11.33±4.94%), 8% 
(14.33±1.52%),  10% (21.33±2.88%) and 1% (13.00±6.244%), 6% (17.00±4.58%) and 
6% ( 22.00±1.00%)  as compare to Bt cell infected with ncp BVDV1b-TGAN or cp 
BVDV1b-TGAC at 24 hr and 48 hr p.i. respectively (Table 4-2, Figure 4-4, Figure 4-4). 
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Effect of autophagy on virus production: 
The Bt cell or MDBK cells were grown in 6-well plates and infected with either 
cp BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV at MOI of 6. The mock 
infected Bt cell or MDBK cells were used as control. After 1 hour incubation non 
attached virus was removed. The 3 ml medium with or without rapamycin (50 nM) or 3-
MA  (10 mM) was added to each well. The cell supernatant was collected at 1 hr, 6 hr, 12 
hr, 24 hr, 48 hr and 72 hr p.i. for virus production.  
There was no virus released in Bt cell supernatant up to 6 hr p.i, infected with 
either cp BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV. The BVDV 
production in ncp BVDV1b-TGAN- or cp BVDV1b-TGAC-infected Bt cell was 
increased from 12 hr p.i. to 48 hr p.i. The Bt cell infected with ncp BVDV1b-TGAN 
showed the virus production as 0.85±1.20 log10/ml, 1.70±0.00 log10/ml and 3.20±0.70 
log10/ml at 12 hr, 24 hr and 48 hr p.i. respectively (Figure 4-6).The Bt cell infected with 
cp BVDV1b-TGAC strain of BVDV showed the virus production as 0.85±1.20 log10/ml, 
2.70±0.00 log10/ml and 4.20±0.70 log10/ml at 12 hr, 24 hr and 48 hr p.i. respectively 
(Figure 4.7). 
The virus production was increased in cell treated with autophagosome inducer 
drug, rapamycin while it is suppressed by autophagosome inhibitor drug, 3MA in both 
ncp BVDV1b-TGAN- and cp BVDV1b-TGAC-infected Bt cells. The rapamycin 
increased one log virus production in ncp BVDV1b-TGAN-infected cells from 1.70±0.00 
log10/ml to 2.70±0.00 log10/ml at 24 hr  p.i. Similarly, rapamycin increased the cp 
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TGAC production in cp BVDV1b-TGAC infected Bt cells. The cp BVDV1b-TGAC 
virus production was increased one log from 0.85±1.20 log10/ml to 1.7±0.00 log10/ml, 
2.69±0.00 log10/ml to 3.69±0.00 log10/ml and 4.19±0.70 log10/ml to 5.19±0.70 
log10/ml at 12 hr, 24 hr and 48 hr p.i. respectively (Figure 4-7). 
 The cp BVDV1b-TGAC or ncp BVDV1b-TGAN- infected and 3MA treated Bt 
cells didn’t show any virus production up to 24 hr p.i. These cells produced ncp 
BVDV1b-TGAN with 1.70±0.00 log10/ml and cp BVDV1b-TGAC as 0.85±1.20 
log10/ml at 48 hr p.i. (Figure 4.6, Figure 4-7). 
The MDBK cells, infected with ncp BVDV1b-TGAN produced virus as 
3.70±0.00 log10/ml and 5.19±0.70 log10/ml at 24 hr and 48 hr p.i. respectively. The 
autophagosome inducing drug, rapamycin facilitated the release of virus one time point 
earlier. Virus production in rapamycin-treated cell start at 12 hr p.i. as  1.70±0.00 
log10/ml. The virus production in ncp BVDV1b-TGAN infected and rapamycin-treated 
cell revealed virus titer as  4.20±0.70 log10/ml and 5.70±0.00 log10/ml at 24 hr and 48 hr 
p.i. respectively that was approximately one log higher at 24 hr and 0.5 log higher at 48 
hr than the MDBK cell infected with ncp BVDV1b-TGAN alone 
The cell treated with 3MA exhibited suppressed virus production. There was no 
virus production in MDBK cells infected with ncp BVDV1b-TGAN and supplemented 
with 3MA up to 24 hr p.i., those cells showed virus production as 1.69±0.00 log10/ml at 
48 hr p.i. (Figure 4-8).  
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The pattern of cp BVDV1b-TGAC virus production was similar in primary (Bt) 
and immortal (MDBK) cell lines. The MDBK cells, infected with cp BVDV1b-TGAC 
start producing virus from 12 hr p.i. The virus titer in those cells was reported as 
0.85±1.20 log10/ml, 3.70±0.00 log10/ml and 5.70±0.00 log10/ml at 12 hr, 24 hr and 48 
hr p.i. respectively. The virus production was increased with autophagy inducing drug, 
rapamycin while it is suppressed by autophagy inhibiting drug, 3MA. The MDBK cell 
infected with cp BVDV1b-TGAC and treated with rapamucine revealed virus production 
as 2.19±0.70 log10/ml, 3.69±0.00 log10/ml, 1.69±0.00 log10/ml at 12 hr, 24 hr and 48 hr 
p.i. that was two logs higher at 12 hr p.i. and one log higher at 48 hr p.i. as compare to 
cells that were  infected with cp BVDV1b-TGAC alone without rapamycin  (Figure 4-
9).The MDBK cell infected with cp BVDV1b-TGAC strain of BVDV and treated with 
3MA did produce any virus up to 24 hr p.i. and produced virus with titer of 1.69±0.00 
log10/ml at 48 hr p.i. that was 4 log lower than the untreated MDBK cells and 5 log 
lower than MDBK cells treated with rapamycin (Figure 4-9). 
Co-localization of autophagy with BVDV proteins:  
The various reports of positive strand RNA virus demonstrated the co-localization 
of autophagosomes and viral proteins, suggested that these viruses replicates in 
autophagosomes. To determine BVDV replicate in autophagosomes, the co-localization 
study of LC3 (autophagosome marker) with NS5A, or E1 protein of BVDV was carried 
out in MDBK cells. None of the above viral proteins were co-localized with LC3, 
indicating that BVDV did not replicate in autophagosomes (Figure 4.10, Figure 4-11), 
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while the increase in virus titer with up regulation of autophagosomes indicate that 
autophagy indirectly facilitated BVDV replication.  
DISCUSSION 
In the current study, the relationship between BVDV infection and autophagy 
induction was investigated. The study revealed that both ncp and cp strains of BVDV 
induced autophagy. The autophagy induction in BVDV infected cells was significantly 
different than mock-infected cells. There was no significant difference between cp and 
ncp strain of BVDV in formation of autophagosomes. The autophagy inducing drug, 
rapamycin, increased autophagy and BVDV replication while autophagy inhibiting drug, 
3MA, suppressed autophagy and BVDV replication. Cells infected with flaviviruses often 
result in persistent infection and cell survival (Brocket al., 1998; Tonry et al., 2005; 
Appleret al.; 2010). The persistent infection with cell survival supported that flaviviruses 
may induce autophagy (Codogno and Meijer, 2005). There is evidence that IFN 
regulation may be part of the mechanism of autophagy enhancement of the viral 
replication. One study with vesicular stomatitis virus (VSV) revealed that the conjugated 
autophagy gene Atg5–Atg12 negatively regulated type I IFN production by direct 
association with the retinoic acid-inducible gene I (RIG-I) and IFN-beta promoter 
stimulator 1 (IPS-1) through the caspase recruitment domains (CARDs) (Jounai et al., 
2007). It is possible then that reduced type I IFN production may result in enhanced viral 
replication with BVDV persistent infection. Noncytopathic (ncp) BVDV did not produce 
sufficient type 1 IFN and cause persistent infection (Charleston et al., 2001) with 
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reduced MHCI expression on antigen presenting cells (Chase et al., 2004).  In contrast, 
the absence of autophagy gene Atg 5, resulted in ROS-dependent amplification of RLR 
(RIG-I-like receptors) signaling and increased type I IFNs (Tal et al., 2009).  
Several hypotheses have been proposed that suggest that regulating 
assembly/metabolism is a mechanism for autophagy to increase virus growth. One 
hypothesis proposes that the autophagosomes may act as a site of replication for several 
viruses families including two other positive sense RNA viruses families, Nidovirales and 
Picornaviridae and also the Flaviviridae. The double membrane autophagosomes provide 
a scaffold for anchoring and concentrating the replication complexes to prevent the 
immune response triggered by dsRNA intermediates and “recruit” or hijack certain lipids 
required for genome synthesis (Wileman, 2006; Miller and Krijnse-Locker, 2008). 
Recent evidence has suggested that autophagy may contribute to the early phase of viral 
life cycle (Reggiori et al., 2010) and increased viral titer. Autophagy regulates the 
cellular metabolism. The virus infection leads to an autophagy dependent processing of 
lipid droplets and triglycerides to release free fatty acids. This results in an increase 
intracellular beta-oxidation and ATP generation. The energy released by beta-oxidation 
may be utilized for efficient viral replication (Heaton and Randall, 2010). In the current 
study, using BVDV NS5A and BVDV E1 proteins with autophagosomes marker LC3 
revealed that BVDV did not replicate in autophagosomes while it facilitated the 
replication of BVDV in infected cells. This indicates that the autophagy machinery likely 
supported viral RNA replication by providing required energy as reported by (Dreux et 
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al., 2009) in HCV replication. The BVDV cytopathic viruses isolated from cattle with 
lethal mucosal disease had been found to contain the LC3 gene in the viral genome that 
allowed specific cleavage of its polyprotein into individual viral proteins presumably by 
the Atg4 protease (Meyers et al., 1998) while the BVDV infected cells, carrying the LC3 
gene did not affect the expression of LC3 in cells (Fricke et al., 2004). The proper 
cleavage of BVDV viral polyprotein may contribute to efficient progeny virion 
generation. Both Dengue-2 and Modoc (a murine flavivirus) infection induced the PI3K-
dependent autophagy in MDCK cells. The PI3K-dependent autophagy was mediated by 
flavivirus NS4A gene. The up-regulation of autophagy markedly enhanced the virus 
replication and prevented cell death (McLean et al., 2011). Similarly, the expression of 
NS4B gene of HCV alone is able to induce autophagy via interactions with both the early 
endosome-associated GTPase Rab5 and a class III phosphoinositide 3-kinase, Vps34 (Su 
et al.,  2011). It will be interesting to know which BVDV viral protein/s is/ are 
responsible to induce autophagy in BVDV infected cells. 
Briefly, this study indicated that both cp and ncp biotypes induced the autophagy 
in immortal as well as primary cell lines. The autophagy induction by BVDV strains was 
significantly different than mock-infected cells at 24 hr and 48 hr p.i. There was no 
difference between cp and ncp biotypes of BVDV in induction of autophagy.  The 
autophagy inducing drug, rapamycin enhanced viral production while autophagy 
inhibiting drug, 3MA suppressed the viral production suggesting that autophagy facilitate 
the BVDV replication. The co-localization study using, BVDV NS5A and E1 proteins 
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with the autophagosome marker, LC3 revealed that BVDV does not replicate in 
autophagosomes. The likely function for autophagy with BVDV infection is to support 
BVDV replication by providing energy for replication.  
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Figure 4-1. Induction of autophagy in MDBK cells after cp BVDV1b TGAC or ncp 
BVDV1b-TGAN infection. The GFP-LC3 transducted MDBK cells were infected with 6 
MOI of either cp BVDV1b-TGAC or ncp BVDV1b-TGAN strains of BVDV for 24 hr. 
A) Mock-infected control cells; B) cp TGAC or C) ncp TGAN infected MDBK cells 
showing autophagosome formation. The formation (LC3) of green dots indicated 
autophagosomes (arrows) 
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Figure 4-2. The percentage of autophagy in MDBK cells after ncp BVDV1b-TGAN 
infection. The GFP-LC3 transducted MDBK cells were infected with ncp BVDV1b-
TGAN strain of BVDV with MOI of 6. The mock infected cells were used as control. 
The infected cells were supplemented with either rapamycin (50 nM), 3-MA (10 mM) or 
none. The percentage of green dots formation (LC3) indicating autophagy in transducted 
cells were calculated at 12 hr, 24 hr and 48 hr p.i.. The ncpBVDV1b-TGAN-treated cells 
that induced autophagy significant differences (p<0.05) then control at 24 hr or 48 hr p.i. 
(The significantly different between two treatment is shown by asterix sign {*}, p<0.05). 
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Figure 4-3. The percentage of autophagy in MDBK cells after cp BVDV1b-TGAC 
infection. The GFP-LC3 transducted MDBK cells were infected with cp BVDV1b-
TGAC strain of BVDV with MOI of 6. The mock-infected cells were used as control. 
The infected cells were supplemented with either rapamycin (50 nM), 3-MA (10mM) or 
no treatment. The percentage of green dots formation (LC3) indicating autophagy in 
transducted cells were calculated at 12 hr, 24 hr and 48 hr p.i. respectively. The cpBVDV 
1b-TGAC- treated cells induced autophagy significantly then control at 24 hr or 48 hr p.i. 
(The significantly different between two treatment is shown by asterix sign {*}, p<0.05). 
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Figure 4-4. The percentage of autophagy in Bt cells after ncp BVDV1b-TGAN 
infection. The GFP-LC3 transducted Bt cells were infected with ncp BVDV1b-TGAN 
strain of BVDV with MOI of 6. The mock infected cells were used as controls. The 
infected cells were supplemented with either rapamycin (50 nM), 3-MA (10mM) or no 
treatment. The percentage of green dots formation (LC3) indicating autophagy in 
transducted cells were calculated at 12 hr, 24 hr and 48 hr p.i. respectively.  
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Figure 4-5. The percentage of autophagy in Bt cells after cp BVDV1b-TGAC 
infection. The GFP-LC3 transducted Bt cells were infected with cp BVDV1b-TGAC 
strain of BVDV with MOI of 6. The mock infected cells were used as control. The 
infected cells were supplemented with either rapamycin (50 nM), 3-MA (10 mM) or no 
treatment. The percentage of green dots formation (LC3) indicating autophagy in 
transducted cells were calculated at 12 hr, 24 hr and 48 hr p.i. respectively.   
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Figure 4-6. The ncp BVDV1b-TGAN virus production by Bt cells in response to 
autophagy inducing or inhibiting drugs. The Bt cells were infected with cp BVDV1b-
TGAN strain of BVDV with MOI of 6. After virus adsorption, the infected cells were 
washed and supplemented with media containing either rapamycin (50 nM), 3-MA 
(10mM) or no treatment. The cell supernatant was collected at 1 hr, 6 hr, 12hr, 24 hr or 
48 hr p.i. The virus titer was measured at each time point.  
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Figure 4-7. The cp BVDV1b-TGAC virus production by Bt cells in response to 
autophagy inducting or inhibiting drugs. The Bt cells were infected with cp BVDV1b-
TGAC strain of BVDV with MOI of 6. After virus adsorption, the infected cells were 
washed and supplemented with media containing either rapamycin (50 nM), 3-MA (10 
mM) or none. The cell supernatant was collected at 1 hr, 6 hr, 12hr, 24 hr and 48 hr p.i. 
The virus titer was measured at each time point.  
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Figure 4-8. The ncp BVDV1b-TGAN virus production by MDBK cells in response 
to autophagy inducing or inhibiting drugs. The MDBK cells were infected with 
ncpBVDV1b-TGAN strain of BVDV with MOI of 6. After virus adsorption, the infected 
cells were washed and supplemented with media containing either rapamycin (50 nM), 3-
MA (10mM) or no treatment. The cell supernatant was collected at 1 hr, 6 hr, 12hr, 24 hr 
and 48 hr p.i. The virus titer was measured at each time point.  
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Figure 4-9. The  cp BVDV1b-TGAC virus production by MDBK cells in response to 
autophagy inducing or inhibiting drugs. The MDBK cells were infected with cp 
BVDV1b-TGAC strain of BVDV with MOI of 6. After virus adsorption, the infected 
cells were washed and supplemented with media containing either rapamycin (50 nM), 3-
MA (10mM) or no treatment. The cell supernatant was collected at 1 hr, 6 hr, 12hr, 24 hr 
and 48 hr p.i. The virus titer was measured at each time point.  
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Figure 4-10. The co-localization of BVDV E1 protein and LC3. The GFP-LC3 transducted MDBK cells were infected with 
ncp BVDV1b-TGAN strain of BVDV with MOI of 6 for 48 hr. After 48 hr infection, cells were fixed and stained with rabbit 
anti BVDV E1 antibody followed by anti rabbit antibody conjugated with rhodamine. A) BVDV E1 proteins with red; B) LC3 
formation in green; C) the blue colored cell nucleus and D) co-localization of BVDV E1 protain and LC3.  
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Figure 4-11. The co-localization of BVDV NS5A protein and LC3. The GFP-LC3 transducted MDBK cells were infected 
with ncp BVDV1b-TGAN strain of BVDV with MOI of 6 for 48 hr. After 48 hr infection, cells were fixed and stained with 
rabbit anti BVDV NS5A antibody followed by anti rabbit antibody conjugated with rhodamine. A) BVDV NS5A proteins with 
red; B), LC3 formation in green; C) the blue colored cell nucleus, and D) co-localization of BVDV NS5A protein and LC3. 
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Table 4-1. The percentage of autophagy in MDBK cells after cp BVDV1b-TGAC or ncpTGAN infection. The GFP-LC3 
transducted MDBK cells were infected with either cp BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV with MOI of 
6 with mock-infected control. The infected cells were supplemented with either rapamycin (50 nM), 3-MA (10 mM) or no 
treatment. The percentage of green dot formation (LC3) indicating autophagy in transducted cells was calculated at 12 hr, 24 
hr and 48 hr p.i. respectively. 
Time Control  cpTGAC cpTGAC+ 
Rapamycin 
cpTGAC+ 
3MA 
ncpTGAN ncpTGAN+ 
Rapamycin 
ncpTGAN+ 
3MA 
12 hr 4.66±1.15 26.66±2.31 26.00±1.63 10.00±5.29 28.00±3.46 29.33±2.31 13.00±1.00 
24 hr 23.33±1.15 74.66±4.00 74.66±9.43 60.66±1.15 72.66±5.03 78.66±12.22 58.00±4.00 
48 hr 30.66±1.15 89.33±1.15 89.33±1.89 64.66±2.31 92.66±1.15 92.66±2.31 64.66±6.11 
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Time Control  cpTGAC cpTGAC+ 
Rapamycin 
cpTGAC+ 
3MA 
ncpTGAN ncpTGAN+ 
Rapamycin 
ncpTGAN+ 
3MA 
12 hr 10.33±0.57 12.66±5.03 23±2.64 13±6.24 17±6.92 24.33±2.08 11.33±4.93 
24 hr 16.33±1.15 23.33±2.51 30.66±4.72 17±4.28 22.66±3.21 32±3.60 14.33±1.52 
48 hr 19.33±2.88 28.66±6.42 31.33±4.04 22±1.00 31.33±7.37 35±3.46 21.88±2.88 
 
Table 4-2. The percentage of autophagy in Bt cells after cp. BVDVb1-TGAC or ncp BVDVb1-TGAN infection. The 
GFP-LC3 transducted Bt cells were infected with either cp BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV with 
MOI of 6 with mock-infected control. The infected cells were supplemented with either rapamycin (50 nM), 3-MA (10 mM) or 
no treatment. The percentage of green dot formation (LC3) indicating autophagy in transducted cells was calculated at 12 hr, 
24 hr and 48 hr p.i. respectively 
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  CHAPTER 5. 
EFFECT OF ACUTE BVDV INFECTION ON ANTIBODY LEVELS AND 
POLARITY OF THE HUMORAL IMMUNE RESPONSE 
ABSTRACT 
Bovine viral diarrhea virus (BVDV) infection causes transient 
immunosuppression in acutely infected animals. The study was conducted to investigate 
the effect of cytopathic (cp) or noncytopathic (ncp) strain of BVDV in 
immunosuppression and polarization of immune response. The concentrations of total 
IgG, IgG1 and IgG2 were used to estimate the T helper -2 (TH-2) and T helper -1 (TH-1) 
immune responses. Fourteen, 5-6 months old BVDV seronegative calves were divided in 
to two groups with seven calves each. One group was infected with ncp BVDV1b-TGAN 
strain of BVDV while the other group was infected with the member of the pair, cp 
BVDV1b-TGAC strain intranasally. Blood was collected at 0, 7, 14, 21 and 35 days post 
infection (p.i.). The serum was separated and the concentration of total IgG, IgG1 and 
IgG2 was measured by ELISA.  The concentrations of total IgG and IgG1 were reduced 
by 40-60%by day 7 p.i. in both the groups. The concentrations of total IgG and 
IgG1gradually increased from day 7 to day 35 in both the groups. The IgG2 
concentration fluctuated in both the groups throughout the study.  
The IgG2 concentration increased significantly (doubled) from day 0 to day 7 in 
calves infected with ncp BVDV1b-TGAN strain of BVDV than was reduced by about 
30% at 21 days p.i. and then increased at 35 days to the level seen at day 7. The 
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concentration of IgG2 at day 35 was almost twice the initial IgG2 concentration in calves 
infected with ncp BVDV1b-TGAN strain of BVDV and the IgG1/IgG2 ratio was 
0.94±0.43, (normal 1.1-1.2) indicating that ncp BVDV1b-TGAN appears to direct the 
immune response toward a stronger T helper-1 (TH-1) or cellular immune response.  
The IgG2 concentration in calves infected with cp BVDV1b-GAC strain of 
BVDV significantly reduced about 10% from 0 day to 14 days p.i. and then increased 
significantly approximately 40% at 21 days and reduced again at 35 days to day 14 levels 
that was lower than the initial concentration of IgG2. The IgG1/IgG2 ratio at 35 days p.i. 
was 1.34±0.54. The reduced concentration of IgG2 at 35 days p.i. in calves infected with 
cp BVDV1b-TGAC strain of BVDV indicated that cytopathic BVDV divert the immune 
response toward T helper -2 (TH-2) or humoral immune response.  
The reduction in total IgG following BVDV infection in both the groups 
suggested that BVDV caused transient humoral immunosuppression following infection. 
The results of this study supported that the infection of calves with bovine virus diarrhea 
virus (BVDV) is a transient and self-limiting infection that can result in a period of 
humoral immunosuppression with the type of TH response affected dependent up on the 
viral strains.  
INTRODUCTION 
BVDV is one of the important disease of ruminants in USA and worldwide. 
BVDV induce immunosuppression at all levels of adaptive response from antigen 
presentation to B cell apoptosis (Chase, 2013).  BVDV infection affects the number of 
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circulating T-lymphocytes and B-lymphocytes. The effect of BVDV infection on the 
number of circulating T-lymphocytes is strain dependent and varies from a mild 
lymphopenia (10-20%) with ncp type 1b NY-1  (Brodersen  et al., 1999; Ellis et al., 
1988) to 40-50% with ncp type 1b R2360  (Ridpath et al., 2007) to a severe 
lymphopenia (50-70% decrease) with ncp type 2 field isolate 24515 (Archambault et al., 
2000) or ncp type 1b CA0401186a (Ridpath et al., 2007). The number of circulating B-
lymphocytes also decreased following infection with ncp NY1 BVDV from days 3 to 12 
(Ellis et al., 1988) while other studies did not found any effect on circulating B-
lymphocytes following infection with ncp type 2 field isolate 24515 (Archambault et 
al., 2000).  
BVDV infections have their major effect on follicular B-lymphocytes. In the 
lymphoid tissue, depletion of B cells occurs in the lymphoid follicles of the lymph nodes 
with highly virulent ncp BVDV and in Peyer's patches with both mucosal disease and 
highly virulent BVDV infections (Chase, 2013).  Circulating B lymphocytes have a 
direct effect on antibody synthesis and induction of humoral immune response. 
Intrabronchial BVDV infection with Singer strain increased, BVDV-specific IgA in 
bronchial alveolar fluid (BAF). The IgA in bronchial alveolar fluid increased to four-fold 
greater than background titers by day 7 post-primary infection, and to levels 20-fold 
above background within 7 days of the secondary viral infection (Silflow et al., 2005).  
The development of active immunity eliminates the virus and virus is rarely 
detected in buffy coat cells or nasal secretions (Howard et al., 1989).  The current study 
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was done to evaluate the effect of cp and ncp BVDV on immunosuppression and 
polarization of immune response in postnatal calves. The polarization of immune 
response was measured indirectly through concentrations of IgG1 and IgG2 to estimate 
the TH2 and TH1immune responses respectively (Kawasaki et al., 2004) 
MATERIALS AND METHODS 
Animals and viral infection:  
Fourteen (14) Holstein Friesian calves (5-6 months of age) were divided in to two 
groups with seven calves each, housed at in separate isolated pens, at SDSU, Brookings, 
SD, U.S.A.. The SDSU Institutional Animal Care and Use Committee approved the 
animal protocol procedures. All animals were healthy and seronegative for BVDV. A 
homologous pair of ncp and cp type 1b viruses Tifton GeorgiA Non-cytopathic (TGAN) 
or Tifton GeorgiA Cytopathic virus (TGAC) recovered from an animal that died of 
mucosal disease (Brownlie et al., 1984; Fritzemeier et al., 1995; Ridpath et al., 1991) 
were used to infect the animals. One group was infected with cp BVDV1b-TGAN strain 
of BVDV while the other group was infected with the other partner of the pair, cp 
BVDV1b-TGAN strain of BVDV. A total volume of 4 ml (1x10
6
pfu/ ml) virus was 
administered intranasally for each animal. Blood was collected at 0, 7, 14, 21 and 35 days 
p.i. The serum was separated and analyzed for total IgG, IgG1 and IgG2 concentrations 
via ELISA. 
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Measurement of Total IgG Serum:  
The serum concentration of total IgG was measured by bovine IgG ELISA kit 
(Bethyl Laboratories Inc, Montgomery, TX, USA), The 50 mMTris buffer containing 
0.14% M NaCl and 0.05% tween, pH 8.0 was used as sample and standard diluting 
buffer, blocking buffer and wash buffer as per the manufacture’s guidelines. To perform 
the ELISA for total IgG, the serum was diluted 1:160,000 in sample diluting buffer. The 
standard of known concentration for IgG was serially diluted in standard diluting buffer 
to achieve the concentrations of IgG of 10,000 ng/ml, 500 ng/ml, 250 ng/ml, 125 ng/ml, 
62.5 ng/ml, 31.25 ng/ml, 15.625 ng/ml and 7.8 ng/ml. The ELISA plates were coated 
with 100µl IgG capture antibody diluted in 0.05 M carbonate- bicarbonate buffer (pH 
9.6). The plates were incubated with capture antibody at room temperature for 60 
minutes.  Following coating, the plates were washed three times with wash buffer and 
blocked with 200 µl blocking buffer for 30 minutes at room temperature. The ELISA 
plates were washed three times with wash buffer. The 100 µl serially diluted IgG 
standards and samples were added to different wells of ELISA plates along with blank. 
The plates were incubated at room temperature for 60 minutes.  The plates were washed 
five times with wash buffer. Following washing, 100 µl of horseradish peroxidase (HPR) 
(1:22,500 dilution in HRP diluting buffer from the ELISA kit) was added to each well. 
The plates were incubated for 60 minutes at room temperature and washed five times 
with wash buffer. One hundred (100) µl substrate was added to each well as per 
manufacture’s guidelines. The plates were incubated in the dark for 15 minutes at room 
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temperature. The reaction was stopped using 2M H2S04 and the OD value was measured 
by Biotek ELx808 ELISA plate reader (Thermo Fisher Scientific Inc., Waltham, MA, 
USA) at 450 nm wavelength. The standard curved was plotted using Soft-Max pro 
software. The concentration of total IgG for each sample was estimated using the 
standard curve.  
Measurement of IgG1 Serum:  
The concentration of IgG1 in serum was detected by using a bovine IgG1 ELISA 
kit (Bethyl Laboratories Inc, Montgomery, TX, USA). The 50 mM Tris buffer containing 
0.14% M NaCl and 0.05% tween, pH 8.0 was used as HRP, sample and standard diluting 
buffer as well as blocking and wash buffer as per the manufacture’s guidelines. The 
serum was diluted in sample diluting buffer to achieve final dilution of 1:80,000. The 
IgG1 standard was serially diluted in standard diluting buffer to achieve the 
concentrations of 10,000 ng/ml, 1000 ng/ml, 500 ng/ml, 250 ng/ml, 125 ng/ml, 62.5 
ng/ml, 31.25 ng/ml and 15.625 ng/ml. 
The ELISA plates were coated with 100µl IgG1 capture antibody diluted in 0.05 
M carbonate-bicarbonate buffer (pH 9.6). The plates were incubated at room temperature 
for 60 minutes.  Following coating, the plates were washed three times with wash buffer 
and blocked with 200 µl blocking buffer for 30 minutes at room temperature. The ELISA 
plates were washed three times with wash buffer. The 100 µl serially diluted IgG1 
standards and samples were added to different wells of ELISA plate along with blank. 
The plates were incubated for 60 minutes at room temperature.  The plates were washed 
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five times with wash buffer. Following washing, 100 µl HPR (1:22,500 diluted in HRP 
diluting buffer) was added to each well. The plates were incubated for 60 minutes at 
room temperature and washed five times with wash buffer. The 100 µl substrate was 
added to each well. The plates were incubated for 15 minutes in the dark at room 
temperature. The reaction was stopped by adding 100 µl 2M H2S04 in each well. The OD 
value for each well was measured by Biotek ELx808 ELISA plate reader (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) at 450 nm wavelengths. The standard curved was 
plotted using Soft-Max pro software and concentration of IgG1 for each sample was 
estimated using the standard curve.  
Measurement of IgG2 Serum:  
The concentration of IgG2 in the calves’ serum was measured by using a bovine 
IgG2 ELISA kit (Bethyl Laboratories Inc, Montgomery, TX, USA). The 50 mM Tris 
buffer containing 0.14% M NaCl and 0.05% tween, pH 8.0 was used as sample, standard 
and HPR diluting buffer as well as blocking and wash buffer as per the manufacture’s 
guidelines. To perform the ELISA for total IgG2, the serum was diluted to 1:80,000 in 
sample diluting buffer. The IgG2 standard was serially diluted in standard diluting buffer 
to achieve the concentrations of IgG2 of 10,000 ng/ml, 500 ng/ml, 250 ng/ml, 125 ng/ml, 
62.5 ng/ml, 31.25 ng/ml, 15.625 ng/ml and 7.8 ng/ml. The ELISA plates were coated 
with 100µl IgG2 capture antibody diluted in 0.05 M carbonate- bicarbonate buffer (pH 
9.6). The plates were incubated with the capture antibody for 60 minutes at room 
temperature.  The plates were washed three times with wash buffer and blocked with 200 
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µl blocking buffer for 30 minutes at room temperature. Following blocking, the ELISA 
plates were washed three times with wash buffer. The 100 µl serially diluted IgG2 
standards and samples were added to different wells of ELISA plates along with blank. 
The plates were incubated at room temperature for 60 minutes.  The plates were washed 
five times with wash buffer. Following washing, 100 µl HPR (1:50,000 in HRP diluting 
buffer) was added to each well. The plates were incubated for 60 minutes at room 
temperature and washed five times with wash buffer. The 100 µl substrate was added to 
each well as per manufacture’s guideline. The plates were incubated at dark for 15 
minutes at room temperature. The reaction was stopped by adding 100 µl, 2M H2S04. 
The OD value was measured by Biotek ELx808 ELISA plate reader (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) at 450 nm wavelength. The standard curved was 
plotted using Soft-Max pro software. The concentration of IgG2 for each sample was 
estimated using a standard curve. 
Statistical analysis:  
The mean concentration of IgG, IgG1 and IgG2 was calculated. The variations in 
results were measured by standard deviation at each time points. The significance 
difference in IgG, IgG1, IgG2 concentration or IgG1/IgG2 ratio at each time point as well 
as between the cp and ncp BVDV groups were calculated through student’s T test at 5% 
(0.05) and 10% (0.1) level of significance (Glantz, 2002). 
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RESULTS 
Concentration of total IgG: 
The concentration of total IgG in serum of calves infected with either cp 
BVDV1b-TGAC or ncp BVDV1b-TGAN strain of BVDV was measured at 0, 7, 14, 21 
and 35 days p.i. In both groups the concentration of total IgG was significantly (p<0.05, 
p<0.1) reduced by 7 days p.i. The initial concentration of total IgG in calves infected with 
cp BVDV1b-TGAC strain of BVDV was 16.14±1.46 mg/ml that reduced significantly 
(p<0.05, p<0.1) 43% to 9.00±0.75 mg/ml at 7 days p.i. The total IgG concentration in 
calves infected with cp BVDV1b-TGAC strain of BVDV increased from day 7 p.i. to day 
35 p.i. At day 14 the IgG concentration was 13.62±0.87 mg/ml, that was 50% more than 
at 7 days p.i. The concentration of IgG remained almost same at day 21 (14.68±1.38 
mg/ml) and then increased significantly (p<0.05, p<0.1) 26.66±2.56 mg/ml at 35 days p.i. 
(Table 5-1, Figure 5-1, Figure 5-3). Similarly, the concentration of total IgG in calves 
infected with ncp BVDV1b-TGAN was significantly reduced (p<0.05, p<0.1) from 
14.17±1.44 mg/ml initial to 10.35±1.11 mg/ml at 7 days p.i. then increased around 30% 
from at 7 days p.i. to at14 days p.i. (13.17±1.58 mg/ml). The concentration of total IgG 
remained almost same between 14 days p.i. to 21 days p.i (14.09±1.33 mg/ml) then 
increased to 19.78±2.43 mg/ml at 35 days p.i. (Table 5-2, Figure 5-1, and Figure 5-3). 
Concentration of IgG1: 
The concentration of serum IgG1 in calves infected with either cp BVDV1b-
TGAC or ncp BVDV1b-TGAN was measured at 0, 7, 14, 21 and 35 days p.i. The cp 
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BVDV1b-TGAC infection significantly reduced (p<0.05, p<0.1) the serum IgG1 
concentration ~62% (3.95±0.27 mg/ml) at 7 days of infection compared to the initial 
concentration of 10.75±1.3 mg/ml (Table 5-1). The concentration of IgG1 increased 
~54% from day 7. (3.95± 0.27 mg/ml) to day 14 (6.08±0.6 mg/ml) in cp BVDV1b-TGAC 
infected calves. As was seen with total IgG, the concentration of IgG1 in serum increased 
slightly from day 14 day (6.08±0.6 mg/ml) to day 21 days (6.68±2.94 mg/ml) and 
significantly increased (p<0.1) from  21 days p.i. to 35 days (9.98±1.18 mg/ml) .p.i. in 
calves infected with cp BVDV1b-TGAC strain of BVDV. At 35 days p.i. the level of 
IgG1 was similiar to initial concentration at day 0 (10.75±1.3 mg/ml) (Table 5-1, Figure 
5-1, and Figure5-2).The ncp BVDV1b-TGAN infection also reduced serum IgG1 
concentration. The serum IgG1 concentration was significantly reduced (p<0.05, p<0.1) 
~60% from 12.93±2.00 mg/ml at initial infection to 7.26±1.18 mg/ml at 7 days p.i (Table 
5-2). The serum IgG1 concentration increased 30% from 7.26±1.18 mg/ml at 7 days 
p.i.to9.71±1.18 mg/ml at 14 days p.i. There was little change in serum IgG1 
concentration from 14 days p.i. (9.71±1.18 mg/ml) to 21 days p.i. (9.05±1.66 mg/ml) in 
calves infected with ncp BVDV1b-TGAN strain. The serum IgG1 concentration returned 
to levels seen prior to infection at 35 days p.i. (12.91±1.77 mg/ml) in calves infected with 
ncp TGAN strain of BVDV (Table5-2, Figure 5-1, Figure 5-2).  
Concentration of IgG2: 
The concentration of IgG2 fluctuated in both the groups, infected with either ncp 
BVDV1b-TGAN or cpBVDV1b-TGAC strain of BVDV. The calves infected with 
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cpBVDV1b-TGAC strain of BVDV showed significant reduction (p<0.05, p<0.1)  in 
IgG2 concentration from 11.44±2.17 mg/ml initial to 10.48±3.94 mg/ml at 7 days p.i. 
The concentration of IgG2 remained almost the same at 14 days p.i. (10.32±2.02 mg/ml) 
and then significantly increased (p<0.05, p<0.1) almost 36% (14.09±2.00 mg/ml) at 21 
days p.i. The IgG2 concentration showed its minimum level at 35 days p.i. as 8.50±3.39 
mg/ml in calves infected with cpTGAC strain of BVDV (Table 5-1, Figure 5-1, Figure 5-
4). 
The calves infected with ncp BVDV1b-TGAN strain of BVDV showed different 
dynamics for IgG2 concentration than the calves infected with cpBVDV1b-TGAC strain 
of BVDV. The concentration of IgG2 in calves infected with ncp BVDV1b-TGAN strain 
of BVDV significantly increased (p<0.05, p<0.1) IgG2 concentration from 7.20±3.27 
mg/ml initial to 15.88±3.59 mg/ml at 7 days p.i., which was almost double the initial 
level. The concentration of IgG2 reduced from 7 days p.i. to 21 days p.i. The 
concentration of IgG2 reduced approximately 20% from 7 days p.i. (15.88±3.59 mg/ml) 
to 14 days p.i. (12.75±4.00 mg/ml) and further reduced to 11.54±4.03 mg/ml at 21 days 
p.i. The concentration of IgG2 increased from day 21 p.i. (11.54±4.03 mg/ml ) to 35 days 
p.i. as 14.00±2.42 mg/ml that was almost double than the initial concentration of IgG2 
(7.20±3.27 mg/ml) in calves infected with ncpBVDV1b-TGAN strain of BVDV.  
IgG1/IgG2 ratio: 
The ratio of serum IgG1 concentration and IgG2 concentration in calves infected 
with either ncp BVDV1b-TGAN or cp bvdv1B-TGAC strain of BVDV was performed to 
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determine the diversion of immune response to either T helper-2 (TH-2) or T helper -1 
(TH-1) arm.  
The IgG1/IgG2 ratio in calves infected with ncp BVDV1b-TGAN strain of 
BVDV remained low than the initial up to 35 day p.i. The IgG1/IgG2 ratio in calves 
infected with ncp BVDV1b-TGAN strain of BVDV showed as 1.11±0.11, 0.46±0.24, 
0.90±0.65, 0.83±0.65 or 0.94±0.43 at 0, 7, 14, 21 or 35 days p.i. 
The IgG1/IgG2 ratio in calves infected with cp BVDV1b-TGAC strain of BVDV 
reduced at 7 days p.i. than increased up to 35 days p.i. The IgG1/IgG2 ratio in calves 
infected with cpTGAC strain of BVDV revealed as 0.99±0.44, 0.52±0.47, 0.63±0.16, 
0.80±0.59 or 1.34±0.54 at 0, 7, 14, 21 or 35 days p.i.  
DISCUSSION 
It is well know that acute BVDV infection results in transient leukopenia with 
decreases in absolute numbers of circulating B lymphocytes, T lymphocytes and 
neutrophils(Bolin et al. 1985). Reduced circulating B lymphocytes may result in transient 
reduction in total IgG and IgG1 concentration in BVDV infected animals. 
Study related to tissue distribution of BVDV following BVDV infection(cp or ncp 
or both) in  colostrum-deprived or colostrum-fed calves indicated that BVDV localized in 
lymphoid and gastrointestinal system to induce effective immune response (Spagnuolo-
Weaver  et al.,  1997) while BVDV infected APC have reduced Fc and C3 receptor 
expression that reduced antigen uptake and presentation (Welsh et al., 1995) and fail to 
induce sufficient immune response.  
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The ncp BVDV reduced MHC II expression (Archambaultet al., 2000). The 
reduced antigen uptake and presentation through MHCII may reduce the T helper cell 
activation that may result in reduced B cell proliferation. Reduced B cell proliferation 
may be the reason for low IgG production in calves infected with ncp strain of BVDV. 
Previous studies demonstrated that cp BVDV induces type one interferon (type 1 IFN), 
whereas ncp BVDV fail to induce type 1 INF (Adler et al., 1997). The effect of cp and 
ncp strains of BVDV is different in in vivo than in vitro experiments.  In contrast to the 
results of previous in vitro studies, experimental infection of calves with ncpBVDV 
induce strong alpha/beta and gamma interferon responses in gnotobiotic animals 
(Charleston  et al., 2002). Type I IFN enhances antibody production both in vitro and in 
vivo, including promoting class-switch recombination and polarizing antibody responses 
toward IgG2 production (Finkelman et al. 1991). This finding is in agreement with the 
observation of current study where ncpTGAN strain of BVDV showed more IgG2 
concentration as compare to ncpBVDV1b-TGAN strain of BVDV at 7, 14 and 35 days 
p.i.  
An in vitro study conducted using ncp Pe515 strain of BVDV showed that ncp 
BVDV directed the immune response toward TH2 with high levels of B cell growth 
factor and IL-4 activity with comparatively low levels of IL-2 activity and IFN- gamma 
(Rhodes et al. 1999) while current finding revealed more IgG2 concentration (Th1 
immune response) in calves infected with ncpBVDV1b-TGAN strain of BVDV. The 
difference in result may be due to study design. In previous study, they did not take 
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paired cp and ncp strains of BVDV to compare difference in biotypes to determine the 
TH1 or TH2 immune response. The previous study was in  In vitro while current study 
was performed in vivo. In previous study, they determine the T helper cell polarity on the 
basis of memory cell proliferation while in current study T helper immune response was 
measured indirectly via IgG1 and IgG2 concentration in BVDV free calves that were not 
exposed to BVDV previously.  
A study conducted using cp Pe515 and ncp Pe515 strain of BVDV indicated that 
ncp strain induced a more rapid and superior primary antibody response (TH2) than the 
homologous cytopathic biotype within 156 days of infection while cp Pe515  showed 
rapid cellular response (TH1) following challenge (Lambot et al. 1997). The difference 
in experimental design, the previous study looked the anamnestic immune response while 
in current study primary immune response was measured.  In this study, the antibody 
concentration was measured within 35 days p.i. where antibody concentration returned to 
almost the pre-infection levels at 35 days p.i. 
From these findings, it can be concluded that both cp and ncp BVDV cause 
transient humoral immunosuppression. The ncp BVDV1b-TGAN strain of BVDV 
induced more IgG2 as compare to its homologous cp BVDV1b-TGAC strain of BVDV. 
More IgG2 concentration indicated that ncp strain of BVDV polarize the immune 
response toward TH1 (cellular immune response) while cp strain of BVDV polarize the 
immune response toward TH2 (humoral immune response). To draw any definitive 
conclusion, the study should be conducted for a longer time with combination the effect 
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of BVDV on cell proliferation and cytokine production with multiple pairs of cp and ncp 
BVDVs. 
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Figure 5-1. The concentration of serum IgG, IgG1 and IgG2 in calves infected with 
BVDV.
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Figure 5-2. The concentration of serum IgG1 in calves infected with BVDV. 
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Figure 5-3. The concentration of total serum IgG in calves infected with BVDV. 
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Figure 5-4. The concentration of serum IgG2 in calves infected with BVDV.(The 
asterix sign showing the significant difference in IgG2 concentrations affected by either 
cp BVDV1b-TGAC  or ncp BVDV1b-TGAN (* p>0.1, ** p>0.05) 
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Figure 5-5. The serum IgG1/IgG2 ratio in calves infected with BVDV. 
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Table 5-1. The concentration of serum IgG, IgG1 and IgG2 in calves infected with 
cp BVDV1b-TGAC strain of BVDV. (The asterix sign showing the significant change 
in concentration of immunoglobulin * p>0.1, ** p>0.05)
Days of infection IgG (mg/ml) IgG1 (mg/ml) IgG2 (mg/ml) 
0 day 16.14±1.46 10.75±1.3 11.44±2.17 
7 days 9.00±0.76** 3.95± 0.27** 10.48±3.94** 
14 days 13.62±0.87 6.08±0.60 10.32±2.02 
21 days 14.68±1.38 6.68±2.94 14.09±2.00** 
35 days 26.66±2.56** 9.98±1.18* 8.50±3.39 
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Table 5-2. The concentration of serum IgG, IgG1 and IgG2 in calves infected with 
ncp BVDV1b-TGAN strain of BVDV.(The asterix sign showing the significant change 
in concentration of immunoglobulin, ** p>0.05).
Days of infection IgG (mg/ml) IgG1 (mg/ml) IgG2 (mg/ml) 
0 day 14.17±1.44 12.93±2.0 7.20±3.27 
7 days 10.35±1.11** 7.26±1.18** 15.88±3.59** 
14 days 13.17±1.58 9.71±1.88 12.75±4.00 
21 days 14.09±1.33 9.05±1.66 11.54±4.03 
35 days 19.78±2.43 12.91±1.77 14.00±2.42 
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Table 5-3. The ratio of IgG1 and IgG2 concentrations in calves’s serum infected 
with either ncp BVDV1b-TGAN or cp BVDV1b-TGAC strain of BVDV 
Days of infection 
IgG1/IgG2 ratio 
(TGAN)  
IgG1/IgG2 ratio 
(TGAC)  
0 day 1.11±0.11 0.99±0.44 
7 days 0.46±0.24 0.52±0.47 
14 days 0.90±0.65 0.63±0.16 
21 days 0.83±0.65 0.80±0.59 
35 days 0.94±0.43 1.34±0.58 
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CHAPTER 6 
GENERAL DISCUSSION 
Antigen presenting cells (APC) play a key role in mounting the immune response. 
Dendrite cells (DC) are unique APC that make a critical link between the innate and 
adaptive immune response (Colino and Snapper, 2003). DC activate naïve T cell and 
produce pro- and anti-inflammatory cytokines. The DC do active surveillance for the 
antigens. The immature DC are highly phagocytic cells that capture, process and present 
antigen to T cell in secondary lymphoid organs. The tissue-resident DC migrate from 
peripheral sites to lymphoid organs to initiate the adaptive immune response and for the 
maintenance of peripheral tolerance. DC infected with virus may have altered phenotypes 
and functions that may affect the development of effective immune response.  The 
previous studies with hepatitis C virus (HCV) have shown that virus infected DC have 
impaired cell surface marker expression.  The impaired cell surface marker expression 
reduced DC maturation and T cell activation (Saito et al., 2008; Shen et al., 2010). 
 In the current study, we had two DC hypothesis: 1) BVDV-infected DC could 
serve as a site for virus replication and play a role in virus dissemination 2) DC infected 
with BVDV have impaired cell surface marker expression associated with antigen 
presentation (MHCI and II) and co-stimulaiton signals (CD86).  If the expression of these 
surface makers was impaired, T cells activation would be suppressed and this could 
contribute to immunosuppression .  Regardless of the virulence of the strain, BVDV 
infects the host through the oronasal route. The primary viral replication occurs in nasal 
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mucosa, tonsils and their leukocytes. The virus spreads from the nasal cavity to regional 
lymph nodes through lymphatics and blood vessels. In regional lymph nodes, the virus 
infects the lymphocytes, monocytes and monocyte-derived cells (i.e. macrophages and 
dendritic cells) (Brodersen and Kelling, 1998; Bruschke et al., 1998; Kelling et al., 
2002). The antigen-presenting cells (APC) (dendritic cells (DC), monocytes, and 
macrophages) and lymphocytes (T and B) are the main target for BVDV (Bruschke et 
al., 1998; Liebler-Tenorio et al., 2003).  
The major objective of this study was to investigate the effect of BVDV infection 
on DC’s surface marker expression and its ability to produce infectious BVDV. Due to 
DC’s anatomical location in skin, mucosa and lymphoid tissue, it is difficult to isolate DC 
without affecting their cell surface markers and functions. In the current study,  an in 
vitro culture system was used to differentiate monocytes into monocyte-derived dendritic 
cells (MDDC) in large quantity (Mwangi et al., 2005). During differentiation of MDDC, 
a breed difference was found as monocytes isolated from Brown Swiss (6 of 6; 100%) 
differentiated better than Holstein Friesian (1 of 18; 5.5%). The MDDC were 
morphologically and phenotypically similar to classical DC. The MDDC were used as 
model to classical DC in the in vitro study.  
A third hypothesis was that BVDV induced cell autophagosomes.  BVDV infects 
almost almost all types of cells. Since it can infect most cells, any effect on the 
autophagosome system may be important for cellular function, antigen presentation 
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and/or innate immunity. BVDV may induce the autophagy in infected cells and utilize 
autophagocytic components for its robust replication as it has been seen with other 
flaviviruses (Ait-Goughoulte et al., 2008; Dreux et al., 2009a; Heaton and Randall, 
2010; Li et al., 2011; Panyasrivanit et al., 2009; Tang et al., 2012). This dissertation 
investigated the effect of autophagy in BVDV replication  
The fourth hypothesis was that the BVDV cause transient humoral 
immunosuppression in primary infection. The cp biotype of BVDV polarize the immune 
response toward T helper -2 (TH-2: humoral immune response) while ncp biotype of 
BVDV polarize the immune response toward T helper -1 (TH-1: cellular immune 
response). BVDV affect the number of circulating as well as follicular B lymphocytes.  
The number of B lymphocytes directly affects the production of antibody. Along with 
this different BVDV biotypes have different effect of cell cultures as well in in vivo. 
Previous studies has shown that the cp BVDV induces type one interferon (type 1 IFN), 
whereas ncp BVDV fail to induce type 1 IFN in in vitro experiments in contrast to that 
experimental infection of calves with ncpBVDV induced strong type 1 IFN  and type 2 
IFN. Type I IFN enhances antibody production both in vitro and in vivo, and promotes 
class-switch recombination and polarizing antibody responses toward IgG2 production. 
The current study investigated the effect of primary BVDV infection on humoral 
response and differential effect of ncp and cp BVDV strains on T helper -2 (TH-2) and T 
helper -1 (TH-1) immune polarity indirectly through IgG1 and IgG2 concentration using 
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a homologous pair of ncp and cp type 1b viruses Tifton Georgia non-cytopathic (TGAN) 
or Tifton Georgia cytopathic virus (TGAC) recovered from an animal that died of 
mucosal disease.   
To summarize, the hypotheses were: 1) Infection of monocyte-derived dendritic 
cells (MDDC) with BVDV causes changes in the phenotype of MDDC (cell surface 
molecules expression); 2) MDDC are targets of BVDV production resulting in 
dissemination of BVDV to secondary lymphoid tissues and other tissues; 3) BVDV 
infection induces autophagy and uses autophagosome for its replication and productive 
infection; 4) In vivo antibody response against cytopathic BVDV polarizes the T cell 
response to TH2 response while the antibody response to noncytopathic BVDV is 
polarized to TH1 response 
In the current study, the cp TGAC strain of BVDV enhanced MHCI and MHCII 
expression during course of infection. While the BVDV ncp strains including sever acute 
1373, mild acute 28508-5 and TGAN, reduced the MHCI and MHCII expression during 
the course of infection from 1 hr p.i. to 12 p.i. and from 24 hrs p.i. to 72 hrs p.i. Among 
the ncp strains of BVDV used in the study, 1373 strain reduced the MHCI and MHCII 
most followed by 28508-5 and TGAN strain of BVDV. The cp strain of BVDV 
significantly enhanced the CD86 expression as early as 1 hr p.i. while all ncp strains of 
BVDV down regulated the CD86 expression through course of experiment.  Similarly, a 
decreased expression of MHC class II was observed in monocytes and monocyte-derived 
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macrophage (MDM) infected with ncp and cp BVDV (Chase et al., 2004) Additionally, 
decreased expression of MHC class I in monocytes and MDM infected by ncp strain of 
BVDV and an increase in the case of cp strain of BVDV was observed (Archambault et 
al., 2000; Chase et al., 2004). The MHCI and MHCII expression is directly related to T 
cell activation. Reduced T cell proliferation was observed in ncp BVDV infection as 
compare to cp BVDV infection (Brackenbury et al., 2003; Collen and Morrison, 
2000). 
The current study revealed the significant up regulation of MHCI, MHCII and 
CD86 expression in MDDC infected with cpTGAC strain of BVDV while MHCI, 
MHCII and CD86 expression was reduced in MDDC infected with ncp strains of BVDV. 
The increased expression of MHCI in MDDC infected with cp BVDV and reduced 
expression in MDDC infected with ncp BVDV may be due to influence of type 1 IFN.  
The effect of BVDV on type 1 IFN production varied greatly between  in vitro 
experiments (laboratory experiment) and in vivo experiments (field experiment).In vitro 
infection of bovine cells with cp BVDV resulted in the induction of type one interferon 
(IFN-alpha/beta) while most ncp BVDV isolates have not been shown to induce type 1 
interferon (Diderholm and Dinter, 1966). Type one IFN up regulates MHCI expression 
(Tovey et al., 1996).  In vivo acute infection of naive cattle with ncp BVDV resulted in 
IFN-alpha/beta production (Brackenbury et al., 2005). To better understand  the effect 
of cp and ncp BVDV infection on APC surface marker expression, an in vivo trial should 
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be carried out.  The APC like DC or its precursor (eg. monocytes) should be collected 
from animals either infected with cp or ncp BVDV. The DC are present in small quantity 
in circulating blood. These DC population can be isolated from experimentally infected 
animals by enrichment of cells displaying receptors for plasma fibronectin, followed by 
adherence and separation on Metrizamide  as described earlier (Renjifo et al., 1997) or 
by magnetic microbeads labeled  for antibodies against DC markers (Szczotka et al., 
2012) or by Fluorescence activated cell sorting (Stasiolek et al., 2012).  The collected 
APC should be examined for up and/or down regulation of cell surface marker expression 
with proper controls. The Change in cell surface marker expression can also be 
determined in DC in fixed tissue through IHC (Immunohistochemistry) and cell surface 
marker expression can be measured on the basis of intensity of expression in fixed tissue 
as used earlier (Hughes et al., 2004). 
It will be interesting to know how BVDV regulates the MHC molecules and 
which viral protein(s) is/are responsible for regulation. The MHC I molecules assembles 
with antigenic peptides in the endoplasmic reticulum (ER) and are transported to the cell 
surface. At the cell surface, MHC I-peptide complexes interact with cytotoxic T cells 
(CTL) for their proper activation (Townsend and Bodmer, 1989).  These antigenic 
peptides are generated and processed in the cytosol and are translocated into the ER by 
the transporter associated antigen processing protein (TAP).  The TAP is composed of 
two polypeptide chains, TAP1 and TAP2 (Ritz and Seliger, 2001).  To escape the 
immune response, viruses have developed various strategies to subvert the antigen 
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processing and presentation. The HCV core protein enhances the MHCI expression via 
p53-dependent upregulation of TAP1. Upregulation of MHCI expression resulted in 
impaired NK cell (natural killer cell) cytotoxicity (Herzer et al., 2003). Several viruses 
down regulate MHCI.  Herpes simplex virus (HSV) downregulates the MHCI molecule 
expression by retaining the MHC I proteins in the endoplasmic reticulum (ER), possibly 
through interference with the TAP (Rosenberg, 1999).  Similarly the adenoviral 
glycoprotein E3/19K down-regulate cell surface MHC I expression by retention of MHC 
H chains in the ER (Andersson et al., 1985; Burgert and Kvist, 1985). The Nef protein 
of HIV (Human immunodeficiency virus) down-regulates the MHC I expression via 
enhanced MHCI endocytosis by the PI3K-regulated ARF6 pathway 
(Blagoveshchenskaya et al., 2002; Piguet et al., 2000).  The human pathogen Kaposi’s 
sarcoma-associated herpesvirus encodes two gene products, K3 and K5. The K3 and K5 
reduce the number of MHC class I molecules at the cell surface by facilitating their 
endocytosis (Ishido et al., 2000).  Along with this the K3 protein targets the MHCI for 
lysosomal degradation following endocytosis (Hewitt et al., 2002). 
One of the more interesting approaches to understand how BVDV down regulates 
the MHC molecules would be to analyze the viral protein(s) that is/are responsible for 
down regulation.  Our lab has cloned various structural and non-structural proteins of 
BVDV. To evaluate the effect of different viral proteins on MHC molecule expression in 
MDDC, the MDDC should be transfected with each viral protein separately and should 
be examined for MHC molecule expression. The only limitation in this study is that, we 
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are not able to transfecte the MDDC so far while bovine endothelial cell is transfected 
well with these proteins. The endothelia cells express high amount of MHCI molecules. 
The effect of BVDV viral proteins on MHCI expression can be measured in BVDV 
protein transfected bovine endothelial cells. To determine the strain effect of ncp or cp 
BVDV, the bovine endothelial cells can be transfected either with NS23 protein to 
measure the effect of ncp BVDV or with NS2 or NS3 or both to measure the effect of ncp 
BVDV on MHCI expression.  
The major difference between cp and ncp biotypes of BVDV is that ncp BVDV 
has uncleaved NS23, whereas this protein is cleaved into NS2 and NS3 in cells infected 
with the cp biotype of BVDV (Brownlie, 1990). The NS2 protein, in conjunction with 
the amino terminus of NS3, functions as an autoprotease that cleaves the NS2-NS3 
junction of the polyprotein (Kummerer and Meyers, 2000; Lackner et al., 2004) NS3 
acts as serine protease (Tautz et al., 1997; Wiskerchen and Collett, 1991; Xu et al., 
1997), NTPase (Tamura et al., 1993) and helicase (Warrener and Collett, 1995). These 
functions are essential in pestiviral RNA replication which cannot be supplied by its 
NS23 precursor (Lackner et al., 2004). Because of the multifactorial effect of NS3 
protein, it will be interesting to know the role of NS3 protein in regulation of MHCI, 
MHCII or CD86 molecules.   
In the second study, we determined that MDDC do not support the production of 
infectious BVDV. The progenitor cells of the MDDC, the monocytes, became infected 
with BVDV and produced infectious virus.  
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For MDDC, bovine herpesvirus 1 (BHV1) was use as a positive control virus 
while the MDBK cells were used as permissive cell control. BHV-1 productively infects 
many different cell types. These cells include monocytes and macrophages (Forman et 
al., 1982; Nyaga and McKercher, 1979). MDBK cells produced infectious BVDV as 
early as 12 hrs p.i. Both MDDC and MDBK cells produced infectious BHV1.The MDDC 
produced infectious BHV1 at 12 hrs p.i. and the maximum viral titer was reached within 
48 hrs p.i. These results were in sharp contrast to another study that showed that bovine 
DC did not support BHV1 replication (Renjifo et al., 1999).  The major difference in 
these results may be due to differences in DC population used in the studies. In previous 
study, two DC populations were isolated from peripheral blood by physical means  while 
in current study, MDDC were differentiated from monocyte in the presence of GMCSF 
and IL-4 and characterized phenotypically and morphologically to be dendritic cell. 
MDDC do not support BVDV production while their progenitor cells, the monocytes, 
became infected and produced infectious BVDV. To investigate at which stage of 
differentiation MDDC lose the ability of to produce infectious BVDV, the monocytes 
were cultured for 1, 2, 3, 4, or 5 days with GMCSF and IL-4 and then infected with 
BVDV. The intermediate stages of monocytes-MDDC were collected at different time 
points and infected with BVDV. We found that MDDC lost the ability to produce 
infectious BVDV at 120 hrs of differentiation.  
Since MDDC were unable to produce infectious BVDV, where did the block in 
virus production occur? To investigate this question, the MDDC were infected with 
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different strains of BVDV and viral RNA was extracted at different time points. The viral 
RNA was quantified using RT-PCR. We found that the viral RNA replicated in MDDC.  
The kinetics of viral RNA production was different between different viral stains. For 
negative control, the MDDC infected with UV inactivated 1373 strain of BVDV neither 
produced infection virus nor replicated the viral RNA, This control experiment eliminate 
the chance of residual viral RNA contamination in MDDC that can be measured by 
highly sensitive qRTPCR assay and confirmed the MDDC are susceptible for infectious 
BVDV. 
 The western blot using MDDC lysate infected with 1373 strain of BVDV 
revealed the presence of NS5A. The presence of viral protein indicated that viral proteins 
are translated in MDDC. The BVDV viral RNA is translated into polyprotein. The viral 
polyprotein is cleaved into 10-11 different structural and non-structural viral proteins 
including NS5B either by viral or cellular protease (Donis, 1995; Harada et al., 2000). 
The NS5B act as a RNA dependent RNA polymerase and replicates the viral genome. 
The presence of viral RNA and viral proteins in MDDC indicated that BVDV infects 
MDDC and replicates the viral RNA and translates the viral protein but does not release 
infectious virus. The inability to release infectious virus from MDDC may be due to 
hindrance in viral assembly or release. 
At this stage we cannot rule out the different possibilities that may block the 
production of infectious BVDV. Inability to produce infectious BVDV by MDDC may 
be due to insufficient synthesis of viral proteins or instability of one or more viral 
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proteins as was observed in influenza A virus in Vero cells (Lau and Scholtissek, 1995). 
Additional studies needs to be done to quantify the viral proteins in MDDC and 
determine  their stability. 
The presence or absence of particular host factors in MDDC may also restrict the 
viral assembly. Studies with parainfluenza virus 5 have shown that the regulatory protein 
14-3-3 can inhibit viral assembly by sequestering M protein, thereby preventing its 
incorporation into virions (Pei et al., 2011). BVDV is an enveloped virus and released 
through budding. It is prerequisite that viral glycoprotein should integration into the host 
cell membrane before budding. Studies have shown that BVDV glycoproteins (Erns and 
E2) aew integrated to ER membrane prior to release into its cisternae by budding 
(Grummer et al., 2001). To confirm the proper assembly of BVDV glycoproteins (Erns 
and E2) into ER membrane, a co-localization study should be done in MDDC with the 
proper cell control.  
In third study both ncp and cp strains of BVDV induced autophagy. The 
autophagy induction in BVDV infected cells was significantly different than non-infected 
cells. We could not find any significant difference between cp and ncp strain of BVDV in 
formation of autophagosomes. The autophagy inducing drug, rapamycin, increased the 
autophagy and BVDV replication while autophagy inhibiting drug, 3MA suppressed the 
autophagy and BVDV replication. The co-localization study using BVDV NS5A and 
BVDV E1 proteins with autophagosomes marker LC3 revealed that BVDV did not 
replicate in autophagosomes while the increase of autophagosomes facilitated the 
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replication of BVDV in infected cells. These results indicated that the autophagy 
machinery supported viral RNA replication by possibility providing energy or factors 
required for translation of incoming hepatitis C virus (Dreux et al., 2009). There have 
been three major autophagosome induction pathways that have been well studied. The 
first pathway involves the mammalian target of rapamycin (mTOR). The mTOR 
negatively regulates autophagy (Jung et al., 2010; Yang and Klionsky, 2010). The 
second pathway is mediated by Atg6/Beclin1 (Furuya et al., 2005).The third is regulated 
by two ubiquitin-like molecules, Atg12 and LC3/Atg8 (Fujita et al., 2008). The Atg12 
and LC3/Atg8 molecules are involved in autophagosome biogenesis. Until now, none of 
these pathways have been studied for autophagy induction by BVDV. Further study 
needs to be carried out to determine whether any one of the above mechanism or 
combination of them could be responsible for autophagy induction in BVDV infected 
cells.  
Autophagy pathways have been characterized in other flaviviruses. The NS4B 
protein of HCV induces autophagy via interactions with both the early endosome-
associated GTPase Rab5 and a class III phosphoinositide 3-kinase, Vps34 (Su et al., 
2011).The Dengue-2 and Modoc (a murine flavivirus) infection induced the PI3K-
dependent autophagy in MDCK cells. The PI3K-dependent autophagy was mediated by 
flavivirus NS4A gene.  A further study is needed to determine which BVDV protein(s) is/ 
are responsible for induction of autophagy by tranfecting the bovine endothelia cells with 
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different BVDV protein(s) and measuring the gene expression of either mTOR or Beclin1 
or Atg12 or LC3/Atg8 or all.  
In the fourth study, both cp TGAC and ncp TGAN strains of BVDV caused 
humoral immunosuppression by reducing total serum IgG and the IgG1 concentration 
(reduced Th2 or humoral immune response). The immunosuppression was transient and 
was restored by 35 days p.i.  The ncp TGAN strain of BVDV enhanced the IgG2 
production while cp BVDV strain enhanced the IgG1 production through the study. 
These result indicated that ncp strain polarized the immune response toward T-helper 1 
(cellular immune response) while the cp strain of BVDV polarized the immune response 
toward T- helper 2 (humoral immune response).   
In this study the fourteen BVDV seronegative calves were divided in to two 
groups with seven calves each. One group was infected with ncp TGAN strain of BVDV 
while another group was infected with homologous cp TGAC strain of BVDV 
intranasally. The blood was collected and serum was separated to measure the 
concentration of total IgG, IgG1 and IgG2 at at 0, 7, 14, 21 and 35 days p.i. Both cp and 
ncp BVDV reduced the total IgG concentration to two third amounts than the initial 
within 7 days p.i. The total IgG concentration gradually increased from 7 days p.i. to 35 
days p.i. The total IgG concentration increased approximately 1.6 times at 35 days p.i 
than initial concentration in calves infected with cp TGAC strain of BVDV while it 
increased around 1.3 times than initial concentration in calves infected with ncp TGAN 
strain of BVDV at 35 days p.i.  
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A similar pattern was observed in serum IgG1 in calves infected with cp TGAC or 
ncp TGAN. Both cp and ncp BVDV caused transient humoral immunosuppression. To 
draw any definitive conclusions, the study should be conducted for longer period of time 
with combination of the findings of cell proliferation and cytokine production following 
BVDV infection. The multiple pairs of cp and ncp BVDV should be included in the study 
for strengthen the results. 
In summary, there are several key questions that emerged from these studies:   
The ncp strains of BVDV down regulated the MHCI, MHCII and CD86 
expression on MDDC while cp BVDV upregulated the MHCI, MHCII and CD86 
expression. The major difference in cp and ncp strain of BVDV is cleavage of NS23 
protein. The NS23 protein is not cleaved in ncp BVDV while it is cleaved into NS2 and 
NS3 in cp BVDV. Is NS2 or NS3 or other BVDV viral proteins having an effect in 
regulation of MHC molecules? Our lab has cloned the NS2 and NS3 protein and other 
BVDV proteins. It will be worth interesting to transfect the MDDC with each of these 
proteins separately and evaluate their effect on MHC molecule expression.  
1) Is the increased MHCI module expression in cp BVDV infection and down 
regulation in ncp BVDV infection due to the effect of type one interferon?  To 
answer this question the MDDC infected with either cp or ncp BVDV should be 
examined for expression of type 1 IFN gene. The supernatant of infected cells 
could also be quantified for type one IFN release. To further confirm the effect of 
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type one IFN on cell surface expression, the ncp BVDV infected MDDC should 
be supplemented with type one IFN and examined for MHCI expression.  
2) Since it is well known that MHCI and MHCII expression affect T cell activation 
and BVDV affects MHCI and MHCII expression the obvious question is-what 
effect does BVDV infection of MDDC have on T cell activation? To answer this 
question, MDDC should be infected with BVDV and used as APC to T helper 
cells. MDDC cells should be “infected” with BVDV neutralized with BVDV 
antibody. The antibody neutralized BVDV would enter the MDDC through 
antibody dependent endocytosis and process and present antigen through MHCII. 
The effect of BVDV on T helper cell activation could be measured using this 
procedure.  
3) In this study, MDDC did not support BVDV production. The progenitor cell of 
the MDDC, the monocyte, became infected and produced infectious BVDV. As 
monocytes differentiated to MDDC, they lost virus production capacity at 120 hrs 
of differentiation. The presence of viral RNA and viral proteins in MDDC 
indicated that BVDV replicate and translate viral proteins in MDDC but do not 
release infectious virus. The inability to release infectious virus from MDDC may 
be due to hindrance in viral assembly or release. The next questions that arise are 
what are the factors that prevent either assembly or release of virus? There may be 
presence or absence of particular host factors in MDDC that restrict viral 
assembly or release. In the next experiment a protein profile comparison could be 
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done between viral permissive cells (like MDBK cells, Bt cells) and non-
permissive cells (MDDCs and MDM) to determine the preliminary difference. 
The BVDV structural viral protein ((Erns and E2 glycoproteins) assembly occur 
at ER membrane and immature virus is released in to into cisternae of ER by 
budding. To know whether there is hindrance in viral assembly, a co-localization 
study using BVDV viral proteins and ER should be done in MDDC. There may 
be insufficient synthesis of viral proteins or instability of one or more viral 
proteins that result in abortive infection of BVDV in MDDC as it was seen for 
influenza virus and mouse dendritic cells (Ioannidis et al., 2012) A further study 
needs to be done to quantify the viral proteins in MDDC and their stability in 
MDDCs at different time points with proper control.  
4) In this study determined that both ncp and cp strains of BVDV induced 
autophagy. The next question that arises is which viral factor(s) (structural or 
nonstructural proteins) induce autophagy?  Secondily, what pathways are used by 
BVDV to induce autophagy? To answer the first question, the cell could be 
tranfected with different viral proteins separatly and examined for autophagy 
induction. To answer the later question the all three well known pathways a) the 
mammalian target of rapamycin (mTOR) pathway, b) Atg6/Beclin1 pathway, and 
c) Atg12 and LC3/Atg8 pathway should be examined after BVDV infection and 
corelated with induction of autophagy. 
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